UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant o

Check the appropriate box:

 o
Preliminary Proxy Statement
 o
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
 o
Definitive Additional Materials
 o
Soliciting Material Pursuant to §240.14a-12

CROSS COUNTRY HEALTHCARE, INC.

(Name of Registrant as Specified In Its Charter)


(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.
 o
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)
Title of each class of securities to which transaction applies:
(2)
(2)
Aggregate number of securities to which transaction applies:
(3)
(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)
(4)
Proposed maximum aggregate value of transaction:
(5)
(5)
Total fee paid:
 o
Fee paid previously with preliminary materials.
 o
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)
Amount Previously Paid:
(2)
(2)
Form, Schedule or Registration Statement No.:
(3)
Filing Party:
(3)
(4)
Filing Party:
(4)
Date Filed:


CROSS COUNTRY HEALTHCARE, INC.
5201 Congress Avenue, Suite 100B

6551 Park of Commerce Boulevard, N.W.

Boca Raton, FloridaFL 33487

April 1, 2019

March 30, 2021

Dear Cross Country Healthcare Stockholder:

We invite you to attend ourthe 2021 annual meeting of stockholders of Cross Country Healthcare, Inc. (the “Annual Meeting”). The Annual Meeting of Stockholders. The meeting will be held on Tuesday,Friday, May 14, 20192021 at 12:00 p.m. Eastern Daylight TimeTime. This year’s Annual Meeting will be a virtual meeting via live audio cast on the internet. You will be able to attend the Annual Meeting, vote and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/CCRN2021 and entering your 16-digit control number included in our notice of internet availability of the proxy materials, on your proxy card or in the instructions that accompanied your proxy materials. As always, we encourage you to vote your shares prior to the Annual Meeting.

2020 In Review

In 2020, we further executed on our turnaround strategy and have positioned the Company for continued growth in both revenue and profitability, through better operational execution, enhanced employee productivity and a world-class client and candidate experience. We realigned and optimized our teams, invested in revenue producing capacity, reduced overhead by more than $20 million annually, permanently closed more than 50 offices (primarily local staffing while maintaining a local presence), implemented and successfully deployed a new applicant tracking software system, and launched our new proprietary on-demand mobile app, Cross Country Marketplace, for the local staffing market. These actions allowed us to deliver two percent consolidated revenue growth and improved profitability for 2020, despite the impacts from COVID-19 on our business, such as the mandatory deferral of elective procedures or the closure of schools. As of December 31, 2020, we believe that our turnaround is complete, though in 2021 and beyond we will continue to innovate, digitally transform and improve both the candidate and client experience. For the first time in five years, we exceeded our profitability targets which resulted in awards earned above 100% of target levels consistent with our pay-for-performance philosophy. The 2018 performance stock awards were also forfeited in conformance with our pay-for-performance policy.

COVID-19

2020 was a challenging year to say the least, but it refocused the Company and made us accelerate projects and processes to enhance our support of our healthcare professionals, clients and our communities. We quickly transitioned to a completely remote workforce, fielded more than 13,000 calls from healthcare professionals on our hotline, staffed more than 5,000 healthcare professionals on COVID assignments, and adopted a pricing policy to ensure patients in hospitals throughout the country were cared for at the officesbedside while maintaining our long-term relationships with clients. Our team worked tirelessly to deliver exceptional results for our clients, candidates and stockholders, and our ability to embrace change and innovate has made the Company more effective overall.

Diversity, Equality and Inclusion; Sustainable Long-Term Growth

In 2020 we continued to expand our environmental, social and governance initiatives. We were proud once again in 2020 that 75% of Cross Country Healthcare, Inc.our corporate workforce is female and 37% is composed of historically underrepresented groups. During the year, we also welcomed Dr. Janice Nevin, the President and CEO of ChristianaCare Health System, to our Board of Directors. We also made additional investments in social initiatives, such as the sponsorship of nursing scholarships at 5201 Congress Avenue, Suite 100B, Boca Raton, Florida 33487.Atlantic University. Our culture, our aspirations to improve the environment and support our communities while significantly improving financial results for our stockholders and having an overall positive impact on society is reflective of our performance and values-based culture that is in direct alignment with our business strategy.

On the following pages, you will find the Notice of Annual Meeting, which lists the matters to be considered and acted upon at the meeting,Annual Meeting, and the Proxy Statement. After the formal business session, we will discuss the financial results for 2018 and report on current operations.

Your vote is very important regardless of the number of shares you own. Detailed voting instructions appear on page 1 of the Proxy Statement. The Board of Directors unanimously recommends that you vote “FOR” Proposals I, II,Proposal Nos. 1, 2, and III3 described in the Proxy Statement.

Sincerely,
Sincerely,
 

 
Thomas C. Dircks,
Chairman
Chairman
��
Kevin C. Clark,
President Co-Founder and Chief Executive Officer

CROSS COUNTRY HEALTHCARE, INC.6551 Park of Commerce Boulevard, N.W.
5201 Congress Avenue, Suite 100B
Boca Raton, Florida 33487

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD MAY 14, 2019

 

Meeting Date and Time

Friday, May 14, 2021 at 12:00 p.m. Eastern Time

Meeting Location

Due to continuing concerns relating to the coronavirus pandemic (COVID-19), and to support the health and well-being of our stockholders, Cross Country Healthcare, Inc. will have a virtual only annual meeting of stockholders in 2021, conducted exclusively via live audio cast at www.virtualshareholdermeeting.com/CCRN2021. There will not be a physical location for our 2021 Annual Meeting of Stockholders (our “Annual Meeting”), and you will not be able to attend the meeting in person. See below for important information. 

To the Holders of Common Stock:

The Annual Meeting of Stockholders of Cross Country Healthcare, Inc.:

Cross Country Healthcare, Inc. (the “Company”) will be held athold the offices2021 Annual Meeting of Cross Country Healthcare, Inc. at 5201 Congress Avenue, Suite 100B, Boca Raton, Florida 33487Stockholders as a virtual meeting via live webcast on Tuesday,the internet on Friday, May 14, 2019,2021, at 12:00 p.m. Eastern Daylight Time for the following purposes:

Agenda1.Board’s Voting Recommendation
Proposal 1The election ofTo elect eight directors to serve for a one-year term as specified in the Company’s Board of Directors to hold office until the next Annual Meeting or until their respective successors are duly elected and qualified;attached Proxy StatementFOR each director nominee
Proposal 22.The approval and ratification ofTo ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company for the fiscal year ending December 31, 2019;2021FOR
Proposal 33.TheTo approve, on a non-binding, advisory votebasis, the compensation paid to approve compensation of the Company’sour named executive officers in 2020, as describedreported in this proxy statement; andProxy StatementFOR
4.To transact such other business, if any, as may properly come before the meeting or any adjournment thereof.

Stockholders

We also will consider and act upon such other business as may properly come before the Annual Meeting or any adjournment thereof.

Only the Company’s stockholders of record at the close of business on March 18, 20192021 (the “Record Date”) are entitled to receive noticethis Notice of Internet Availability of Proxy Materials (this “Notice”) and to vote at the Annual Meeting.Meeting and any adjournment thereof.

Important Notice Regarding

Stockholders of record as of the Availability of
Proxy Materials forRecord Date will be able to participate in the Annual Meeting online at www.virtualshareholdermeeting.com/CCRN2021. To participate in the Annual Meeting, you will need the 16-digit control number on this Notice. We encourage you to access the Annual Meeting before the start time of Stockholders
to be Held12:00 p.m. Eastern Time on May 14, 20192021. Please allow ample time for online check-in, which will begin at 11:45 a.m. Eastern Time on May 14, 2021.

The date on which the Proxy Statement is first being made available to the Company’s Stockholders is on or about March 30, 2021. The Proxy Statement, andwhich more fully describes the matters to be considered at the Annual Meeting, is attached to this Notice. Copies of our Annual Report to stockholders are available online at our website at http://ir.crosscountryhealthcare.com. We are pleased to take advantage ofon Form 10-K for the fiscal year ended December 31, 2020 (the “2020 Annual Report”) (including the financial statements and schedules thereto, as filed with the Securities and Exchange Commission rules(the “SEC”)) accompany this Notice, but are not deemed to be part of the Proxy Statement.

It is important that allow usyour shares be represented at the Annual Meeting. We urge you to furnish thesereview the attached Proxy Statement and, whether or not you plan to participate in the Annual Meeting, to vote your shares promptly by completing, signing, and returning the accompanying proxy materialscard. You do not need to affix postage to the enclosed reply envelope if you mail it within the United States. If you participate in the virtual meeting, you may withdraw your proxy and ourvote your shares electronically during the Annual Report to stockholders on the Internet. We believe that posting these materials on the Internet enables us to provide stockholders with the information that they need more quickly, while lowering our costs of printing and delivery and reducing the environmental impact of our Annual Meeting.

By Order of the Board of Directors,

 
Susan E. Ball
Executive Vice President,
Chief Administrative Officer,
General Counsel and Secretary
April 1, 2019
March 30, 2021

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD MAY 14, 2021:Cross Country Healthcare Inc.’s 2021 proxy statement for the 2021 Annual Meeting of Stockholders and 2020 Annual Report are available via the Internet at www.proxyvote.com.

YOUR VOTE IS IMPORTANT. ACCORDINGLY, THE COMPANY URGES YOU TO COMPLETE, DATE,
SIGN AND RETURN THE ENCLOSED PROXY CARD REGARDLESS OF WHETHER YOU PLAN TO
ATTEND THE ANNUAL MEETING. STOCKHOLDERS CAN ALSO RETURN THEIR VOTE BY THE
INTERNET OR BY PHONE – PLEASE SEE THE PROXY CARD FOR VOTING INSTRUCTIONS.

Forward-Looking Statements

This Proxy Statement contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including in our Chairman’s letter to our stockholders, which represent our expectations or beliefs concerning future events. Forward-looking statements include those containing such words as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “outlook,” “plans,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would,” or other words of similar meaning. These forward-looking statements rely on assumptions and involve risks and uncertainties, many of which are beyond our control, including, but not limited to factors detailed herein and under Part I, “Item 1A. Risk Factors” and in other sections of our 2020 Annual Report and in other filings with the SEC.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on our forward-looking statements. Each forward-looking statement speaks only as of the date of the particular statement, and, except as required by law, we undertake no duty to update or revise any forward-looking statement.

Website Information

This document includes several website addresses. These website addresses are intended to provide inactive, textual references only. The information on these websites is not part of this Proxy Statement.

Table of Contents

CROSS COUNTRY HEALTHCARE, INC.6551 Park of Commerce Boulevard, N.W.
5201 Congress Avenue, Suite 100B
Boca Raton, Florida 33487

PROXY STATEMENT
FOR THE 2021 ANNUAL MEETING OF STOCKHOLDERS

GENERAL INFORMATION

These proxy materials (the “Proxy Statement”) are furnished in connection with the solicitation by the Board of Directors (the “Board”) of Cross Country Healthcare, Inc. (“Cross Country,” “the Company,” “our,” “we,” or “us”), a Delaware corporation, of proxies to be voted at our 20192021 Annual Meeting of Stockholders (the “Annual Meeting”), or at any adjournment or postponement thereof.

2021 Annual Meeting of Stockholders
•    Time and Date:May 14, 2021, at 12:00 p.m. Eastern Time
•    Virtual Meeting Site:www.virtualshareholdermeeting.com/CCRN2021
•    Record Date:March 18, 2021
•    Voting:Stockholders of the Company as of the record date, March 18, 2021, are entitled to vote on the proposals being acted upon at the meeting. Each share of the Company’s common stock is entitled to one vote for each director nominee and one vote for each of the other proposals to be voted upon at the Annual Meeting.

Matters to be Voted Upon

The purposes of the Annual Meeting are to seek stockholder approval of the following three proposals:

 i.To elect eight directors to serve for a one-year term as specified in the attached Proxy Statement;

ii.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2021; and

1

iii.To approve, on a non-binding, advisory basis, the compensation paid to our named executive officers in 2020, as reported in this Proxy Statement.

We also will consider and act upon any other matters that properly come before the Annual Meeting or any adjournment or postponement thereof.

How to Attend the Virtual Annual Meeting

The year’s Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted via live audio cast. You are invitedentitled to attend ourparticipate in the Annual Meeting only if you were a stockholder as of the close of business on Tuesday, May 14, 2019, beginningthe Record Date or if you hold a valid proxy for the Annual Meeting.

To be admitted to the Annual Meeting at www.virtualshareholdermeeting.com/CCRN2021, you must enter the control number on your proxy card or voting instruction form you previously received. You also may vote online and examine our stockholder list during the Annual Meeting by following the instructions provided on the meeting website during the Annual Meeting.

You will be able to participate in the Annual Meeting online and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/CCRN2021. You also will be able to vote your shares and submit questions electronically at the Annual Meeting during the webcast. During the live Q&A session of the meeting, members of our executive leadership team will answer questions as they come in, as time permits. To ensure the meeting is conducted in a manner that is fair to all stockholders, the Chairman may exercise broad discretion in recognizing stockholders who wish to participate, the order in which questions are asked and the amount of time devoted to any one question. However, we reserve the right to edit or reject questions we deem inappropriate.

To participate in the Annual Meeting, you will need the 16-digit control number included on your proxy card or on the instructions that accompanied your proxy materials.

The meeting webcast will begin promptly at 12:00 p.m. Eastern Daylight Time on May 14, 2021. Online access will begin at 11:45 a.m. Eastern Time, and we encourage you to access the meeting prior to the start time.

We will have technicians ready to assist with any technical difficulties you may have. You will have the ability to test the systems before the Annual Meeting starts, and a technical phone number will be provided when the meeting opens.

Who May Vote

Stockholders of record of our common stock, par value $0.0001 per share (the “Common Stock”) as of the close of business on the Record Date are entitled to notice of, and to vote at the officesAnnual Meeting and any adjournment thereof. As of Cross Country Healthcare, Inc.the Record Date, we had issued and outstanding 37,512,543 shares of Common Stock. We have no other securities entitled to vote at 5201 Congress Avenue, Suite 100B, Boca Raton, Florida 33487.the Annual Meeting. Each share of Common Stock is entitled to one vote on each matter. There is no cumulative voting.

2

If the shares you own are held in “street name” by a bank or brokerage firm, your bank or brokerage firm, as the record holder of your shares, is required to vote your shares according to your instructions. In order to vote your shares, you will need to follow the directions that your bank or brokerage firm provides to you. Many banks and brokerage firms solicit voting instructions over the internet or by telephone. Even if your shares are held in street name, you are welcome to participate in the Annual Meeting; however, you may not vote your shares via participation in the Annual Meeting. If you hold your shares in street name and wish to vote by participating in the Annual Meeting, please contact your bank or brokerage firm before the Annual Meeting to obtain the necessary proxy from the holder of record.

If the beneficial owner does not provide voting instructions, banks and brokerage firms cannot vote the shares with respect to “non-routine” matters, but can vote the shares with respect to “routine” matters. “Broker non-votes” occur when a beneficial owner of shares held in street name fails to provide instructions to the bank or brokerage firm holding the shares as to how to vote on matters deemed “non-routine.” We believe Proposal No. 2 (the ratification of the selection of our independent registered public accounting firm) is a “routine” matter and, as a result, we do not expect there to be any broker non-votes. Proposal No. 1 (the election of directors) and Proposal No. 3 (the non-binding advisory approval of the compensation of the Company’s named executive officers for 2020) are “non-routine” matters, and banks and brokerage firms cannot vote your shares on such proposals if you have not given voting instructions.

The presence at the Annual Meeting of a majority of the outstanding shares of Common Stock as of the Record Date, represented by virtual attendance or by proxy, is required for a quorum. As long as one of the matters is deemed to be a “routine” matter, proxies reflecting broker non-votes (if any) will be counted towards the quorum requirement.

Electronic Notice and Mailing.Mailing

Pursuant to the rules promulgated by the Securities and Exchange Commission or the Commission,(the “SEC”) we are making our proxy materials available to you on the Internet. Accordingly, we will mail a Notice of Internet Availability of proxy materials (which we refer to as the Notice of Internet Availability) to the beneficial owners of our common stock, par value $.0001 per share, or Common Stock on or about April 1, 2019.March 30, 2021. From the date of the mailing of the Notice of Internet Availability until the conclusion of the Annual Meeting, all beneficial owners will have the ability to access all of the proxy materials at www.proxyvote.com. All stockholders will have an opportunity to request a paper or e-mail delivery of these proxy materials.

The Notice of Internet Availability will contain:

the date, time, and instructions to attend the Annual Meeting online, the matters to be acted upon at the Annual Meeting and the Board’s recommendation with regard to each matter;
the Internet address that will enable access to the proxy materials;
a comprehensive listing of all proxy materials available on the website;
a toll-free phone number, e-mail address and Internet address for requesting either paper or e-mail delivery of proxy materials;

the date, time and location
3
the Internet address that will enable access to the proxy materials;
a comprehensive listing of all proxy materials available on the website;
a toll-free phone number, e-mail address and Internet address for requesting either paper or e-mail delivery of proxy materials;
the last reasonable date a stockholder can request materials and expect them to be delivered prior to the meeting; and
instructions on how to access the proxy card.

the last reasonable date a stockholder can request materials and expect them to be delivered prior to the meeting; and
instructions on how to access the proxy card.

You may also request a paper or e-mail delivery of the proxy materials on or before the date provided in the Notice of Internet Availability by calling 1-800-579-1639. We will fill your request within three business days. You will also have the option to establish delivery preferences that will be applicable for all your future mailings.

How to Vote. StockholdersVote

If you were a record holder of record (that is, stockholders who hold their shares in their own name) canof Common Stock on the Record Date, you may vote any one of four ways:as follows:

(1)By Internet: Go to the website www.proxyvote.com to vote via the Internet. You will need to follow the instructions on your proxy card and the website. If you vote via the Internet, you may incur telephone and Internet access charges.

(2)By Telephone: Call the toll-free number 1-800-690-6903 to vote by telephone. You will need to follow the instructions on your proxy card and the recorded instructions.

(3)By Mail: If you prefer, you can contact us to obtain copies of all proxy materials, including proxy cards, by calling 1-800-579-1639, or by mail: Cross Country Healthcare, Inc., General Counsel, at 5201 Congress Avenue, Suite 100B,6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida, 33487. If you contact us to request a proxy card, please mark, sign and date the proxy card and return it promptly in the self-addressed, stamped envelope that we will provide, if you are the stockholder of record, or by signing the voter instruction form provided by your bank or broker and returning it by mail, if you are the beneficial owner but not the stockholder of record. This way your shares will be represented whether or not you are able to attend the meeting. If you sign and return your proxy card but do not give voting instructions, the shares represented by that proxy will be voted as recommended by the Board.

1

card, please mark, sign and date the proxy card and return it promptly in the self-addressed, stamped envelope that we will provide. If you sign and return your proxy card but do not give voting instructions, the shares represented by that proxy will be voted as recommended by the Board of Directors.

(4)In PersonVirtual Participation: You canThis year’s Annual Meeting will be held entirely online. Stockholders may participate in the Annual Meeting by visiting the following website: www.virtualshareholdermeeting.com/CCRN2021. To participate in the Annual Meeting, you will need the 16-digit control number included on your Notice, on your proxy card or on the instructions that accompanied your proxy materials. Shares held in your name as the stockholder of record may be voted electronically during the Annual Meeting. Shares for which you are the beneficial owner but not the stockholder of record also may be voted electronically during the Annual Meeting. However, even if you plan to attend the Annual Meeting, or send a personal representative with an appropriate proxy, tothe Company recommends that you vote by ballot. Record holders and other beneficial owners holdingyour shares in the name of a bank, broker or other holder of record (“street name”) or their proxies mayadvance, so that your vote will be counted if you later decide not to attend the Annual Meeting in person. When you arrive at the Annual Meeting, you must present photo identification, such as a driver’s license.meeting.

If you vote via the Internet or by telephone, your electronic vote authorizes the named proxies to vote in the same manner as if you signed, dated and returned your proxy card. If you vote via the Internet or by telephone, do not mail a proxy card.

4

If your shares of Common Stock are held in street name you will receive instructions from“street name” through a bank, broker or other institution, then that bank, broker or other institution is considered the holder of record thatof your shares, and you must follow in ordershould refer to information forwarded to you by such holder of record for your sharesvoting options. You may vote as follows:

By Internet or Telephone: You will receive instructions from your broker or other nominee if you are permitted to vote by internet or telephone.

By Mail: You will receive instructions from your broker or other nominee explaining how to vote your shares.

Board’s Voting Recommendations 

The Board recommends a vote:

Proposal No. 1: “FOR” the election of each of the eight director nominees to be voted. Internet and telephone voting alsoserve on the Board for a one-year term.

Proposal No. 2: “FOR” ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.

Proposal No. 3: “FOR” approval, on an advisory basis, of compensation paid to our named executive officers in 2020, as reported in this Proxy Statement.

Required Vote

Shares of Common Stock represented by any proxy duly given will be offered to stockholders owning shares through most banks and brokers.

Stockholders Entitled to Vote. Persons holding shares of our Common Stockvoted at the close of business on March 18, 2019, the record date for the Annual Meeting in accordance with the instructions of the stockholder. If no specific instructions are entitledgiven, the shares will be voted “FOR” the election of each of the director nominees, “FOR” ratification of the independent registered public accounting firm, and “FOR” approval, on an advisory basis, the compensation paid to receive notice of and to vote their shares atour named executive officers in 2020, as reported in this Proxy Statement. In addition, if any other matters come before the Annual Meeting. As of that date, there were 36,143,420 shares of Common Stock outstanding.Meeting, the persons named in the accompanying Proxy Card will vote in accordance with their best judgment with respect to such matters. Each share of Common Stock isoutstanding on the Record Date will be entitled to one vote on each matter properly brought beforeall matters.

Proposal No. 1 - Election of Directors

Each director will be elected if more votes are cast “for” the director’s election than are cast “against” the director’s election. Abstentions and broker non-votes are not counted as a vote cast either “for” or “against” the director’s election and therefore have no effect on voting outcomes.

Proposal No. 2 - Ratification of the Selection of Deloitte & Touche LLP

The affirmative vote of a majority of the votes cast by holders of our Common Stock, voting electronically at the Annual Meeting.Meeting or by proxy, is required to ratify the appointment of our independent registered public accounting firm. Abstentions will not be treated as votes cast for

Revocability

5

this purpose and, therefore, will not affect the outcome of the election. Because the ratification of the independent registered public accounting firm is a routine matter, a nominee holding shares in street name may vote on this proposal in the absence of instructions from the beneficial owner.

Proposal No. 3 – Approval of the 2020 Executive Compensation

The vote on executive compensation is advisory and non-binding; however, the Company will record the number of votes cast in favor of and against this proposal and will report the voting results at the Annual Meeting. The Compensation Committee will, however, take into account the outcome of the vote when considering future compensation arrangements.

You should read the “Compensation Discussion and Analysis You” section and the compensation tables in determining whether to approve this proposal.

Revoking Your Proxy

If you are a holder of record, you may revoke your proxy and reclaim your right to vote up to and including the day of the Annual Meeting by giving written notice of revocation to us (to the attention of the Inspectors of Election), timely delivering a valid, later-dated proxy or voting by ballot at the Annual Meeting. Please note that attendance at the Annual Meeting will not by itself revoke a proxy.

Vote at the Annual Meeting. Your mail-in vote, your e-vote or vote by telephone will not limit your right to vote at the Annual Meeting if you later decide to attend in person. If your shares are held in “street name,” you may revoke your voting instructions by following the specific directions provided to you by your bank or broker.

If the Annual Meeting is postponed or adjourned for any reason, at any subsequent reconvening of the Annual Meeting, all proxies will be voted in the same manner as described above, you must obtain a proxy, executed in your favor, from the holder of record to be able to voteproxies would have been voted at the meeting.original convening of the Annual Meeting (except for any proxies that have at that time effectively been revoked or withdrawn).

Proxy Cards 

All shares that have been properly voted and not revoked will be voted at the Annual Meeting in accordance with your instructions. If you sign and return your proxy card, or vote by internet or telephone but fail to give voting instructions, the shares represented by the proxy will be voted by the Proxy Committee as recommended by the Board of Directors.Board. The Proxy Committee consists of Kevin C. Clark and Thomas C. Dircks.

Other Matters.

Proxy cards, unless otherwise indicated by the stockholder, confer upon the Proxy Committee discretionary authority to vote all shares of stock represented by the proxies on any matter which may be properly presented for action at the Annual Meeting even if not covered herein. If any of the nominees for director named in Proposal I—Election of Directors should be unavailable for election, the proxies will be voted for the election of such other person as may be recommended by the Board of Directors in place of such nominee. The Board of Directors is not aware of any matter for action by the stockholders at the Annual Meeting other than the matters described in the Notice.

Quorum.

Quorum 

The presence, in person or by proxy, of the holders of a majority of the shares of Common Stock issued and outstanding entitled to vote at the Annual Meeting is required to constitute a quorum. Abstentions and broker non-votes (i.e., proxies from brokers or nominees indicating that such persons have not received instructions from the beneficial owner or other persons entitled to vote shares as to a matter with respect to which the brokers or nominees do not have discretionary

6

power to vote) are counted as present for purposes of determining the presence or absence of a quorum for the transaction of business.

Required Vote; Abstentions and Broker Non-Votes. Directors will be elected by a majority

Solicitation of the votes cast at the Annual Meeting in an uncontested election. Votes withheld, abstentions and broker non-votes will not have any effect on the outcome of voting with respect to the election of directors, unless no affirmative votes are received for a nominee. The affirmative vote of holders of a majority of shares represented at the Annual Meeting, in person or by proxy, and entitled to vote is required for approval of (i) the election of eight directors to the Company’s Board of Directors to hold office until the next Annual Meeting or until their respective

2

successors are duly elected and qualified, (ii) the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019, and (iii) the non-binding vote regarding the compensation of the Company’s named executive officers as described in this proxy statement. Abstentions have the same effect as a vote against these proposals. Broker non-votes are deemed not entitled to vote and are not counted as votes for or against any proposal.Proxies 

Proxy Solicitation.

We will bear the cost of solicitation, including the preparation, assembly, printing and mailing of the proxy materials. Copies of solicitation materials will be furnished to brokerage houses, fiduciaries and custodians holding shares in their names that are beneficially owned by others so that they may forward this solicitation material to such beneficial owners. In addition, we may reimburse such persons for their costs in forwarding the solicitation materials to such beneficial owners. The original solicitation of proxies by mail may be supplemented by a solicitation by telephone, telegram or other means by our directors, officers or employees. No additional compensation will be paid to these individuals for any such services. Except as described above, weWe do not presently intend to solicit proxies other than by mail.

Stockholder Communications.Communications

The Board of Directors has adopted a process by which stockholders may communicate with our directors. Any stockholder wishing to do so may call our toll-free phone number at 800-354-7197 or send an e-mail to governance@crosscountryhealthcare.com.governance@crosscountry.com. All such communications will be forwarded directly to the Board of Directors or any individual director or committee of the Board, of Directors, as applicable.

Code of Ethics and Business Ethics Policy. We have adopted a code of ethics and a business ethics policy that applies to all of our employees, including executive officers and the Board of Directors. The code of ethics and business ethics policy are available on our website at www.crosscountryhealthcare.com by choosing the “Investors” link, clicking on the “Corporate Governance” section, and selecting the respective document under “View.” A copy is on file with the Commission as an exhibit to our Form 10-Q for the quarter ended March 31, 2018 (filed as Exhibit 14.1 on May 4, 2018).

3

SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information, as of March 18, 2019, regarding the beneficial ownership of our Common Stock by each person who is known by us to be the beneficial owner of 5% or more of our Common Stock, our Chief Executive Officer, and our Chief Financial Officers during our fiscal year ended December 31, 2018 and the three most highly compensated persons (other than the CEO and CFO) who were serving as executive officers at December 31, 2018 (referred to herein as Named Executive Officers, or the NEOs), each of our directors and director nominees, and all directors and executive officers as a group. The percentages in the last column are based on 36,143,420 shares of Common Stock outstanding on March 18, 2019, plus the number of shares of Common Stock deemed to be beneficially owned by such individual or group pursuant to Rule 13d-3(d)(1) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In each case, except as otherwise indicated in the footnotes to the table, the shares shown in the second column are owned directly by the individual or members of the group named in the first column and such individual or group members have sole voting and dispositive power with respect to the shares shown. For purposes of this table, beneficial ownership is determined in accordance with federal securities laws and regulations. Persons shown in the table disclaim beneficial ownership of all securities not held by such persons directly and inclusion in the table of shares not owned directly by such persons does not constitute an admission that such shares are beneficially owned by the director or officer for purposes of Section 16 of the Exchange Act or any other purpose. Shares of Common Stock subject to options that are currently exercisable or exercisable within 60 days of March 18, 2019 are deemed outstanding for computing the ownership percentage of the stockholder holding such shares, but are not deemed outstanding for computing the ownership percentage of any other stockholder.

Name
Number of Shares of
Common Stock
Beneficially Owned
Percentage of
Outstanding
Common Stock
Owned
BlackRock Inc.
 
5,257,750
(a)(b)
 
14.6
%
T Rowe Price Associates Inc.
 
2,424,831
(a)(c)
 
6.7
%
Dimensional Fund Advisors, LP
 
2,387,342
(a)(d)
 
6.6
%
Vanguard Group
 
2,192,859
(a)(e)
 
6.1
%
Susan E. Ball
 
144,145
(f)(g)
 
 
*
William J. Burns
 
141,156
(f)(g)
 
 
*
W. Larry Cash
 
118,834
(f)(g)
 
 
*
Kevin C. Clark
 
(f)(g)
 
 
*
Thomas C. Dircks
 
134,595
(f)(g)
 
 
*
Timothy L. Fischer
 
6,878
(a)(f)
 
 
*
Gale Fitzgerald
 
102,584
(f)(g)
 
 
*
Darrell S. Freeman, Sr.
 
7,730
(f)(g)
 
 
*
William J. Grubbs
 
355,557
(a)(f)
 
 
*
Richard M. Mastaler
 
82,957
(f)(g)
 
 
*
Mark Perlberg
 
33,156
(f)(g)
 
 
*
Christopher R. Pizzi
 
35,976
(f)(g)
 
 
*
Joseph A. Trunfio, Ph.D.
 
139,034
(f)(g)
 
 
*
Buffy S. White
 
15,180
(f)(g)
 
 
*
All directors and executive officers as a group
 
1,377,412
(h)
 
3.8
%
*Less than 1%
(a)Addresses are as follows: BlackRock, Inc., 55 East 52nd Street, New York, NY 10055; T Rowe Price Associates Inc., 100 E. Pratt Street, Baltimore, MD 21202; Dimensional Fund Advisors, LP, Building One, 6300 Bee Cave Road, Austin, TX 78746; Vanguard Group Inc., 100 Vanguard Blvd, Malvern, PA 19355; Timothy L. Fischer, 3425 Newport Bay Drive, Alpharetta, GA 30005; and William J. Grubbs, 166 Fisher Avenue, Brookline, MA 02455.
(b)The information regarding the beneficial ownership of shares by BlackRock, Inc. was obtained from its statement on Schedule 13G/A, filed with the Commission on January 24, 2019. Such statement discloses that BlackRock, Inc. has sole voting power of 5,183,269 shares and has sole dispositive power of 5,257,750 shares.

4

(c)7The information regarding the beneficial ownership of shares by T Rowe Price Associates Inc. was obtained from its statement on Schedule 13G/A, filed with the Commission on February 14, 2019. Such statement discloses that T Rowe Price Associates Inc. possesses sole voting power over 420,737 shares and sole dispositive power over 2,424,831 shares.

DIRECTORS AND EXECUTIVE OFFICERS

Directors

 (d)The information regarding the beneficial ownership of shares by Dimensional Fund Advisors LP was obtained from its statement filed on Schedule 13G, filed with the Commission on February 8, 2019. Such statement discloses that Dimensional Fund Advisors LP possesses sole voting power over 2,276,191 shares and sole dispositive power over 2,387,342 shares.  
Kevin C. Clark(e)The information regarding the beneficial ownership of shares by Vanguard Group Inc. was obtained from its statement on Schedule 13G/A, filed with the Commission on February 11, 2019. Such statement discloses that Vanguard Group Inc. possesses sole voting power over 36,203 shares, shared voting power over 3,100 shares, sole dispositive power over 2,158,556 shares, and shared dispositive power over 34,303 shares.
(f)Includes shares of Common Stock which such individuals have the right to acquire through the exercise of equity awards within 60 days of March 18, 2019 as follows: Susan E. Ball, 5,625; William J. Burns, 0; W. Larry Cash 0; Kevin C. Clark, 0; Thomas C. Dircks 0; Timothy L. Fischer, 0;
   
Gale Fitzgerald 0; Darrell S. Freeman, Sr.Janice E. Nevin, M.D., 0; William J. Grubbs, 0; Richard M. Mastaler, 0; MPH
  
Mark Perlberg, 0; Christopher R. Pizzi, 0; Joseph A. Trunfio, 0; and Buffy S. White, 0. Includes Restricted Shares as follows: Susan E. Ball, 28,943; William J. Burns, 54,899; W. Larry Cash, 17,649; Kevin C. Clark, 0; Thomas C. Dircks, 17,649; Timothy L. Fischer, 0; Gale Fitzgerald, 17,649; Darrell S. Freeman, Sr., 7,730; William J. Grubbs, 0; Richard M. Mastaler, 17,649; Mark Perlberg, 17,649; Christopher R. Pizzi, 26,419; Joseph A. Trunfio, 17,649; and Buffy S. White, 13,142.
JD(g)Address is c/o Cross Country Healthcare, Inc., 5201 Congress Avenue, Suite 100B, Boca Raton, Florida 33487.
(h)Includes 5,625 shares of Common Stock which the directors and executive officers have the right to acquire through the exercise of equity awards within 60 days of March 18, 2019 and 270,162 shares of Restricted Stock.

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

The members of our Board of Directors, our executive officers and persons beneficially owning 10% or more of our outstanding Common Stock are subject to the reporting requirements of Section 16(a) of the Exchange Act that requires them to file reports with respect to their ownership of our Common Stock and their transactions in such Common Stock. Based solely upon a review of (i) the copies of Section 16(a) reports that we have received from such persons or entities for transactions in our Common Stock and their Common Stock holdings for the year ended December 31, 2018 and (ii) the written representations received from one or more of such persons or entities that no annual Form 5 reports were required to be filed by them for such fiscal year, we believe that all reporting requirements under Section 16(a) for such fiscal year were met in a timely manner by our directors, executive officers and beneficial owners of 10% or more of our Common Stock.

5

BOARD OF DIRECTORS

The Board of Directors currently consists of eight members. All of the directors currently serving on the Board of Directors have been nominated by the Governance and Nominating Committee of the Board of Directors to stand for re-election at the Annual Meeting of Stockholders for one-year terms. The Board of Directors unanimously approved these nominations. Each nominee elected will hold office until the Annual Meeting of Stockholders to be held in 2020 and until a successor has been duly elected and qualified unless, prior to such meeting a director shall resign, or his or her directorship shall become vacant due to his or her death, resignation or removal. All nominees were elected at the Annual Meeting of Stockholders held in 2018, other than Darrell S. Freeman, Sr., who was appointed as a director on August 1, 2018, and Kevin C. Clark. Mr. Clark replaced William J. Grubbs as President, Chief Executive Officer and Director, upon Mr. Grubbs’ retirement, effective January 15, 2019.

Each nominee has agreed to serve, if elected, and management has no reason to believe that they will be unavailable to serve. If any of the nominees should be unavailable for election, the proxies will be voted for the election of such other person as may be recommended by the Board of Directors in place of such nominee. Shares properly voted will be voted FOR the nominees unless the stockholder indicates on the proxy that authority to vote the shares is withheld for one or more or for all of the nominees listed. A proxy cannot be voted for a greater number of persons than the eight nominees named below. Directors are elected by a majority of the votes cast in an uncontested election. Votes withheld, abstentions and broker non-votes will not have any effect on the outcome of voting with respect to the election of directors unless no affirmative votes are received for a nominee. The following eight individuals have been nominated for election at the Annual Meeting of Stockholders for a one-year term ending upon the 2020 Annual Meeting of Stockholders:

Name
Age
Position
Kevin C. Clark
58
President, Chief Executive Officer and Director
W. Larry Cash
70
Director
Thomas C. Dircks
61
Chairman of the Board and Director
Gale Fitzgerald
68
Director
Darrell S. Freeman, Sr.
54
Director
Richard M. Mastaler
73
Director
Mark Perlberg
63
Director
Joseph A. Trunfio, Ph.D.
72
Director

The Board recommends that holders vote “FOR” the election of the nominees.

In selecting qualified individuals to serve on our Board of Directors, among other attributes, we look for those individuals who possess characteristics that include integrity, business experience, financial acumen and leadership abilities, familiarity with our business and businesses similar or analogous to ours, and the extent to which a candidate’s knowledge, skills, background and experience are already represented by other members of our Board of Directors. In addition, in composing a well-rounded Board of Directors, we look for those individuals possessing a diversity of complementary skills, core-competencies and expertise, including diversity with respect to age, gender, national origin and race, for the optimal functioning of the Board of Directors and with a view toward constituting a Board with the appropriate skills and experience necessary to oversee our business.

The following information sets forth the principal occupation and employment during at least the past five years of each director nominee, positions and offices with us, specific skills, attributes and qualifications and certain other information. In addition, we have summarized for each director nominee why such director nominee has been chosen to serve on our Board of Directors.Board. No family relationship exists among any of the director nominees or executive officers.

Kevin C. Clark became President, Chief Executive Officer, and a director of the CompanyCompany’s Board on January 16, 2019. Prior to joining the Company, he served as Chairman and Chief Executive Officer of Talivity, Inc., a provider of staffing, marketing and technology services, from

8

2015 to 2018. Prior to that he served as Chairman and Chief Executive Officer of OGH, LLC, a healthcare staffing, technology and workforce solutions company, from 2002 to 2015, and as the Chairman and Chief Executive Officer of Pinnacor Inc. from 1999 to 2001, a provider of content and financial software application services. From 1996 to 1998, Mr. Clark served as Chairman and

6

Chief Executive Officer of Poppe Tyson, Inc,Inc., a global digital marketing agency, and from 1986 to 1994 he served as the Chairman and Chief Executive Officer of Cross Country, Inc., a healthcare staffing company, which he co-founded. Mr. Clark earned his Bachelor of Business Administration from Florida Atlantic University.

The Board has concluded that Mr. Clark should serve as a director due to his extensive executive level management skills, and experience building and leading healthcare staffing, workforce solutions, and other technology companies.

W. Larry Cash has been a director and a member of the Audit Committee member since October 2001 and a Compensation Committee member since May 2005. Mr. Cash has served as the Lead Director of the Board since 2019. Mr. Cash is Chairman of the Audit Committee. Mr. Cash retired as President of Financial Services, and Chief Financial Officer and a member of the board of directors of Community Health Systems, Inc. in May 2017 and currently serves as a consultant to Community Health Systems.Systems, Inc. He joined Community Health Systems, Inc. as Executive Vice President and Chief Financial Officer in September 1997. Prior to joining Community Health Systems, Inc., Mr. Cash served as Vice President and Group Chief Financial Officer of Columbia/HCA Healthcare Corporation from September 1996 to August 1997. Prior to Columbia/HCA Healthcare Corporation, Mr. Cash spent 23 years at Humana, Inc., most recently as Senior Vice President of Finance and Operations from 1993 to 1996. He has served as a member of the board of directors and the audit committee of AAC Holdings, Inc. (OTC: AACH), a provider of substance use treatment centers, from October 2017 through October 2019. He received his B.S. in Accounting from the University of Kentucky at Lexington. He has served as a member of the Board of Directors and the Audit Committee of AAC Holdings, Inc. since October 2017, a provider of substance use treatment centers.

The Board has concluded that Mr. Cash should serve as a director due to his extensive executive level management skills, corporate financial management, and operational experience. Additionally, Mr. Cash has a vast understanding of many aspects of the healthcare industry and brings solid expertise and proven leadership skills to the Board.

Thomas C. Dircks has been a director since July 1999 and was elected to serve as Chairman of the Board of Directors on August 2, 2013. Mr. Dircks is a Managing Director of Charterhouse Strategic Partners LLC, a provider of strategically focused investments in growth companies in the United States. Mr. Dircks was previously Managing Partner of Charterhouse Equity Partners (“CEP”) and was responsible for managing and overseeing the investment of Charterhouse’sCEP’s multi-billion dollars of North America focused institutional private equity funds. CharterhouseCEP was one of the earliest investors in private equity and raised funds and invested in middle market companies for over three decades. Prior to joining Charterhouse,CEP, he was employed by PricewaterhouseCoopers LLP as a Certified Public Accountant. Mr. Dircks currently serves as a member of the board of directors of Silvergate Capital Corporation (NYSE: SI), a Federal Reserve member bank and the leading provider of innovative financial infrastructure solutions and services for the growing digital currency industry. He holds a B.S. in Accounting and a Masters of Business Administration from Fordham University.

9

The Board has concluded that Mr. Dircks should serve as a director due to his extensive executive management, accounting, tax, mergers and acquisition, and strategic planning expertise. Additionally, Mr. Dircks’ risk management skills and financial acumen add an important dimension to our Board’s composition.

Gale Fitzgerald has been a director and member of the Audit Committee since May 2007, and since January 2014 has served as the Chairperson of the Governance and Nominating Committee. Ms. Fitzgerald is a retired principal of TranSpend, Inc., a consulting company. Before co-founding TranSpend, Inc. in 2003, she served as the President of QP Group, Inc. Prior to joining QP Group, Inc., she served as the Chairman and Chief Executive Officer of Computer Task Group, Inc. from 1994 to 2000. She joined Computer Task Group, Inc. in 1991 as Senior Vice President and was promoted to President and Chief Operating Officer in July 1993. Prior to joining Computer Task Group, Inc., she was Vice President, Professional Services at International Business Machines Corporation, which evolved into IBM Global Services. Ms. Fitzgerald worked at IBM for 18 years in various technical, marketing and management positions. She isMs. Fitzgerald was a member of the Boardboard of Directorsdirectors of Diebold Nixdorf, Inc. (NYSE: DBD) through April 2019. Ms. Fitzgerald has a B.A. in Government from Connecticut College and a Masters in Theology from Augustine Institute.

The Board has concluded that Ms. Fitzgerald should serve as a director because of her extensive executive leadership experience, management skills, and public board experience. Ms. Fitzgerald’s expertise in the areas of Information Technology, Staffing and Healthcare provides an invaluable resource to the Board with respect to corporate and strategic planning and assessing and managing risks.

Darrell S. Freeman, Sr. has been a director and Audit Committee member since August 2018.2018, and a Compensation Committee member since May 2020. He currently serves as the Executive Managing Director of Zycron, Inc., an information technology services and solutions firm he founded in 1991 and later sold to BG Staffing in 2017. Zycron, Inc. is now a division of BG Staffing, Inc. Zycron,

7

Inc. provides IT staffing, outsourcing and project management services primarily in the healthcare, energy, and government sectors. Mr. Freeman also co-founded Tennessee-based Reliant BankBancorp, Inc. (Nasdaq Stock Market LLC (“Nasdaq”): RBNC) (“Reliant Bank”) in 2006, and has served as a board member and a member of the audit and compensation committees of Commerce Union Bancshares, Inc., the holding company for Reliant Bank, since its inception. Additionally, in 2007 Mr. Freeman co-founded Pinnacle Construction Partners, a construction management firm, and has served as the chairman since 2007. Since 2016, Mr. Freeman has also served as the chairman of the board of directors of S3 Asset Management, a technology and medical equipment recycling company. He has also served on the board of directors and was the lead director of American Addiction Centers sinceInc. (OTC: AACH) from 2013 and is currently its lead director.through October 2019. Mr. Freeman holds a B.S. in Industrial Technology and a Master’s Degree in Industrial Studies, both from Middle Tennessee State University.

The Company’s Board of Directors believeshas concluded that Mr. Freeman is qualified to serve as a director as a result of his extensive staffing, outsourcing, technology and healthcare expertise, as well as his extensive background in business development.

Richard M. MastalerJanice E. Nevin, M.D., MPH has been a director and Audit Committee member since June 21, 2011. Mr. MastalerMay 2020. She has served on the Audit Committee and Governance and Nominating Committee since January 2014. In 2017, Mr. Mastaler retired as the ChairmanPresident and Chief Executive Officer of ManagedChristianaCare Health Ventures, Inc.,System, the largest health system in Delaware, since November 2014. Dr. Nevin received an A.B. 

10

in History and Science from Harvard University and a managed care consulting firm, which he founded in 2002. He previously held the positionDoctor of Chief Executive Officer with CCN Managed Care, Inc., Preferred Health Networks, QualMed, Inc., Unilab Corporation, and three Humana hospitals. Mr. Mastaler was a founder and Vice President with HumanaMedicine from Sidney Kimmel Medical Plan. He also is a Fellow of the American College of Healthcare Executives. Mr. Mastaler holds a B.S. degree in Business Administration from Florida Stateat Thomas Jefferson University, and a Masters of Public Health from University of Pittsburgh. In 2017, Dr. Nevin was inducted into the Delaware Women’s Hall of Fame and was recognized among 100 Great Healthcare Leaders to Know in Healthcare Administration2017 by Becker’s Hospital Review. For her commitment to the community, she received Delaware’s Grassroots Champion Award from George Washington University.the American Hospital Association and the David G. Menser Award from the Wilmington Senior Center, both in 2017. She was named the 2016 Woman of Distinction by the Girl Scouts of the Chesapeake Bay.

The Board has concluded that Mr. MastalerDr. Nevin should serve as a director becausedue to her extensive knowledge of his extensive healthcare and management experience. Mr. Mastaler’s experience in the healthcare industry provides an excellent resource toand her expertise in leading the Board for strategic planning, marketing,operations of a large health care system with first-hand knowledge of healthcare staffing, as well as her physician experience, and leadership purposes.innovative leadership.

Mark Perlberg, JD has been a director and Compensation Committee member since May 12, 2015.2015, and has served on the Governance and Nominating Committee since May 2020. He is currently serving as a Managing Director with Nautic Partners, LLC, a private equity firm. Prior to that he was the President and Chief Executive Officer of Oasis Outsourcing [Holdings Inc.] (“Oasis Outsourcing”), one of the nation’s leading Professional Employer Organizations. He has served in that capacity sinceOrganizations from October 2003.2003 to March 2020. Prior to joining Oasis Outsourcing, Mr. Perlberg held a series of executive positions with Profit Recovery Group Inc., the John H. Harland Group,Company, and The Western Union.Union Company (“Western Union”). Prior to joining Western Union, he practiced law in New Jersey. Mr. Perlberg received his B.A. degree in History from the University of Rochester and his Juris Doctor degree from Boston College Law School.

The Board has concluded that Mr. Perlberg should serve as a director due to his extensive executive management and leadership experience in growing companies both organically and through acquisitions. Mr. Perlberg’s success during his career in overseeing the delivery of alternative workforce solutions provides a unique perspective to the Company.

Joseph A. Trunfio, Ph.D. has been a director since October 2001. He has served on the Governance and Nominating Committee since May 2006 and was appointed to the Compensation Committee as its Chairman, effective January 1, 2014. He served as President and Chief Executive Officer of Atlantic Health System Inc., a not-for-profit hospital group, from March 1999 until his retirement in May 2015, where he was a member of the Boardboard of Trustees.trustees. From July 1997 to February 1999, Mr. Trunfio served as President and Chief Executive Officer of Via Caritas Health System, a not-for-profit hospital group. Prior to his position with Via Caritas Health System, he served as President and Chief Executive Officer of SSM Healthcare Ministry Corp., a not-for-profit hospital group. Mr. Trunfio received his B.A. from St. John’s University (N.Y.) and holds a Ph.D. in Clinical Psychology from the University of Miami.

The Board has concluded that Mr. Trunfio should serve as a director due to his extensive executive management and leadership experience. Mr. Trunfio brings to the Board a depth of understanding of the delivery of healthcare delivery system in the United States, our business and the various challenges we face in the evolving healthcare industry.

11

Executive Officers 

The following table sets forth certain information with respect to our current executive officers other than Mr. Clark, whose information is set forth above:

NameAgePosition
Daniele Addis, MBA61SVP, Business Services
Susan E. Ball, JD, MBA, RN57EVP, Chief Administrative Officer, General Counsel and Secretary
William J. Burns, MBA, CPA51EVP, Chief Financial Officer and Principal Accounting Officer
William G. Halnon62Chief Information Officer
John A. Martins53Group President, Nurse and Allied
Colin P. McDonald, MS53SVP, Human Resources
Karen Mote56Division President, Cross Country Locums
Stephen A. Saville, JD54Group President, Locums, Education and Corporate Development
Buffy S. White47Group President, Workforce Solutions

Daniele Addis has served as Senior Vice President, Business Services since January 29, 2014. From September 2011 to January 2014, Ms. Addis was Senior Vice President, Shared Services of Randstad Professionals, a staffing company. Prior to that, she was Vice President, Shared Services and held various other positions at SFN Group, Inc. From January 1998 to January 2006, Ms. Addis was Senior Finance Manager of Office Depot, Inc. Ms. Addis holds a Bachelor in Business from Ecole Superieure de Commerce, Nantes, France, a Master of Arts in Economics from George Mason University and a Master of Business Administration from Jacksonville University.

Susan E. Ball has served as an Executive Vice President of the Company since January 1, 2017, as Chief Administrative Officer since February 22, 2021, as General Counsel since May 2004 and Secretary since March 2010. Prior to that, Ms. Ball served as our Corporate Counsel from March 2002 to May 2004. Before joining us, Ms. Ball practiced law at Gunster, Yoakley & Stewart, P.A. from November 1998 to March 2002 and at Skadden, Arps, Slate, Meagher and Flom from 1996 to November 1998. Prior to practicing law, Ms. Ball was a registered nurse. Ms. Ball received her Bachelor of Science degree in Nursing from The Ohio State University, her Juris Doctor degree from New York Law School, and her Masters of Business Administration from Florida Atlantic University.

William J. Burns served as Chief Operating Officer from January 25, 2018 through January 31, 2019 at which time he became Chief Financial Officer and Principal Accounting Officer. He also served as Chief Financial Officer, effective from April 1, 2014, and Principal Accounting Officer, from December 1, 2014 in each case through January 24, 2018. He has served as an Executive Vice President of the Company since January 1, 2017. Prior to joining the Company, Mr. Burns served as Group Vice President and Corporate Controller for Gartner, Inc., a technology research and advisory firm, since 2008. From 2006 until 2008, Mr. Burns was the Chief Accounting Officer for CA Technologies, Inc. Mr. Burns earned his Bachelor of Arts in Accounting and Information Systems from Queens College and a Masters of Business Administration from New York University’s Stern School of Business. Mr. Burns is a Certified Public Accountant.

12

William G. Halnon has served as Chief Information Officer since February 2017. Prior to joining the Company, from February 2016 to February 2017, Mr. Halnon served as President of Albedon Digital, Inc. From January 2007 to February 2016, Mr. Halnon served as Senior Vice President and Chief Information Officer of Republic Services, Inc. and, from January 2005 to January 2007, he served as Senior Vice President and Chief Information Officer of Spherion, Inc. Mr. Halnon holds a Bachelor of Arts in Accounting from Langston University.

John A. Martins has served as Group President, Nurse and Allied since February 2021. Prior to joining Cross Country, Mr. Martins served as the SVP of Operations Strategy for Aya Healthcare, Inc. from November 2017 to January 2020. He also served as SVP, General Manager of AMN Healthcare Services, Inc. from January 2015 to October 2017, and as President, Onward Healthcare and in various other positions from February 2008 to January 2015. Mr. Martins earned a Bachelor of Science from William Peterson University.

Colin P. McDonald was appointed Senior Vice President, Human Resources in March 2020. Prior to that, he served as Vice President, Human Resources & Labor Relations from December 2014. Prior to joining the Company Mr. McDonald held various human resource positions at Carnival Cruise Lines, RandCol Staffing and Citrix. Mr. McDonald earned his Bachelor of Arts at State University of New York at New Paltz and his Master of Science degree in Organizational Leadership at Mercy College.

Karen Mote has served as Division President, Cross Country Locums since May 2020. Prior to that, she was President of Medical Doctor Associates (MDA) since February 2019. From March 2015 to February 2019, she served as the Vice President of MDA’s Advanced Practices, after being promoted from Director where she served from 2008 to March 2015. Prior to that, she served as the Manager of Allied Health Group, also a division of MDA from 2000 to her promotion in 2008. Ms. Mote began her career with Medical Doctor Associates in July 1998 in the Physician Permanent Placement Division. Ms. Mote earned a Clinical Laboratory Degree of Applied Science from North Georgia Technical College.

Stephen A. Saville has served as Group President, Locums, Education and Corporate Development since February 2021. Prior to that, he was Executive Vice President of Operations since April 2019. Prior to joining Cross Country Healthcare, he was President, CareerStaff Unlimited - A Genesis HealthCare Company from March 2016 through April 2019, Senior Vice President, Workforce Solutions at Genesis from July 2017 through March 2019, Executive Vice President, OGH, LLC from January 2014 through March 2016, and Chief Executive Officer of Medefis, Inc. from September 2010 through January 2015. Mr. Saville earned his Bachelor of Science and Bachelor of Administration from Cabrini University and his Juris Doctor degree from Widener University School of Law.

Buffy S. White was appointed Group President, Workforce Solutions in February 2021. She had previously served as President, Workforce Solutions since January 2019. Prior to that, she served as President, Travel Nurse and Allied since January 2018. She served as Senior Vice President, Recruiting Strategy and Operations since September 30, 2016. Before joining Cross Country Healthcare, Inc., Ms. White served as Executive Vice President, Global Services and Solutions Consulting, of Pontoon (a division of Adecco) from June 2015 to November 2015.

13

Affirmative Determinations Regarding Director IndependenceTable of Contents

Ms. White served in various capacities at Pontoon and Other MattersAdecco since 2006 and, prior to that, in various roles at SFN Group, Inc. from August 2001 to July 2006. Ms. White studied international business at IMD Business School and innovation and leadership at Millsaps College.

PROPOSAL NO. 1
ELECTION OF DIRECTORS

The Board of Directors observes all criteria for independence establishedcurrently consists of eight members. All of the directors currently serving on the Board have been nominated by the Nasdaq Stock Market, or NASDAQ, under its applicable Listing Rules. As such, the Board of Directors has determined each of the following directors and nominees to be an “independent director” under the meaning of Rule 5605(a) (2) of the Nasdaq Listing Rules:

W. Larry Cash
Thomas C. Dircks
Gale Fitzgerald
Darrell S. Freeman, Sr.
Richard M. Mastaler
Mark Perlberg
Joseph A. Trunfio, PhD

The Board of Directors has also determined that each member of the Audit, Compensation and Governance and Nominating Committees meets the applicable independence requirements set forth by NASDAQ, the Commission and the Internal Revenue Service. The Board of Directors has further determined that W. Larry Cash, a member and Chairman of the Audit Committee is an “audit committee financial expert” as defined in the rules promulgated by the Commission and, as such, Mr. Cash satisfies the requirements of Rule 5605(c)(2) of the Nasdaq Listing Rules.

Board Committees and Meetings

Meetings of the Board of Directors. During the year ended December 31, 2018, there were 12 meetings of the Board of Directors. Each director who served in such capacity during the year ended December 31, 2018 attended 100% of the aggregate number of meetings of the Board of Directors during the period in which he or she served as a director, and 100% of the committee or committees thereof on which he or she served. Other than Mr. Freeman and Mr. Clark, all of the directors nominatedto stand for election to the Board were members of the Board for the entire 2018 year. It is the practice of the Board of Directors to have the independent directors meet in an executive sessionre-election at each meeting of the Board. It is also our practice that all directors should attend the Annual Meeting of Stockholders.Stockholders for one-year terms. The Board unanimously approved these nominations. Each nominee elected will hold office until the Annual Meeting of Stockholders to be held in 2022 and until a successor has been duly elected and qualified unless, prior to such meeting a director shall resign, or his or her directorship shall become vacant due to his or her death, resignation or removal. All nominees were elected at the Annual Meeting of Stockholders held in 2020. Mr. Richard M. Mastaler retired from the Board in May 2020.

Each nominee has agreed to serve, if elected, and management has no reason to believe that he or she will be unavailable to serve. If any of the directorsnominees should be unavailable for election, the proxies will be voted for the election of such other person as may be recommended by the Board in place of such nominee. Shares properly voted will be voted FOR the nominees unless the stockholder indicates on the proxy that authority to vote the shares is withheld for one or more or for all of the nominees listed. A proxy cannot be voted for a greater number of persons than the eight nominees named below. Directors are elected by a majority of the votes cast in an uncontested election. Votes withheld, abstentions and broker non-votes will not have any effect on the outcome of voting with respect to the election of directors. The following eight individuals have been nominated for election at the time attendedAnnual Meeting of Stockholders for a one-year term ending upon the 20182022 Annual Meeting.Meeting of Stockholders:

NameAgePosition
Kevin C. Clark60President, Chief Executive Officer and Director
W. Larry Cash72Chairman of the Audit Committee and Lead Director
Thomas C. Dircks63Chairman of the Board and Director
Gale Fitzgerald70Chairperson of the Governance and Nominating Committee and Director
Darrell S. Freeman, Sr.56Director
Janice E. Nevin, M.D., MPH60Director
Mark Perlberg, JD65Director
Joseph A. Trunfio, Ph.D.74Chairman of Compensation Committee and Director

For information as to the shares of the Common Stock held by our director nominees, see “Security Ownership of Certain Beneficial Owners and Management” below and for a biographical summary of our director nominees, see “Directors and Executive Officers” above. There are no arrangements or understandings between the nominee, directors, or executive officers and any other person pursuant to which our nominee, directors, or executive officers have been selected for their respective positions.

14

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE
DIRECTOR NOMINEES TO SERVE ON THE BOARD OF DIRECTORS FOR A
ONE-YEAR TERM.
(PROPOSAL NO. 1 ON YOUR PROXY CARD)

CORPORATE GOVERNANCE
AND THE BOARD OF DIRECTORS

Governance Guidelines and Code of Conduct and Business Ethics Policy 

The Board and management are dedicated to effective corporate governance. The Company’s Governance Guidelines provide a framework for the Company’s governance. The Board also has adopted the Code of Conduct and Business Ethics Policy, which applies to all of our employees, including executive officers, and our directors. The Governance Guidelines and Code of Conduct and Business Ethics Policy are each available on our website at www.crosscountryhealthcare.com by choosing the “Investors” link, clicking on the “Corporate Governance” section, and selecting the respective document under “View.” Copies of these materials are available, in print at no charge, upon request to our Corporate Secretary at 6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487. We will disclose any changes in, or waivers from, our Code of Conduct and Business Ethics Policy by posting such information on the same website or by filing a Form 8-K, in each case if such disclosure is required by the rules of the SEC or Nasdaq.

Board Leadership Structure and Role in Risk Oversight.

Our Company is led by Mr. Kevin C. Clark, who has served as our President and Chief Executive Officer since January 16, 2019. Our Board of Directors is currently comprised of Mr. Clark, our President and Chief Executive Officer, and seven independent directors. Mr. Dircks has served as the Chairman of the Board since 2013.2013, and Mr. Cash has served as the Lead Director of the Board since 2019.

The Board has determined that our current board leadership structure is appropriate and helps to ensure proper risk oversight for us for a number of reasons, the most significant of which are as follows:

our Chief Executive Officer is the individual selected by the Board to manage us on a day-to-day basis and his direct involvement in our operations makes him best positioned to consult with our Board to create appropriate agendas for Board meetings and determine the time allocated to each agenda item in discussions of our short- and long-term objectives, as well as lead productive strategic planning sessions with the Board;

members of the Board are kept informed of our business by various documents sent to them before each meeting and as otherwise requested, as well as through oral reports made to them during these meetings by our Chief Executive Officer, Chief Financial Officer and other senior executives;

15

our Board structure provides strong oversight by independent directors, in particular because non-management directors meet separately, the Board is advised of all actions taken by the various committees of the Board, they have full access to all of our books, records and reports;

members of the Board have direct access to the management team and those individuals are available at all times to answer questions from Board members;

our Board has extensive management experience in business and, in particular, the healthcare industry in which we operate; and

the continuity and tenure of our Board provides a valuable source of institutional knowledge.

Board Independence 

Our securities are listed on Nasdaq and, as set forth in our Governance Guidelines, we use the standards of “independence” prescribed by Nasdaq requirements. Under Nasdaq rules, a majority of a listed company’s board of directors must be comprised of independent directors. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed company’s audit committee and compensation committee be independent and satisfy additional independence criteria set forth in Rules 10A-3 and 10C-1, respectively, under the Exchange Act. Under Nasdaq rules, a director will only qualify as an “independent director” if, in the opinion of that company’s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Annually, each member of the Board is required to complete a questionnaire designed in part to provide information to assist the Board in determining if the director is independent under the Nasdaq rules. Based upon information requested from and provided by each director concerning their background, employment, and affiliations, including family relationships, our Board has determined, upon the recommendation of our Governance and Nominating Committee, that the following directors are independent and have no material relationship with the Company:

W. Larry Cash

Thomas C. Dircks

Gale Fitzgerald

Darrell S. Freeman, Sr.

Janice E. Nevin, M.D., MPH

Mark Perlberg, JD

Joseph A. Trunfio, Ph.D.

The Board has also determined that each of the current members of our Audit Committee and our Compensation Committee satisfies the independence standards for such committee established by Rules 10A-3 and 10C-1 under the Exchange Act, the SEC rules, and the Nasdaq rules, as applicable, and that the current members of the Governance and Nominating Committee are also independent.

16

Board Skills, Tenure, and Diversity 

Our directors bring to our Board a wide variety of skills, qualifications, and viewpoints that strengthen the Board’s ability to carry out its oversight role on behalf of our stockholders. The table below is a summary of the range of skills and experiences that each director brings to the Board, each of which we find to be relevant to our business. Because it is a summary, it does not include all of the skills, experiences, and qualifications that each director offers, and the fact that a particular experience, skill, or qualification is not listed does not mean that a director does not possess it. All of our directors exhibit high integrity, an appreciation for diversity of background and thought, innovative thinking, a proven record of success, and deep knowledge of corporate governance requirements and best practices.

ATTRIBUTES, EXPERTISE & SKILLS 

Kevin C. ClarkW. Larry CashThomas C. DircksGale FitzgeraldDarrell S. Freeman, Sr.Janice E. Nevin, M.D., MPHMark Perlberg, JDJoseph A. Trunfio, Ph.D.
Leadership Experience
Financial Literacy
Audit Committee Financial Expert
Relevant Industry Experience
Human Capital Management Experience
Risk Management Expertise

As discussed below, while we do not have a formal policy on diversity, we are committed to comprising our Board with well-rounded individuals possessing a diversity of complementary skills, core-competencies and expertise, including diversity with respect to age, gender, national origin and race, for the optimal functioning of the Board. Additionally, the Board does not believe that arbitrary term limits on directors’ service are appropriate, nor does it believe in a mandatory retirement age. Directors who have served on the Board for an extended period of time are able to provide valuable insight into the operations and future of the Company based on their experience with and understanding of the Company’s history, policies, and objectives. The Board

17

self-evaluation process described below will be an important determinant for Board tenure. Below provides a snapshot of certain characteristics of our current Board.

18

Evaluation of Director Nominees 

Our Board is responsible for selecting its own members. The Board delegates the selection and nomination process to the Governance and Nominating Committee, with the expectation that other members of the Board, and of management, will be requested to take part in the process as appropriate. The Governance and Nominating Committee makes recommendations to the Board regarding the size and composition of the Board. The Governance and Nominating Committee is responsible for ensuring that the composition of the Board accurately reflects the needs of the Company’s business and, in furtherance of this goal, for proposing the addition of members and the necessary resignation of members for purposes of obtaining the appropriate members and skills. The Governance and Nominating recommends, and the Board nominates, candidates to stand for election as directors.

Director Candidates. In selecting qualified individuals to serve on our Board, among other attributes, we look for those individuals who possess characteristics that include integrity, business experience, financial acumen and leadership abilities, familiarity with our business and businesses similar or analogous to ours, and the extent to which a candidate’s knowledge, skills, background and experience are already represented by other members of our Board. While we do not have a formal policy on diversity, in composing a well-rounded Board, we look for those individuals possessing a diversity of complementary skills, core-competencies and expertise, including diversity with respect to age, gender, national origin and race, for the optimal functioning of the Board and with a view toward constituting a Board with the appropriate skills and experience necessary to oversee our business.

The Board’s current policy with regard to the consideration of director candidates recommended by stockholders is that the Governance and Nominating Committee will review and consider any director candidates who have been recommended by stockholders in compliance with the procedures established from time to time by the Board (the current procedures are described below), and conduct inquiries as it deems appropriate. Any candidates for the position of director recommended by stockholders or others would be evaluated by the Governance and Nominating Committee in the same manner as candidates from other sources. The Governance and Nominating Committee will consider for nomination any such proposed director candidate who is deemed qualified by the Governance and Nominating Committee in light of the minimum qualifications and other criteria for Board membership approved by the Board from time to time. To date, we have not received any recommendation from stockholders requesting that the Governance and Nominating Committee consider a candidate for inclusion among the Governance and Nominating Committee’s slate of nominees in our Proxy Statement.

In considering director nominees, the Governance and Nominating Committee will consider the following:

the needs of the Company with respect to particular areas of specialized knowledge;

the relevant business experience of the nominee including, but not limited to, extensive experience in healthcare, staffing, IT, business, finance, or accounting;

the personal and professional integrity of the nominee;

the nominee’s ability to commit the resources necessary to be an effective director of a public company, including the nominee’s ability to attend meetings; and

the overall balance and diversity of the Board.

19

Other than the foregoing, there are no stated minimum criteria for nominees, although the Governance and Nominating Committee may also consider other facts as it may deem are in the best interests of the Company and its stockholders.

All stockholder recommendations for director candidates must be submitted to our legal department at 6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida, 33487, which will forward all recommendations to the Governance and Nominating Committee.

There have been no changes to the procedures by which stockholders may recommend nominees to our Board since our last disclosure of such procedures, which appeared in the definitive proxy statement for our 2020 Annual Meeting of Stockholders.

Committees of the Board 

Our Board has three standing committees: Audit, Compensation and Governance and Nominating Committees. Each of ourthese committees is comprised solely of independent directors within the meaning of Rule 5605(a)(2) of the Nasdaq Listing Rules. Each committee operates pursuant to a committee charter. The charters of each of the Audit, Compensation and Governance and Nominating Committees are comprised entirelyavailable on our website at www.crosscountryhealthcare.com by choosing the “Investors” link, clicking on the “Corporate Governance” section, and selecting the respective charter under “View.”

The following chart provides a summary of the committees’ duties, responsibilities and composition.

CommitteeResponsibilities and DutiesMembersMeetings
in 2020
Audit Committee

●     The Audit Committee is the principal agent of the Board in overseeing (i) the quality and integrity of our financial statements, (ii) legal and regulatory compliance, (iii) the independence, qualifications, and performance of our independent registered public accounting firm, (iv) the performance of our internal auditors and (v) the integrity of management and the quality and adequacy of disclosures to stockholders.

●     The Audit Committee is directly responsible for hiring and terminating our independent registered public accounting firm and pre-approving all auditing, as well as any audit-related, tax advisory and any other non-auditing services to be performed by the independent registered public accounting firm.

●     In carrying out its duties and responsibilities, the Audit Committee shall have the authority to engage outside legal, compliance, accounting and other advisers and seek any information it requires from employees, officers and directors. 

Cash*♦ 

Freeman♦ 

Fitzgerald♦ 

Nevin♦

8

20

CommitteeResponsibilities and DutiesMembersMeetings
in 2020
●     The Audit Committee may form and delegate authority to subcommittees consisting of one or more of its members as the Audit Committee deems appropriate to carry out its responsibilities and exercise its powers, subject to such reporting to or ratification by the Audit Committee as the Audit Committee shall direct.
Compensation
Committee
●     The role of the Compensation Committee includes (i) reviewing and approving corporate goals and objectives relevant to Chief Executive Officer (“CEO”) compensation; (ii) evaluate the CEO’s performance in light of the goals and objectives, and determine and approve the CEO’s compensation level based on this evaluation; (iii) make recommendations to the Board with respect to compensation, incentive compensation plans and equity-based plans for all executive officers of the Company, and develop guidelines and review compensation and overall performance of all executive officers of the Company; and (iv) produce a Compensation Committee report on executive compensation as required by the SEC to be included in the Company’s annual proxy statement or Annual Report on Form 10-K filed with the SEC; and (v) evaluate on an annual basis the performance of the Compensation Committee in accordance with applicable rules and regulations.

Trunfio† 

Cash 

Freeman 

Perlberg

5

●     Under its charter, the Compensation Committee has the authority and may, in its sole discretion, obtain advice and seek assistance from internal and external legal, accounting and other consultants. The Compensation Committee has the sole authority to select or receive advice from, and terminate a compensation consultant or other advisor to the Compensation Committee (other than in-house legal counsel) to assist in the evaluation of the compensation of our CEO, executive officers and directors, including sole authority to approve such firm’s fees and other retention terms, and we provide appropriate funding as determined by the Compensation Committee. In selecting advisers, the Compensation Committee will take into consideration certain independence factors.

●     The Compensation Committee may establish one or more subcommittees consisting of one or more members of the Board to focus on specific aspects of its duties and responsibilities and may delegate any of its responsibilities to any such subcommittee if it so chooses, provided that the subcommittee decisions are presented to the full Compensation Committee for ratification at its next scheduled meeting.

21

CommitteeResponsibilities and DutiesMembersMeetings
in 2020
●    The Compensation Committee shall be directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel and other adviser retained by the Compensation Committee, and the Company must provide appropriate funding, as determined by the Compensation Committee, for the payment of reasonable compensation to any compensation consultant retained by the Compensation Committee.
Governance
and  Nominating
 Committee

●     The role of the Governance and Nominating Committee is to: (i) develop and recommend to the Board of Directors a set of corporate governance principles and review them at least annually; (ii) determine the qualifications for board membership and recommend nominees to the stockholders; and (iii) ensure a robust and effective performance evaluation process is in place for the Board, the CEO, and senior management, as well as an effective succession planning process for these positions.

●     The Committee shall have the sole authority to retain and terminate any search firm to be used to identify director candidates and shall have the authority to approve the search firm’s fees and other retention terms.

●     The Committee may form and delegate authority to subcommittees consisting of one or more of its members, other Board members and officers of the Company as the Committee deems appropriate and permitted under applicable rules and regulations in order to carry out its responsibilities. 

Fitzgerald

Perlberg

Trunfio

4
Committee Chair

*Audit Committee Financial Expert, as defined in the applicable SEC regulations

Possesses requisite financial sophistication required by Nasdaq Rule 5605(c)(2)(A)

Board and Committee Meetings 

During the fiscal year ended December 31, 2020 (“Fiscal 2020”), there were eleven meetings of the Board, including one strategy meeting. For Fiscal 2020, each director attended more than 75% of the aggregate of (i) the total number of meetings of the Board and (ii) the total number of meetings held by all committees on which he or she served (for the period that such director served on the Board and/or committee during 2020). All of the directors attended 100% of the meetings of the Board during the period in which he or she served as a director, and at least 96% of the committee or committees thereof on which he or she served. All of the directors nominated for election to the Board were members of the Board for the entirety of Fiscal 2020, with the exception of Dr. Nevin, who became a director in May 2020. It is the practice of the Board to have the independent directors. directors meet in an executive session at each meeting of the Board. While we do not have a formal policy, it is also our practice that all directors should attend the Annual Meeting of Stockholders. All of the directors, with the exception of Dr. Nevin, who was not a director at that time, virtually attended the 2020 Annual Meeting of Stockholders. 

22

Risk Oversight 

While risk management is primarily the responsibility of our management team, the Board is responsible for the overall supervision of our risk management activities which occurs at both the full Board level and at the committee level. Our Audit Committee also has the responsibility to, among other things, review with management, the Company’s policies regarding major financial risk exposures and the steps management has taken to monitor and control such exposures. The Audit Committee also reviews with management, the policies governing the process by which risk assessment and risk management are undertaken and has oversight for the effectiveness of management’s enterprise risk management process that monitors key business risks facing us. In addition to our Audit Committee, the other committees of the Board consider the risks within their areas of responsibility. For example, the Compensation Committee assesses risk that could result from the structure and design of our executive compensation programs, our incentive compensation plans, director compensation, perquisites and compliance with the Sarbanes-Oxley Act of 2002 regarding prohibitions on loans to executive officers and directors. TheIn addition, the Governance and Nominating Committee evaluates risks with respect to, among other things, corporate governance matters and the background and suitability of director nominees. Additionally, the Board of Directors continually evaluates our risks related to liquidity, operations, credit, regulatory compliance and fiduciary risks, and the processes in place to monitor and control such exposures. Management also provides regular updates throughout the year to the respective committees regarding management of the risks they oversee, and each of these committees report their findings to the full Board, including any areas of risk that require Board attention. Additionally, the full Board reviews our short- and long-term strategies, including consideration of risks facing us and their potential impact.

Human Capital Management 

Our ability to be successful in our marketplace directly depends on attracting and retaining talented and skilled employees, and keeping those individuals fully engaged in our business. Human Capital Management is both a Board and management issue, and we employ a comprehensive approach to this matter.

From hiring, career development and compensation to safety and wellness, we are invested in creating programs and resources that enhance our workplace environment, our employee experience and retain and engage our talent. Our initiatives include:

Diversity, Equality and Inclusion: We are committed to maintaining a diverse workplace that respects everyone’s race, gender, sexual orientation, and physical abilities, as well

23

as diversity of thought. Our diverse workforce is the cornerstone of our business, as we believe varying perspectives and backgrounds are the only means of solving complex and challenging business and social issues. As of December 31, 2020, our corporate workforce was comprised of 75% women and 25% men. Our total corporate workforce is 63% white and 37% non-white. 

Health and Wellness: We are committed to the physical and mental health and well-being of our employees. Among other things, we provide free biometric healthcare screenings, a 24/7 hotline for healthcare workers who are experiencing emotional stress, and incentives to employees who achieve specific fitness goals in our corporate cycling program. Our wellness activity calendar features monthly events and educational sessions to help employees reach and maintain their health and wellness goals.
Talent Development: Our mission regarding talent management and development is to support organizational results and success by employing strategies to attract, engage, develop, and retain employees, and to partner with our leaders to nurture and grow leadership talent. These investments include providing clear insight into employee performance, creating career paths, promoting from within whenever possible, maintaining open communication, and offering professional development opportunities.
Compensation and Benefits: We are committed to rewarding, supporting, and developing the associates who make it possible to deliver on our strategy. To that end, we offer a comprehensive total rewards program aimed at the varying health, home-life, and financial needs of our diverse associates. Our total rewards package includes market-competitive pay, healthcare benefits, retirement savings plans, paid time off and family leave, various discount programs, and tuition assistance.
Community and Social Impact: We participate in numerous events with a variety of non-profit organizations. Our mission to deliver quality patient care extends to our community and we are committed to action that fosters positive impact in our community and around the U.S. Our human resources department develops and implements programs to help our employees realize their potential through volunteering and supporting our communities. Employees are able to donate to a charity of their choice directly from their paychecks, either as a one-time donation or ongoing. We have also launched an employee-led council which encourages employees from a wide variety of backgrounds and of diversity to come together, connect, build relationships, and have their voices heard.

We have a long-standing commitment to our employees to create a business working environment that fosters engagement through personal innovation, achievement, wellness, advancement and training/development opportunities, promoting health and safety, and investments in their communities. These efforts culminate in creating a business culture of achievement and loyalty that enables us to minimize turnover in our workforce and succeed in competitive and challenging marketplaces.

Corporate Responsibility

People, Planet and Practices are the broad themes to our approach towards Corporate Responsibility. Our Corporate Responsibility program is designed to solicit engagement with, and involvement of, our key stakeholders – employees and stockholders (including face-to-face meetings and discussions with investors). Our Corporate Responsibility program’s priority areas are

24

The

informed by these engagements, reports from ESG rating agencies and the practices of our industry peers. In 2020, we continued to expand our environmental, social and governance initiatives. With a 35-year history, we are proud of our commitment to diversity, equality and inclusion, and in 2020 75% of our corporate team members were women and 37% from historically underrepresented groups. In addition, we added another woman to our Board of Directors, has determined thatDr. Janice Nevin, President and CEO of ChristianaCare Health System. During the year, we continued to invest in social initiatives, including sponsorship of nursing scholarships at Florida Atlantic University, and we were the presenting sponsor of the Leukemia and Lymphoma Society Light the Night walk. Our culture and commitment to improve the environment and support our currentcommunities is reflective of our value-based culture and is in direct alignment with our business strategy to deliver profitable growth.

Stockholder Engagement

We take pride in our engagement with our stockholders and welcome their insights and feedback, taking stockholders’ points of view into account when developing our governance practices. The Board firmly believes the mutual trust we build with our stockholders is one of the key components of good governance and is a key element of driving board leadership structure is appropriateresponsibility and helpsa strong governance culture. We initiated a formal stockholder corporate governance outreach program to ensure proper risk oversightsupplement our financial-related program and gain feedback from our stockholders. In 2020, discussions resulting from our corporate governance outreach program focused on social and governance issues, diversity, equality and inclusion and board refreshment.

25

DIRECTOR COMPENSATION

In Fiscal 2020, our independent directors were awarded fees based on the schedule set forth below. Beginning in May 2020, the fees were paid on a quarterly basis. However, in May 2020, the Board voluntarily elected to take a 10% reduction in cash compensation in response to the COVID-19 pandemic. The fees in the schedule below resumed on a quarterly basis in October 2020 as the Company’s financial performance continued to stabilize and improve.

Board Cash Retainer$70,000
Chairman of Board Service$85,000
Audit Committee Chair Service$25,000
Compensation Committee Chair Service$15,000
Governance and Nominating Committee Chair Service$10,000
Lead Director Service$25,000

No payments were made for usnon-chair committee member services in Fiscal 2020. Directors who are not independent directors do not receive any compensation for their services as directors.

Equity Compensation 

During Fiscal 2020, Messrs. Cash, Dircks, Freeman, Perlberg, Trunfio and Ms. Fitzgerald and Ms. Nevin also received a grant of restricted shares of Common Stock on June 1, 2020, under the Company’s Cross Country Healthcare, Inc. 2020 Omnibus Incentive Plan (the “2020 Omnibus Incentive Plan”). Each such grant consisted of a number of reasons,shares of restricted Common Stock equal to approximately $110,000, based on the most significantclosing price of which are as follows:

our Chief Executive Officer isCommon Stock on the individual selected bydate of grant.

In November 2019, the Board ofCompensation Committee modified the vesting period for restricted shares granted to Directors to manage us on a day-to-day basis and his direct involvement in our operations makes him best positionedone year to consult with our Board to create appropriate agendas for Board meetings and determine the time allocated to each agenda item in discussions of our short- and long-term objectives, as well as lead productive strategic planning sessionsalign with the Board;

membersCompany’s annual board term and typical market practice. Restricted shares granted prior to November 2019 vest in three equal installments on the first, second and third anniversaries of the grant date; restricted shares granted to independent directors after November 2019 will vest on the first anniversary of such grant date.

Travel Reimbursement 

All independent directors are reimbursed for the reasonable travel expenses they incur in attending meetings of the Board or Board committees.

Stock Ownership Requirement 

Directors are kept informedrequired to hold an amount of the Company’s common stock equal to two times the annual cash retainer of $70,000, which amount may be accumulated over five years. As of December 31, 2020, all directors have achieved this threshold.

26

2020 DIRECTOR COMPENSATION TABLE

The following table provides compensation information for our directors for Fiscal 2020 except for Mr. Clark, our President and Chief Executive Officer. Compensation earned by Mr. Clark for Fiscal 2020 is included in the Summary Compensation Table on page 51 of this proxy statement.

Name Fees Earned
or Paid in
Cash ($)(1)
 Stock
Awards
($)(2)(3)(4)
 Total ($)
W. Larry Cash 84,000 110,000 194,000
Thomas C. Dircks 108,500 110,000 218,500
Gale Fitzgerald 56,000 110,000 166,000
Darrell S. Freeman, Sr. 49,000 110,000 159,000
Janice E. Nevin, M.D., MPH 49,000 110,000 159,000
Mark Perlberg, JD 49,000 110,000 159,000
Joseph A. Trunfio, Ph.D. 59,500 110,000 169,500

(1)On March 23, 2020, fees became payable on a quarterly basis. Thereafter, the Board of Directors unanimously agreed to reduce their quarterly cash compensation payments by 10% in response to the COVID-19 pandemic. Normal quarterly payments resumed in October 2020 as the Company’s financial performance continued to stabilize and improve.

(2)Amounts in this column reflect the aggregate grant date fair value of awards of restricted stock granted under our 2020 Omnibus Incentive Plan and computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 718, Compensation-Stock Compensation (ASC Topic 718). The assumptions used in determining the amounts in this column are set forth in Note 15 to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on February 25, 2021. The aggregate grant date fair value per share of restricted stock granted on June 1, 2020 was $6.14. The restricted stock granted on June 1, 2020 will vest on the first anniversary of their grant date. Based on a grant date fair value of approximately $110,000, the actual number of shares of restricted stock granted to each director was 17,916 shares.

(3)Aggregate restricted shares outstanding as of December 31, 2020 for each director were as follows: W. Larry Cash: 31,236; Thomas C. Dircks: 31,236; Gale Fitzgerald: 31,236; Darrell S. Freeman, Sr.: 30,805; Janice E. Nevin: 17,916; Mark Perlberg: 31,236; and Joseph A. Trunfio: 31,236.

(4)In November 2019, the Governance and Nominating Committee modified its Guidelines to provide for accelerated vesting of stock grants to an independent director upon retirement so long as the director was at least 70 years old or has served on the Board for 7 years.

27

SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information, as of March 18, 2021, regarding the beneficial ownership of our businessCommon Stock by various documents senteach person who is known by us to them before each meeting and as otherwise requested, as well as through oral reports made to them during these meetings bybe the beneficial owner of 5% or more of our Common Stock, our Chief Executive Officer, Chief Financial Officer and the three most highly compensated persons (other than the CEO and CFO) who were serving as executive officers at December 31, 2020, each of our directors and director nominees, and all directors and executive officers as a group. The number of shares of Common Stock beneficially owned by the Company’s directors and named executive officers and all directors and executive officers as a group includes shares of Common Stock they have the right to acquire within 60 days of March 18, 2021. The percentages in the last column are based on 37,512,543 shares of Common Stock outstanding on March 18, 2021, plus the number of shares of Common Stock deemed to be beneficially owned by such individual or group pursuant to Rule 13d-3(d)(1) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In each case, except as otherwise indicated in the footnotes to the table, the shares shown in the second column are owned directly by the individual or members of the group named in the first column and such individual or group members have sole voting and dispositive power with respect to the shares shown. For purposes of this table, beneficial ownership is determined in accordance with federal securities laws and regulations. Persons shown in the table disclaim beneficial ownership of all securities not held by such persons directly and inclusion in the table of shares not owned directly by such persons does not constitute an admission that such shares are beneficially owned by the director or officer for purposes of Section 16 of the Exchange Act or any other senior executives;purpose.

NameNumber of Shares
of Common Stock
Beneficially Owned
Percentage of
Outstanding
Common
Stock Owned

BlackRock Inc. 

55 East 52nd Street 

New York, NY 10055 

5,436,060(a)14.5%

Aristotle Capital Boston, LLC 

One Federal Street, 36th Floor 

Boston, MA 02110 

2,473,371(b)6.6%

T Rowe Price Associates Inc. 

100 E. Pratt Street 

Baltimore, MD 21202 

2,457,589(c)6.6%

Vanguard Group 

100 Vanguard Blvd 

Malvern, PA 19355 

2,232,415(d)6.0%

Systematic Financial Management 

300 Frank W. Burr Blvd. 

Glenpointe East, 7th Floor 

Teaneck, NJ 07666 

2,100,084(e)5.6%

Dimensional Fund Advisors, LP 

Building One 

6300 Bee Cave Road

 

  

 

28

Austin, TX 787461,890,229(f)5.0%
Susan E. Ball213,805(g)*
William J. Burns253,976(h)*
W. Larry Cash170,870(i)*
Kevin C. Clark527,665(j)1.4%
Thomas C. Dircks182,988(k)*
Gale Fitzgerald145,972(l)*
Darrell S. Freeman, Sr.49,984(m)*
Janice E. Nevin, M.D., MPH17,916(n)*
Mark Perlberg, JD66,544(o)*
Stephen A. Saville63,548(p)*
Joseph A. Trunfio, Ph.D.188,422(q)*
Buffy S. White65,315(r)*
All directors and executive officers as a group (17 individuals)2,084,887 5.6%

*Less than 1%

(a)The information regarding the beneficial ownership of shares by BlackRock, Inc. was obtained from its statement on Schedule 13G/A, filed with the SEC on January 26, 2021. Such statement discloses that BlackRock, Inc. has sole voting power of 5,402,797 shares and has sole dispositive power of 5,436,060 shares.

(b)The information regarding the beneficial ownership of shares by Aristotle Capital Boston, LLC was obtained from its statement on Schedule 13G, filed with the SEC on February 2, 2021. Such statement discloses that Aristotle Capital Boston, LLC has sole voting power of 1,382,171 shares and sole dispositive power of 2,473,371 shares.

(c)The information regarding the beneficial ownership of shares by T Rowe Price Associates Inc. was obtained from its statement on Schedule 13G/A, filed with the SEC on February 16, 2021. Such statement discloses that T Rowe Price Associates Inc. possesses sole voting power over 549,525 shares and sole dispositive power over 2,457,589 shares.

(d)The information regarding the beneficial ownership of shares by Vanguard Group Inc. was obtained from its statement on Schedule 13G/A, filed with the SEC on February 12, 2021. Such statement discloses that Vanguard Group Inc. possesses shared voting power over 29,214 shares, sole dispositive power over 2,193,884 shares, and shared dispositive power over 38,531 shares.

(e)The information regarding the beneficial ownership of shares by Systematic Financial Management, LP was obtained from its statement on Schedule 13G, filed with the SEC on February 12, 2021. Such statement discloses that Systematic Financial Management, LP possesses sole voting power over 1,317,134 shares and sole dispositive power over 2,100,084 shares.

(f)The information regarding the beneficial ownership of shares by Dimensional Fund Advisors LP was obtained from its statement filed on Schedule 13G/A, filed with the

29

SEC on February 12, 2021. Such statement discloses that Dimensional Fund Advisors LP possesses sole voting power over 1,802,784 shares and sole dispositive power over 1,890,229 shares.

(g)Includes 73,858 shares of Restricted Stock.

(h)Includes 123,426 shares of Restricted Stock.

(i)Includes 31,236 shares of Restricted Stock.

(j)Includes 385,865 shares of Restricted Stock.

(k)Includes 31,236 shares of Restricted Stock.

(l)Includes 31,236 shares of Restricted Stock.

(m)Includes 30,805 shares of Restricted Stock.

(n)Includes 17,916 shares of Restricted Stock.

(o)Includes 31,236 shares of Restricted Stock.

(p)Includes 53,413 shares of Restricted Stock.

(q)Includes 31,236 shares of Restricted Stock.

(r)Includes 50,000 shares of Restricted Stock.

COMPENSATION DISCUSSION AND ANALYSIS

This Compensation Discussion and Analysis is designed to provide our Board structure providesstockholders with a clear understanding of our compensation philosophy and objectives, compensation-setting process, and the compensation paid to our named executive officers, or NEOs, in Fiscal 2020. As discussed in Proposal No. 3, we are conducting a Say-on-Pay vote this year that requests your approval, on an advisory basis, of the compensation of our NEOs as described in this section and in the tables and accompanying narrative.

Our NEOs for Fiscal 2020, which consist of our principal executive officer, our principal financial officer, and our three other most highly compensated executive officers, are:

NamePosition
Kevin C. ClarkChief Executive Officer and President
William J. Burns, MBA, CPAEVP, Chief Financial Officer and Principal Accounting Officer
Susan E. Ball, JD, MBA, RNEVP, Chief Administrative Officer, General Counsel and Secretary
Stephen A. Saville, JDGroup President, Locums, Education and Corporate Development
Buffy S. WhiteGroup President, Workforce Solutions

30

Business Description 

We are a leader in providing total talent management including strategic workforce solutions, contingent staffing, permanent placement, and consultative services for healthcare customers. Leveraging our 35 years of industry expertise and insight, we solve complex labor-related challenges for customers while providing high-quality outcomes and exceptional patient care. As a multiyear Best of Staffing® Award winner, we are committed to an exceptionally high level of service to both our clients and our healthcare professionals. We were the first publicly traded staffing firm to obtain The Joint Commission Certification, which we still hold with a Letter of Distinction. In February 2021, we earned Energage’s inaugural 2021 Top Workplaces USA award. We have a longstanding history of investing in our diversity, equality, and inclusion strategic initiatives as a key component of our overall corporate social responsibility program which is closely aligned with our core values to create a better future for our people, communities, the planet, and our shareholders.

Fiscal 2020 Business Performance Highlights 

During 2020, we completed our turnaround strategy. Specifically, we achieved the following during Fiscal 2020:

-Invested in revenue producing capacity, realigned and optimized our teams, reduced overhead by more than $20 million annually, permanently closed more than 50 offices (primarily local staffing while maintaining a local presence), implemented and successfully deployed an integrated cloud-based platform connecting our recruiters, account managers, and sales teams to enhance productivity, and launched Cross Country Marketplace, our proprietary on-demand mobile app for local market staffing.

-Our 2020 full year financial results once again demonstrated our ability to execute well across multiple fronts, including expanding our base of clinicians on assignment against a backdrop of strong demand. We delivered consolidated revenue growth for the full year of 2%, despite school closures impacting our education business and other impacts from COVID-19 on our local and physician staffing businesses. For the first time in five years, we exceeded our profitability targets which resulted in awards earned above 100% of target levels consistent with our pay-for-performance philosophy. The 2018 performance stock awards were also forfeited in conformance with our pay-for-performance policy.

-Along with solid execution on fulfillment and delivery, we continued on our path of digital innovation with the expansion of a cloud based platform that connects recruiters, account managers and the sales team for the entire travel nurse and allied teams, as well as the deployment of our proprietary on-demand mobile app, Cross Country Marketplace, to all of our local markets.

-We also continued to make investments in social initiatives and diversity, including by electing another woman to our Board of Directors in May 2020. The Company is proud to have sponsored nursing scholarships at Florida Atlantic University and we were the presenting sponsor of the Leukemia and Lymphoma Society “Light the Night” walk -- just to mention a few.

31

Our Response to COVID-19

2020 was a challenging year due to the COVID-19 pandemic, yet a very rewarding year as we saw the best in our people and have been able to help heal the nation patient by patient. At the outset of the pandemic, we committed to adhering to our core values and beliefs by always striving to “do the right thing” for our clients, nurses, communities, employees and stockholders, and by taking a collaborative approach to problem-solving.

In March 2020, we quickly moved to a remote work environment and established protocols aligned with recommendations from the Centers for Disease Control to protect our corporate employees and front-line professionals.  As thousands of our healthcare professionals were on the front-lines, we also established a robust support system for those workers, providing access to a 24/7 hotline for healthcare workers who are experiencing emotional stress, and other resources to help them during a difficult time. During 2020, we responded to nearly 11,000 hotline calls and have aspired to be constant advocates for our healthcare professionals. Perhaps most importantly, we delivered on our value proposition, serving as an integral partner in redistributing the supply of healthcare labor where it was needed most during an unprecedented crisis throughout the country. This was poignantly displayed in a video sent to us by one of our long-time valued clients, showing our nurses receiving a standing ovation as they arrived at the hospital to bring relief to an exhausted staff.

Overall, we outperformed financially in 2020, significantly improving profitability in an extraordinarily challenging environment and positioning the Company for long-term value creation going forward. The crisis resulted in us returning to our roots as an entrepreneurial, innovative company, building an exceptional team of professionals and embracing technology in new and exciting ways. Despite the pandemic, we executed well across multiple fronts, including:

Rapidly expanding our base of clinicians on assignment against a backdrop of rising demand
Taking decisive action to significantly reduce costs, including the closure of more than 50 brick-and-mortar offices
Furthering our digital transformation strategy and reaching key milestones set in our 5-year strategic plan:
Completing the implementation of our integrated, cloud-based Applicant Tracking System for key segments, laying the foundation for a digital ecosystem on one end-to-end platform to improve both productivity and the candidate experience.
Launching phase one of our proprietary on-demand mobile app, Cross Country Marketplace, to our entire local footprint.
Executing the operationalization of our cloud-based CRM to more effectively engage prospective and manage existing client relationships.
Introducing an enterprise business analytics tool to accelerate top and bottom-line revenue growth through adaptive market positioning, leveraging real time AI and machine learning.
Institutionalizing sophisticated digital media strategies to source, engage and efficiently place high quality healthcare professionals faster.

32

Through all of these changes, our team remained focused and continued to uphold our values and our standards of excellence while working to improve the financial performance of the company, advocating for our healthcare professionals and providing consultation and staffing to our clients.

COMPENSATION PHILOSOPHY AND OBJECTIVES

What we doWhat we don’t do
Majority of compensation incentive-based and at risk tied to company performanceXNo guaranteed incentive payments
Engage independent compensation consultantsXNo 280G excise tax gross-ups
Engage in peer group benchmarkingXNo supplemental executive pension or retirement plans
Due diligence in setting compensation targets and goalsXNo option repricing
Periodically assess the compensation programs to ensure that they are not reasonably likely to incentivize employee behavior that would result in any material adverse risks to the companyXPerquisites are not a substantial portion of our NEO pay packages
Provide reasonable severance protection with double trigger protections upon a change in controlXNo pledging and no hedging
Clawback of equity and cash incentive payments in the event of a restatement
Robust stock ownership guidelines: Directors (2x cash component); CEO (3x Base Salary); and Other Senior Executives (1x Base Salary)

The philosophy of our executive compensation program is to align pay with performance, keep overall compensation competitive and ensure that we can recruit, motivate and retain high quality executives. Accordingly, our executives’ compensation is heavily weighted toward compensation that is performance-based or equity-based. Our NEO compensation for Fiscal 2020 reflects this commitment.

The Compensation Committee structured the Fiscal 2020 executive compensation with the goal of ensuring that total direct compensation levels were sufficiently competitive to attract, motivate and retain the highest quality executives, that performance-based “at-risk” incentive compensation was a substantial portion of total compensation opportunities, and that long-term incentive compensation aligned executives’ interests with our stockholders’ interests to create long-term stockholder value. The Compensation Committee structured the Fiscal 2020 equity incentive to retain key executives. In addition, the Compensation Committee also structured the equity incentive to take into account the Company’s near-term and longer-term strategic objectives to provide executives with the opportunity to acquire a significant stake in our growth and prosperity. It was also structured to incentivize and reward executives for sound business management,

33

developing a high performance team environment, fostering the accomplishment of strategic and operational objectives, and compensating executives for improvement in stockholder value, all of which are essential to improving our financial performance and creating success.

Our executives’ compensation for Fiscal 2020 consisted of a base salary, an annual incentive bonus and long-term equity awards (66.7% of which are time vested over three years and 33.3% of which are performance-based). The Compensation Committee increased the weighting on performance-based equity from 25% of target award opportunities in Fiscal 2019 to 33.3% in Fiscal 2020 to further strengthen the alignment of executive pay with long-term sustainable performance. In Fiscal 2020, the performance-based portion of the long-term equity awards was based on two performance metrics: (i) three-year cumulative Adjusted EBITDA (weighted 75%) and (ii) Adjusted EBITDA margin for the third year of the performance period (weighted 25%). For Fiscal 2020, 79% of our CEO’s target total compensation and an average of 63% of our other NEOs’ target total compensation were performance-based or equity-based. We do not provide defined benefit pension, supplemental retirement benefits or executive perquisites to our NEOs as they are not tied to performance.

The three principles of our compensation philosophy are as follows:

PRINCIPLERATIONALE
Total direct compensation levels should be sufficiently competitive to attract, motivate and retain the highest quality executivesOur Committee seeks to establish total direct compensation targets (base salary, short-term and long-term incentives) at the 50th percentile of our Peer Group and market data of companies of like size, thereby providing our executives the opportunity to be competitively rewarded for our financial, operational and stock price growth. We believe paying at the 50th percentile is competitive and promotes employment engagement and high performance. It is also the Compensation Committee’s intention to set total executive compensation at sufficiently competitive levels to attract and retain strong, motivated leadership who will not only strive to meet and exceed our key operating and strategic objectives, but also demonstrate the utmost integrity in doing so.
Performance-based compensation should constitute a substantial portion of total compensationWe believe in a pay-for-performance culture, with a significant portion of total direct compensation being performance-based and/or “at risk.” The performance of our executives, considered in light of general economic and specific company, industry and competitive conditions, serves as the primary basis for determining their overall compensation. Accordingly, a portion of the compensation provided to our executive officers is tied to, and varies with, our financial and operational performance, as well as individual performance. We view our short-term and long-term incentive components of the compensation program as being variable and “at risk.”

34

Long-term incentive compensation should align executives’ interests with our stockholders’ interest to further the creation of long-term stockholder valueAwards of equity-based compensation encourage executives to focus on our long-term growth and prospects and incentivize executives to manage the Company from the perspective as owners with a meaningful stake, and to encourage them to remain with us for long and productive careers. Our stock ownership guidelines further enhance the incentive to create long-term stockholder value. Equity-based compensation also subjects our executives to market risks similar to our stockholders.

This philosophy serves as the basis of the Compensation Committee’s decisions regarding each of the following three components of pay, each of which is discussed below:

base salary

short-term (annual) incentive compensation; and

long-term (equity) compensation.

Consideration of Stockholder Advisory Vote

As part of its compensation setting process, the Compensation Committee also considers the results of the prior year’s advisory vote by our stockholders on our executive compensation to provide useful feedback regarding whether our stockholders believe the Compensation Committee is achieving its goal of designing an executive compensation program that promotes the best interests of the Company and its stockholders by providing its executives with the appropriate compensation and meaningful incentives. For the ninth straight year, our executive compensation program received substantial stockholder support and was approved, on an advisory basis, by 96% of the votes cast at the 2020 annual stockholder meeting. Our Compensation Committee believes that this vote reflected our stockholders’ strong oversightsupport of the compensation decisions made by the Compensation Committee for our NEOs for 2019.

DETERMINATION OF COMPENSATION

Role of the Compensation Committee

The Compensation Committee is composed solely of independent directors and is responsible for determining the compensation of our CEO and other NEOs. The Compensation Committee receives assistance from its independent compensation advisor, Pearl Meyer & Partners, LLC (“Pearl Meyer”).

Our NEO compensation program is implemented yearly during the first quarter, which coincides with the completion of our annual financial statement audit and release of annual earnings, as well as the approval of the budget for the then current year. Annual cash incentives earned for the prior year, if any, are determined by the Compensation Committee and paid out at that time. Current year target objectives are also established at that time and any adjustments to base salaries are typically determined by the Compensation Committee at that time.

35

When making NEO compensation decisions, the Compensation Committee takes many factors into account, including the economy, the NEO’s performance, expected future contributions to the Company’s success, the financial and operational results of individual business units, our financial and operational results as a whole, the NEO’s historical compensation, and any retention concerns. As part of the process, the CEO provides the Compensation Committee with his assessment of the other NEOs’ performance and other factors used in developing his recommendation for their compensation, including salary adjustments, cash incentives and equity grant guidelines for the then current year. In looking at historical compensation, the Compensation Committee looks at the progression of salary increases over time, a NEO’s ability to meet performance objectives in prior years, the value inherent in equity awards to be granted to complete the total compensation program for an NEO for a particular because non-management directors meet separately,year, economic outlook and our stock performance. The Compensation Committee uses the same general factors in evaluating the CEO’s performance and compensation as it uses for the other NEOs; provided, however, the CEO does not participate in his own assessment.

Upon receipt of this information, the Compensation Committee discusses proposed compensation plans for the CEO and other NEOs in detail. Based on our Governance Guidelines, the Compensation Committee is required to approve annually the goals and objectives for compensating the CEO and other NEOs, evaluate their performance in light of these goals before setting their salaries, bonus and other incentive and equity compensation. The Compensation Committee adjusts the cash incentive portion of the NEOs’ total target pay mix consistent with its philosophy to incentivize and reward executives to reach certain financial and strategic objectives and reward them based upon their performance. The Compensation Committee believes that maintaining the flexibility to make upward or downward adjustments to the various components of the NEOs compensation programs allows the Compensation Committee to appropriately provide incentives to individuals and further aligns the NEOs with the objectives of our stockholders.

Role of Management

The Compensation Committee and the Board made all decisions regarding the compensation of our NEOs, after considering recommendations from our CEO, who provides the Compensation Committee with his assessment of the other NEOs’ performance and other factors used in developing his recommendation for their compensation, including salary adjustments, cash incentives and equity grant guidelines for the then current year for NEO compensation other than his own.

Role of the Compensation Consultant

Annually, the Compensation Committee evaluates the Company’s executive and director compensation design, competitiveness and effectiveness. For Fiscal 2020, the Compensation Committee continued to engage Pearl Meyer to review the compensation components for our NEOs against our 2020 Peer Group and market data of like-sized companies, assist in the determination of the Fiscal 2020 compensation for our NEOs, and provide recommendations for our director compensation program. The Compensation Committee annually reviews the independence of Pearl Meyer. Pearl Meyer does not perform any other services for the Company other than its compensation consulting services to the Compensation Committee and is adviseddeemed to be independent and conflict-free under relevant stock exchange standards.

36

Role of Benchmarking

At the beginning of the executive compensation setting process each year, the Compensation Committee, in consultation with its independent compensation consultant, determines the process by which it will work to ensure that the Company’s compensation programs are competitive. For Fiscal 2020, the Compensation Committee, with the recommendation of Pearl Meyer, determined it would be appropriate to maintain the group of peer companies which it had established in 2019. The peer group is composed of companies from both the healthcare staffing and general staffing industry, and it includes the following 10 companies (the “2020 Peer Group”):

2020 PEER GROUP

AMN Healthcare Services, Inc. 

Volt Information Sciences, Inc. 

Heidrick & Struggles International Inc. 

On Assignment, Inc.

Hudson Global, Inc.

GP Strategies Corp.

KForce, Inc.

Korn/Ferry International

Barrett Business Services, Inc.

TrueBlue, Inc.

The Compensation Committee determined that the peer group reflects companies falling within a generally comparable size range that we compete with for business, executive talent, and investor capital.

Although the companies in the 2020 Peer Group are comparable to the Company in certain respects, factors such as revenue, business mix, profitability, business strategy, compensation philosophy, and incentive plan design vary among the peers and such differing factors affect the compensation which they provide to their executives. While informative to the Compensation Committee, such peer practices are not the sole factor that influences the Compensation Committee’s decisions about executive compensation. The Compensation Committee also makes decisions based on the collective experience and knowledge of its members. Generally, our policy has been to pay our NEOs base salaries at the 50th percentile of our 2020 Peer Group.

COMPONENTS OF FISCAL 2020 NEO PAY PROGRAM

The Compensation Committee uses various compensation elements to provide an overall competitive total compensation and benefits package to the NEOs that is tied to creating stockholder value, is commensurate with our financial results and aligns with the business strategy. The Compensation Committee’s specific rationale, design, reward process and relating information are outlined below.

37

Base Salary

We provide the NEOs with a base salary to compensate them for services rendered during the fiscal year. Base salary ranges for NEOs are determined on the basis of each executive’s position, performance and level of responsibility. Base salary levels are reviewed annually. Peer group and market data from like sized companies are utilized in our review. Merit increases for NEOs are considered based on the annual reviews of market data and base salaries, and are adjusted only as needed, not necessarily annually. Base salaries for NEOs are generally benchmarked within a tight range of the market median for our peer groups and companies of like size.

For Fiscal 2020, none of our NEOs received a base salary increase other than Ms. White, whose salary was increased by 7.5% to more closely align with levels provided to other Group President and senior executive officers. As previously noted, as part of our response to the economic impacts of the COVID-19 pandemic, our NEOs voluntarily agreed to a 10% reduction in base salary, effective as of May 1, 2020 for Mr. Clark and as of July 1, 2020 for other NEOs. Effective October 1, 2020, as Company performance continued to stabilize and improve, base salaries for all actions takenNEOs were restored to pre-cut levels.

NEO  2020 Base
Salary ($)(1)
 2019 Base
Salary ($)
 % Increase vs Prior Year
Kevin C. Clark  825,000 825,000 —%
William J. Burns  525,000 525,000 —%
Susan E. Ball  420,000 420,000 —%
Stephen A. Saville  430,000 430,000 —%
Buffy S. White  430,000 400,000 7.5%

(1)Reflects full annual base salaries prior to temporary 10% reductions, which our NEOs voluntarily agreed to for a portion of 2020 in response to the COVID-19 pandemic.

Annual Cash Incentive Program

The annual cash incentive program is a core component of our “pay-for-performance” philosophy. The program is heavily weighted to our financial results or relevant business units and the goals are closely linked to business strategy. The components of this program have historically included the incentive and reward opportunity (expressed as a percentage of base salary) and performance measures determined by the various committeesCompensation Committee, such as revenue, Adjusted EBITDA, and segment contribution income. To ensure the integrity of the goals and minimize the risk of unanticipated outcomes, each goal has had a performance range built around it with a commensurate increase or decrease in the associated award opportunity. The Compensation Committee may adjust performance measures for certain special, unusual or non-recurring items at its sole discretion.

Each annual target cash incentive award opportunity is expressed as a percentage of base salary, which may be earned based on both the achievement of certain financial objectives (the “Objective Bonus” component) and individual subjective considerations tied primarily to individual objectives (the “Subjective Bonus” component). If results fall below pre-established

38

threshold levels, no cash award is payable under the Objective Bonus component, although a Subjective Bonus may still be paid at the discretion of the Compensation Committee. If results exceed pre-established outstanding goals, the cash award payable under the Objective Bonus component is capped at a maximum award opportunity of 180% of the short-term incentive target. The Compensation Committee believes that having a maximum cap serves to promote good judgment by the NEOs, reduces the likelihood of windfalls and makes the maximum cost of the plan predictable. The award opportunity is established for each position with the desired emphasis on pay at risk (more pay at risk for senior executives) and internal equity (comparably positioned executives should have comparable award opportunities).

The Subjective Bonus opportunity also is capped at a maximum amount, expressed as a percentage of the short-term incentive target, which may vary for each position. The use of subjective criteria enables the Compensation Committee to consider a variety of subjective factors relative to each executive’s specific responsibilities. This process allows the Compensation Committee to evaluate performance and to recognize contributions in light of our changing needs and strategic priorities.

Incentive payouts under the Annual Cash Incentive Program, at a reduced level, begin upon achievement of a predetermined percentage of targeted objectives (generally 80% or higher for EBITDA and 95% for revenue) which can vary from year to year and from one performance metric to another, so that there is not a disincentive to the NEOs. Payouts may exceed 100% if the performance exceeds 100% of the target objective as set forth in the table below. We believe that an “all or nothing” approach could provide a disincentive compared to our variable funding approach that is better aligned with our overall operating objectives, and ensures that pay varies in proportion to performance.

Historically, the Compensation Committee has established performance goals and the weighting of each goal during its first Compensation Committee meeting each year. The process for setting the goals begins with the management team establishing preliminary goals based on prior year’s results, the budget, strategic initiatives, industry performance and projected economic conditions. The Compensation Committee assesses the difficulty of the goals and their implications for share price appreciation, revenue growth and other related factors. The iterative process results in final goals presented by management to the Compensation Committee at its March meeting.

The table below sets forth the percentages of the portion of the Fiscal 2020 annual incentive bonus that was payable upon achievement of the minimum, target and maximum levels (with interpolation between levels) of the performance metrics set forth in the table below for each of our NEOs.

Performance Metric Attainment Range (Minimum/
Target/
Maximum)
 Payout Percentage
(Minimum/
Target/
Maximum)
 Clark Burns Ball Saville White
Company Annual Revenue 95%/100%/105% 20%/100%/180% 20% 20% 20% 20% 20%
Company Annual Adjusted EBITDA 80%/100%/120% 20%/100%/180% 60% 60% 60% 60% 60%
Individual Objectives n/a 20%/100%/180% 20% 20% 20% 20% 20%
               

Totals

 

100%

 

100%

 

100%

 

100%

 

100%

39

Company annual Adjusted EBITDA (a non-GAAP financial measure) and Company annual revenue targets for the NEOs for 2020 were $31.3 million and $860.0 million, respectively. See Annex A of this proxy statement for further discussion regarding how annual Adjusted EBITDA was calculated from our Consolidated Financial Statements and a reconciliation of annual Adjusted EBITDA to our results as reported under GAAP.

Determination of Fiscal 2020 Annual Incentive Bonus Payments

The Committee determined that, for Fiscal 2020, the Company achieved annual revenue of $836.4 million, equal to 97.3% of the target goal, and annual Adjusted EBITDA of $36.3 million, equal to 116.2% of the target goal. As a result of the attainment on the respective metrics, the payout percentages for annual revenue and Adjusted EBITDA were 56% and 165%, respectively. Additionally, our NEOs met most or all of their respective individual objectives associated with the subjective component. Resulting awards for our NEOs ranged from approximately 129% to 130% of target, as noted below, marking the first year since Fiscal 2015 that short-term incentives were near or above target award levels. In approving these awards, the Compensation Committee took into consideration our NEOs’ extraordinary efforts to protect, manage, and grow the business and seamlessly maintain operations during a time of tremendous uncertainty. However, no adjustments or discretion were applied to financial performance results to account for the impact of the COVID-19 pandemic.

   Target Bonus
Opportunity
 Annual Incentive Bonus Earned
NEOs  % of Base Salary $ % of Target Bonus
Opportunity
Earned(1)
 $
Kevin C. Clark  100% 825,000 129.3% 1,067,073
William J. Burns  70% 367,500 130.1% 478,272
Susan E. Ball  75% 315,000 130.1% 409,948
Stephen A. Saville  75% 322,500 130.1% 419,708
Buffy S. White  75% 322,500 130.1% 419,708

(1)Based on achievement level of the Company’s financial performance with respect to the annual revenue and Adjusted EBITDA targets and the following achievement of individual objectives: 96% for Mr. Clark and 100% for each of Messrs. Burns and Saville, and Ms. Ball and Ms. White.

40

The table below shows historic short-term bonus payouts:

Three-Year STI Bonus Payment History

NEOs Year Target ($) Payout ($) Payout as
% of Target
 
Kevin C. Clark 2020 825,000 1,067,073 129.3%
  2019 825,000 368,915 44.7%
          
William J. Burns 2020 367,500 478,272 130.1%
  2019 367,500 164,335 44.7%
  2018 393,750 63,000 16.0%
          
Susan E. Ball 2020 315,000 409,948 130.1%
  2019 294,000 131,468 44.7%
  2018 225,000 45,000 20.0%
          
Stephen A. Saville 2020 322,500 419,708 130.1%
  2019 322,500 144,212 44.7%
          
Buffy S. White 2020 322,500 419,708 130.1%
  2019 280,000 186,128 66.5%
  2018 210,000 37,800 18.0%

Long-Term Incentive Compensation

The Company uses equity-based awards to focus executives on long-term performance, to align executives’ financial interests with those of stockholders and to create retention platforms for key executives. Equity-based awards for NEOs are generally made based on the executive’s position, experience and performance, prior equity-based compensation awards and competitive equity-based compensation levels. Further, the Compensation Committee determines the terms and conditions of equity grants taking into account market practices and the objectives of the compensation program. Retaining key talent is a key factor for the Compensation Committee in considering the level of equity awards and the vesting schedule.

In 2020, 66.7% of the equity awards granted to the NEOs were in the form of time-based restricted share awards (RSAs) and 33.3% were in the form of performance-based share awards (PSAs) under our 2020 Omnibus Incentive Plan, as amended (the “Plan”). The Compensation Committee increased the weighting on PSAs (from 25% in Fiscal 2019 to 33.3% in Fiscal 2020) to further strengthen the alignment of NEO compensation with longer-term sustainable performance results. The Company issues PSAs to tie compensation to specific longer-term financial performance goals and focus management on maximizing stockholder value. In 2020, the total targeted long-term opportunities and mix for our NEOs is set forth in the following table:

41

Name RSA Component
 (66.7% Weighting in 2020)
 PSA Component
(33.3% Weighting in 2020)
 Total Target LTI Opportunity
$ Value % of Salary $ Value % of Salary $ Value % of Salary
Kevin C. Clark $ 1,512,500 183.3% $ 756,250 91.7% $ 2,268,750 275.0%
William J. Burns $ 437,500 83.3% $ 218,750 41.7% $ 656,250 125.0%
Susan E. Ball $ 280,000 66.7% $ 140,000 33.3% $ 420,000 100.0%
Stephen A. Saville $ 215,000 50.0% $ 107,500 25.0% $ 322,500 75.0%
Buffy S. White $ 215,000 50.0% $ 107,500 25.0% $ 322,500 75.0%

The Compensation Committee approves a number of RSAs and a target number of PSAs to be granted to the NEOs on March 31st of each year. The grant date values of the RSAs and PSAs granted in Fiscal 2020 are set forth below and were based on the closing price on the grant date. Individual awards are based on a percentage of individual’s respective base salary at the time the awards are granted. The percentages and eligibility are based on the terms of employment for certain individuals or as may be determined by the Compensation Committee.

Name  Grant Date Value
of RSAs
(per share)
 Number
of RSAs
 Grant Date Value
of PSAs at Target
(per share)
 Target Number
 of PSAs
Kevin C. Clark  $ 6.74 224,519 $ 6.74 112,092
William J. Burns  $ 6.74 64,944 $ 6.74 32,424
Susan E. Ball  $ 6.74 41,564 $ 6.74 20,751
Stephen A. Saville  $ 6.74 31,916 $ 6.74 15,934
Buffy S. White  $ 6.74 31,916 $ 6.74 15,934

All of the RSAs granted to the NEOs in 2020 provide for vesting of 33.33% of the award on each of the first, second and third anniversaries of the grant date, subject to the NEO’s continued employment through the vesting date.

The PSAs granted to the NEOs in 2020 provide for the issuance of a number of shares based on the level of attainment of cumulative Adjusted EBITDA (a non-GAAP financial measure) over a three-year period (weighted 75%) and the Adjusted EBITDA margin at the end of that three-year period (weighted 25%) as follows:

Performance Level 3-yr Cumulative Adjusted EBITDA Achieved ($000s) Percentage of the Target Shares Earned Adjusted EBITDA Margin Achieved Percentage of the Target Shares Earned
Below Threshold Less than $110,000 0% Less than 6.50% 0%
Threshold $110,000 20% 6.50% 20%
Target $146,700 100% 7.00% 100%
Maximum $161,300 120% 7.50% 120%

The PSAs granted to the NEOs in 2020 will vest, if at all, on or about March 31, 2023, subject to the achievement of the applicable performance goals and the NEOs’ continued employment through such date. The performance stock awards that were granted in 2018 were not earned and, accordingly, those shares have been forfeited. See Annex A of this proxy statement for a reconciliation of non-GAAP financial measures to our results as reported under GAAP.

42

OTHER COMPENSATION AND BENEFITS

Nonqualified Deferred Compensation Plans

We maintain the 2003 Deferred Compensation Plan and the 2017 Nonqualified Deferred Compensation Plan, each an unfunded non-qualified deferred compensation arrangement, intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”).

Under the deferred compensation plans, designated employees, including our NEOs, may elect to defer the receipt of a portion of their annual base salary, bonus and commission to our deferred compensation plans. We may also make a discretionary contribution to the deferred compensation plans on behalf of certain participants. Discretionary contributions to the 2003 Deferred Compensation Plan generally become vested three years from the date such contribution is made to the plan, upon the occurrence of a change in control or upon a participant’s retirement, death during employment or disability. Discretionary contributions to the 2017 Nonqualified Deferred Compensation Plan are subject to such vesting period as determined by the Company at the time of the contribution. Generally, payments under the deferred compensation plans automatically commence upon a participant’s retirement, termination of employment or death during employment. Under certain limited circumstances described in the deferred compensation plans, participants may receive distributions during employment. To enable us to meet our financial commitment under the deferred compensation plans, assets may be set aside in a corporate-owned vehicle, which assets remain available to all our general creditors in the event of our insolvency. Participants of the deferred compensation plans are our unsecured general creditors with respect to the deferred compensation plan benefits.

401(k) Plan and Other Benefits

We maintain a 401(k) plan. The plan permits eligible employees to make voluntary, pre-tax contributions to the plan up to a specified percentage of compensation, subject to applicable tax limitations. We may make a discretionary matching contribution to the plan equal to a pre-determined percentage of an employee’s voluntary, pre-tax contributions and may make an additional discretionary profit sharing contribution to the plan, subject to applicable tax limitations. Our NEOs are eligible for matching contributions, subject to regulatory limits on contributions to 401(k) plans. Eligible employees who elect to participate in the plan are generally vested in any matching contribution after three years of service with us and fully vested at all times in their employee contributions to the plan. The plan is intended to be tax-qualified under Section 401(k) of the Code, so that contributions to the plan and income earned on plan contributions are not taxable to employees until withdrawn from the plan, and so that our contributions, if any, will be deductible by us when made. In addition to the 401(k) plan, we provide our NEOs with health and dental coverage, company-paid group term life insurance, disability insurance, paid time off and paid holidays programs applicable to other employees in their locality. These benefits are designed to be competitive with overall market practices and are in place to attract and retain the necessary talent in the business.

43

Employment Agreements

Mr. Clark, CEO and President

On January 16, 2019, the Board theyappointed Kevin Clark as our President and Chief Executive Officer. We entered into an employment agreement (the “Clark Agreement”) with Mr. Clark with an initial term expiring on December 31, 2021, subject to automatic renewal for successive one-year terms unless prior to the end of the initial term or any renewal term either party has given at least 90 days’ prior written notice of the intention not to renew the Clark Agreement. The Clark Agreement provides for Mr. Clark to receive an annual base salary of $825,000. Mr. Clark’s base salary will be reviewed for increase on an annual basis by the Board or the Compensation Committee. For each calendar year during the term, Mr. Clark is eligible to participate in the Company’s annual bonus plan with a target bonus of 100% of his base salary, based on achieving performance goals to be established by the Compensation Committee. In addition, for each calendar year during the term, Mr. Clark is eligible to participate in the Company’s long term incentive plan and receive awards valued at 275% of his base salary. Such awards will be upon terms and conditions determined by the Compensation Committee. Mr. Clark is also eligible to participate in all other benefit plans and fringe benefit arrangements available to the Company’s senior executives.

If Mr. Clark’s employment is terminated by the Company without cause (as defined in the Clark Agreement) or if Mr. Clark terminates his employment for good reason (as defined in the Clark Agreement), subject to his execution of a release, he will be entitled to a severance payment equal to the sum of (i) two years of his base salary plus (ii) an amount equal to two times the bonus Mr. Clark would have earned during the year in which such termination occurs (such amount to be determined by the Compensation Committee). In addition, all then-current benefits will continue for a period of two years and all unvested stock appreciation rights, performance stock awards, stock options or other equity awards will immediately vest. If Mr. Clark’s employment is terminated because the Company has given Mr. Clark notice of non-renewal, he will be entitled to a non-renewal payment equal to 18 months of his base salary.

During Mr. Clark’s employment and for a period of two years thereafter, Mr. Clark may not compete with the Company in any jurisdiction in which the Company’s business is conducted nor may he intentionally interfere with the Company’s relationship with any of its suppliers, customers or employees.

Mr. Burns, Executive Vice President and Chief Financial Officer

On February 1, 2019, the Company amended its employment agreement with William J. Burns to appoint him as its Executive Vice President and Chief Financial Officer. Mr. Burns previously served as the Company’s Chief Operating Officer from January 25, 2018 to February 1, 2019 and as the Company’s Chief Financial Officer since April 2013 to January 2018. His base salary is $525,000 per year and remains subject to annual review by the Compensation Committee. Effective February 22, 2021, he is eligible to participate in the Company’s annual bonus plan with a target bonus of 75% of his base salary, based on achieving performance goals to be established by the Compensation Committee. Mr. Burns is also eligible to participate in the Company’s long term incentive plan and receive awards valued at 125% of his base salary based on the

44

level of achievement of performance goals as Chief Financial Officer to be established by the Compensation Committee.

Mr. Burns is eligible to participate in the Company’s equity incentive plan, as well as all benefit plans and fringe benefit arrangements available to our senior executives. If Mr. Burns’ employment is terminated by us without cause or Mr. Burns terminates his employment for good reason, and if he is not otherwise entitled to receive severance benefits under our Executive Severance Plan Amended and Restated as of May 28, 2010 (“Executive Severance Plan”), subject to his execution of a release, he will be entitled to a severance payment equal to one year’s base salary and health insurance benefits.

During Mr. Burns’ employment and for a period of two years thereafter, Mr. Burns may not compete with the Company in any jurisdiction in which the Company’s business is conducted nor may he intentionally interfere with the Company’s relationship with any of its suppliers, customers or employees.

Ms. Ball, Executive Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary

Ms. Ball joined the Company as its Corporate Counsel pursuant to the terms and conditions of an offer letter entered into in March 2002 (the “Ball Offer Letter”).   Her base salary is reviewed for increase on an annual basis by the Board or the Compensation Committee. For each calendar year during the term, Ms. Ball is eligible to participate in the Company’s annual bonus plan with a target bonus of 75% of her base salary, based on achieving performance goals to be established by the Compensation Committee. In addition, for each calendar year during the term, Ms. Ball is eligible to participate in the Company’s long term incentive plan and receive awards valued at 100% of her base salary. Such awards are based upon terms and conditions determined by the Compensation Committee. Ms. Ball is also eligible to participate in all other benefit plans and fringe benefit arrangements available to the Company’s senior executives.

Most recently, the Company amended the Ball Offer Letter on February 22, 2021, to increase her base salary from $420,000 to $430,000 and to change her title to include Chief Administrative Officer.

In addition to increasing her base salary and changing her title, if Ms. Ball’s employment is terminated by the Company without cause (as defined in the offer letter) or if Ms. Ball terminates her employment for good reason (as defined in the offer letter) she will be entitled to a severance payment equal to the sum of: (i) any unpaid base salary through the date of termination; (ii) reimbursement for unreimbursed business expenses incurred through the termination date; (iii) payment of unused vacation and sick time in accordance with the Company’s policy; and (iv) all other applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant pursuant to the terms and conditions of such plans; and continued payments of base salary in effect at the time of termination in accordance with the Company’s regular payroll practices for a period of twelve months following the date of termination (the “Severance Payments”).

Ms. Ball is entitled to participate in the Company’s Executive Severance Plan; provided, however, that if she is or becomes eligible to receive severance benefits under such plan, she

45

will cease to be eligible for severance payments under her offer letter described above and the Company’s sole obligation will be to pay her the amounts and benefits provided in the Executive Severance Plan subject to the terms and conditions thereof.

During Ms. Ball’s employment and for a period of one year thereafter, she may not, among other things, compete with the Company in any jurisdiction in which the Company’s business is conducted nor may she intentionally interfere with the Company’s relationship with any of its suppliers, customers or employees.

Mr. Saville, Group President, Locums, Education and Corporate Development

Mr. Saville joined the Company on April 15, 2019 as its Executive Vice President of Operations pursuant to the terms and conditions of an offer letter entered into on March 11, 2019 (the “Saville Offer Letter”). On January 25, 2021, his title was changed to Group President, Locums, Education and Corporate Development. The Saville Offer Letter provides for Mr. Saville to receive an annual base salary of $430,000. Mr. Saville’s base salary will be reviewed for increase on an annual basis by the Board or the Compensation Committee. For each calendar year during the term, Mr. Saville is eligible to participate in the Company’s annual bonus plan with a target bonus of 75% of his base salary, based on achieving performance goals to be established by the Compensation Committee. In addition, for each calendar year during the term, Mr. Saville is eligible to participate in the Company’s long term incentive plan and receive awards valued at 75% of his base salary. Such awards will be upon terms and conditions determined by the Compensation Committee. Mr. Saville is also eligible to participate in all other benefit plans and fringe benefit arrangements available to the Company’s senior executives.

If Mr. Saville’s employment is terminated by the Company without cause (as defined in the offer letter) or if Mr. Saville terminates his employment for good reason (as defined in the offer letter) he will be entitled to a severance payment equal to the sum of; (i) any unpaid base salary through the date of termination; (ii) reimbursement for unreimbursed business expenses incurred through the termination date; (iii) payment of unused vacation and sick time in accordance with the Company’s policy; and (iv) all other applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant pursuant to the terms and conditions of such plans; and continued payments of base salary in effect at the time of termination in accordance with the Company’s regular payroll practices for a period of twelve months following the date of termination (the “Severance Payments”).

Mr. Saville will be entitled to participate in the Company’s Executive Severance Plan; provided, however, that if he is or becomes eligible to receive severance benefits under such plan, he will cease to be eligible for Severance Payments and the Company’s sole obligation will be to pay him the amounts and benefits provided in the Executive Severance Plan subject to the terms and conditions thereof.

During Mr. Saville’s employment and for a period of one year thereafter, he may not, among other things, compete with the Company in any jurisdiction in which the Company’s business is conducted nor may he intentionally interfere with the Company’s relationship with any of its suppliers, customers or employees.

46

Ms. White, Group President Workforce Solutions

On March 27, 2020, the Company amended Ms. White’s original offer letter to increase her base salary from $400,000 to $430,000 and increase her annual cash incentive bonus eligibility from 70% of her base salary to 75% (based on achieving performance goals to be established by the Compensation Committee). On January 25, 2021, her title was changed to Group President, Workforce Solutions. Ms. White’s base salary will be reviewed for increase on an annual basis by the Board or the Compensation Committee. In addition, for each calendar year during the term, Ms. White is eligible to participate in the Company’s long term incentive plan and receive awards valued at 75% of her base salary. Such awards will be upon terms and conditions determined by the Compensation Committee. Ms. White is also eligible to participate in all other benefit plans and fringe benefit arrangements available to the Company’s senior executives.

Pursuant to Ms. White’s addendum to her original offer letter with the Company entered into on May 21, 2019, if Ms. White’s employment is terminated by the Company without cause (as defined in the offer letter) or if Ms. White terminates her employment for good reason (as defined in the offer letter) she will be entitled to a severance payment equal to the sum of: (i) any unpaid base salary through the date of termination; (ii) reimbursement for unreimbursed business expenses incurred through the termination date; (iii) payment of unused vacation and sick time in accordance with the Company’s policy; and (iv) all other applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant pursuant to the terms and conditions of such plans; and continued payments of base salary in effect at the time of termination in accordance with the Company’s regular payroll practices for a period of twelve months following the date of termination (the “Severance Payments”).

Ms. White will be entitled to participate in the Company’s Executive Severance Plan; provided, however, that if she is or becomes eligible to receive severance benefits under such plan, she will cease to be eligible for severance payments under her offer letter described above and the Company’s sole obligation will be to pay her the amounts and benefits provided in the Executive Severance Plan subject to the terms and conditions thereof.

During Ms. White’s employment and for a period of one year thereafter, she may not, among other things, compete with the Company in any jurisdiction in which the Company’s business is conducted nor may she intentionally interfere with the Company’s relationship with any of its suppliers, customers or employees.

Severance/Change of Control Arrangements

We maintain an Executive Severance Plan pursuant to which, subject to executing a release, each NEO is entitled to receive certain severance payments and benefits if, within 90 days prior to, or within 18 months after, a “Change of Control” (as defined in the Executive Severance Plan) of the Company, such NEO is terminated without cause or incurs an “involuntary termination” (i.e. a resignation for good reason). It is a “double-trigger” policy as a “Change of Control” must occur and the NEO must be terminated without Cause (as defined in the Executive Severance Plan) or the NEO terminates for “Good Reason” (as defined in the Executive Severance Plan).

47

Under the Executive Severance Plan, Mr. Clark, Mr. Burns, and Ms. Ball are entitled to receive continued base salary for a period of two years following termination, plus two times the amount of their target bonus for the year in which a Change of Control occurs; and Mr. Saville and Ms. White are entitled to receive continued base salary for a period of one year following termination, plus one times the amount of their target bonus of the year in which a Change of Control occurs. In addition, during such period, we would continue to make group health, life or other similar insurance plans available to such NEO and his or her dependents, and we would pay for such coverage to the extent we paid for such coverage prior to the termination of employment. The severance benefits payable under the Executive Severance Plan are subject to the execution of a release and reduction to avoid any excise tax on “parachute payments” if the NEO would benefit from such reduction as compared to paying the excise tax.

Under our general severance pay policy for all of our eligible employees, if an NEO (other than Mr. Clark and Mr. Burns whose arrangements are included in their employment agreements and Mr. Saville and Ms. White whose arrangements are included in their offer letters) is terminated without cause (as defined in our general severance pay policy) other than in connection with a Change of Control, the NEO, subject to executing a release would be entitled to one week’s base salary for each full accessyear of continuous service with us.

Perquisites

Our NEOs are not entitled to any perquisites that are not otherwise available to all of our books, recordsemployees. In this regard, it should be noted that we do not provide defined benefit pension arrangements, post-retirement health coverage or similar benefits for our executives or employees.

Anti-Hedging Policy

Pursuant to our Securities Compliance Policy and reports;

membersSecurities Disclosure Compliance Agreement for Employees and Non-Employee Directors, our NEOs and employees may not buy or sell or participate in puts, calls, transferable options or other speculative rights and obligations with respect to equity securities of the Company. In addition, they may not make a “short sale” (i.e., the sale of securities that they do not own at the time of the sale or that will not be delivered for more than twenty days).

Stock Ownership Guidelines

Effective as of January 1, 2014, our Company’s chief executive officer must hold shares of Common Stock equal to three times his base salary, to be accumulated over three years, and the Company’s other senior executives must hold shares of Common Stock equal to one times his or her base salary, to be accumulated over three years. Both unvested and fully vested RSAs and fully vested PSAs, as well as directly-held and indirectly-held shares, count towards this ownership requirement. All senior executives who have served in that capacity for more than three years are in compliance with this guideline.

Impact of Accounting and Tax Matters

As a general matter, the Compensation Committee reviews and considers the various tax and accounting implications of compensation vehicles that we utilize. With respect to accounting

48

matters, the Compensation Committee examines the accounting cost associated with equity compensation in light of ASC Topic 718.

With respect to tax matters, the Compensation Committee considers the impact of Section 162(m) of the Code. Section 162(m) limits the income tax deduction by the Company for compensation paid to certain executive officers to $1,000,000 per year. As a result of amendments to Section 162(m) as part of the Tax Cuts and Jobs Acts of 2017, the Company is generally no longer able to take a deduction for any compensation paid to its current or former NEOs in excess of $1,000,000, with the exception of performance-based awards outstanding on November 2, 2017.

Incentive Compensation Recoupment “Clawback” Policy

The Company has an Incentive Compensation Recoupment Policy (“Clawback Policy”) for executive officers. This policy further strengthens the risk mitigation program by defining the economic consequences that misconduct has on the executive officer’s incentive-related compensation. If there is a Restatement (as defined below) and the Board determines that an executive received incentive compensation over a three-year look back period (during which the policy was in effect) in excess of the amount that would have direct accessbeen paid to the management team and those individuals are available at all times to answer questions fromexecutive had such incentive compensation been calculated based on the restatement, regardless of fault, the Board Members;

our Board has extensive management experience in businessthe discretion to (i) require the executive to repay all or a portion of any cash incentive compensation, (ii) cancel all or a portion of any vested or unvested incentive compensation awarded to the executive, and in particular,(iii) require the healthcare industry in which we operate; and
executive to repay all or a portion of any gains realized with respect to the continuity and tenureaward. Under the policy, “Restatement” means any restatement of our Board provide a valuable source of institutional knowledge.
the Company’s financial statements due to non-compliance with any accounting requirement where such restatement is due to the covered person’s fraud or misconduct, errors or omissions or other related activities.

Compensation-Related Risk.

Compensation Risk Management

Our Compensation Committee has specifically reviewed and, in consultation with Pearl Meyer, considered whether our compensation programs and policies create risks that are reasonably likely to have a material adverse effect on us. In that regard, we design our programs in a balanced and diversified manner while also creating significant, yet appropriate, incentives for strong performance based on our business and strategic plan. In most cases, each component of our performance-based compensation program is subject to a limit on the amount paid. We believe that our compensation programs reflect a balance of short-term, long-term, guaranteed and performance-based compensation in order not to encourage excessive risk-taking. A significant portion of our compensation program includes performance-based compensation. We believe that this ensures that our NEOs and other employees focus on the health of our business that will deliver stockholder value over time and discourages excess risk-taking by our NEOs and other employees.

Committees of the Board of Directors. Our Board of Directors has three standing committees: Audit, Compensation“clawback” and Governance and Nominating Committees. Each of these committees is comprised solely of independent directors within the meaning of Rule 5605(a) (2) of the Nasdaq Listing Rules. Each committee operates pursuant to a committee charter. The charters of each of the Audit, Compensation and Governance and Nominating Committees are available on our website at www.crosscountryhealthcare.com by choosing the “Investors” link, clicking on the “Corporate Governance” section, and selecting the respective charter under “View.”

The current composition of our Board’s standing committees is as follows:

Audit Committee

The Audit Committee consists of Messrs. Cash, Freeman, and Mastaler and Ms. Fitzgerald. Mr. Cash joined the Audit Committee upon his appointment to the Board in October 2001; Ms. Fitzgerald joined the Audit Committee upon her appointment to the Board in May 2007; Mr. Mastaler was appointed to serve on the Audit Committee, effective January 1, 2014; and Mr. Freeman joined the Audit Committee upon his appointment to the Board in August 2018. Mr. Cash is the Chairman of the Audit Committee. Messrs. Cash, Freeman, and Mastaler and Ms. Fitzgerald are independent directors under the Commission’s rules and NASDAQ’s Listing Rules for Audit Committees. The Audit Committee has adopted a written charter, which is available on our website as described under “Committees of the Board of Directors.” The Audit Committee is the principal agent of the Board of Directors in overseeing (i) the quality and integrity of our financial statements, (ii) legal and regulatory compliance, (iii) the independence, qualifications, and performance of our independent registered public accounting firm, (iv) the performance of our internal auditors and (v) the integrity of management and the quality and adequacy of disclosures to stockholders. The Committee also:

is responsible for hiring and terminating our independent registered public accounting firm and pre-approving all auditing, as well as any audit-related, tax advisory and any other non-auditing services to be performed by the independent registered public accounting firm;

10

reviews and discusses with our independent registered public accounting firm their quality control procedures and our critical accountinganti-hedging policies and practices;
regularly reviews the scopestock ownership requirements also help to manage potential risks and results of audits performed by our independent registered public accounting firm and internal auditors;
meetspromote alignment with management to review the adequacy of our internal control framework and our financial, accounting, and reporting and disclosure control processes;
reviews our periodic filings and quarterly earnings releases;
reviews and discusses with our chief executive and financial officers the procedures they follow to complete their certifications in connection with our periodic filings with the Commission; and
discusses management’s plans with respectstockholder interests. Accordingly, there were no material adjustments made to our major financial risk exposures.

During 2018, there were 8 meetings of the Audit Committee. By meeting with independent auditors and internal auditors, and operating and financial management personnel, the Audit Committee oversees matters relating to accounting standards,compensation policies and practices, any changes thereto and the effects of any changes on our financial statements, financial reporting practices and the quality and adequacy of internal controls.

Additionally our Internal Audit function reports directly to the Audit Committee. The Audit Committee regularly meets with our independent registered public accounting firm separate from management and regularly holds executive sessions without management. In addition, the Audit Committee regularly meets with our Chief Financial Officer and Director of Internal Audit in separate executive sessions.

The Audit Committee has established procedures for (i) the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters, and (ii) the confidential, anonymous submission by employees of concerns regarding questionable accounting or auditing matters. A toll-free phone number is available for confidential and anonymous submission of concerns relating to accounting, auditing and other illegal or unethical matters, as well as alleged violations of the Company’s Code of Conduct or any other policies. All submissions are reported to the General Counsel and, in turn, to the Chairman of the Audit Committee. The Audit Committee has the power to retain independent counsel and other advisors as it deems necessary to carry out its duties.

The Board has determined that each member of the Audit Committee is able to read and understand fundamental financial statements, including our balance sheet, income statement and cash flow statement, as required by NASDAQ rules. In addition to determining that Mr. Cash is an “audit committee financial expert” under the Commission’s rules, the Board has determined that Mr. Cash satisfies the Nasdaq rule requiring that at least one member of the Audit Committee have past employment experience in finance or accounting, requisite professional certification in accounting, or any other comparable experience or background which results in the member’s financial sophistication, including being, or having been, a chief executive officer, chief financial officer or other senior officer with financial oversight responsibilities.

Compensation Committee

The role of the Compensation Committee includes (i) reviewing and approving corporate goals and objectives relevant to our Chief Executive Officer’s compensation, (ii) evaluating our Chief Executive Officer’s performance in light of the Company’s goals and objectives, and determining and approving our Chief Executive Officer’s compensation level based on this evaluation, (iii) making recommendations to the Board of Directors with respect to compensation, incentive compensation plans and equity-based plans for all of our employees, and (iv) reviewing and evaluating non-employee/outside director compensation. The members of the Compensation Committee consist of Messrs. Trunfio, Cash, and Perlberg who are independent directors under Rule 5605(a) (2) of the Nasdaq Listing Rules. Mr. Cash was appointed to the Compensation Committee in May 2005 and Mr. Trunfio was appointed to the Compensation Committee as its Chairman, effective January 1, 2014. Mr. Perlberg was appointed to the Compensation Committee, effective May 12, 2015. During 2018, there were 7 meetings of the Compensation Committee. The Compensation Committee has adopted a written charter, which is available on our website as described under “Committees of the Board of Directors.”

11

The agenda for meetings of the Compensation Committee is determined by its Chairman with the assistance of our Chief Executive Officer. Compensation Committee meetings are regularly attended by our Chief Executive Officer and General Counsel, except for portions of the meetings with respect to voting or deliberation. The Compensation Committee’s Chairman reports the Committee’s recommendations on executive compensation to the Board of Directors.

Under its charter, the Compensation Committee has the authority and may, in its sole discretion, obtain advice and seek assistance from internal and external legal, accounting and other consultants. The Compensation Committee has the sole authority to select or receive advice from, and terminate a compensation consultant or other advisor to the Compensation Committee (other than in-house legal counsel) to assist in the evaluation of the compensation of our Chief Executive Officer, executive officers and directors, including sole authority to approve such firm’s fees and other retention terms, and we provide appropriate funding as determined by the Compensation Committee. In selecting advisers, the Compensation Committee will take into consideration certain independence factors.

Continuing its engagement with the Company, Pearl Meyer & Partners, LLC (“Pearl Meyer”) served as its independent compensation consultant in 2018. In its role, Pearl Meyer rendered services specifically requested by the Compensation Committee, which included reviewing the pay of our executive officers and directors and making recommendations to and advising the Compensation Committee on compensation design and levels. The Compensation Committee assessed the independence of Pearl Meyer pursuant to the applicable Nasdaq and Commission requirement and concluded that no conflict of interest exists that would prevent Pearl Meyer from serving as its independent consultant.

Governance and Nominating Committee

The role of the Governance and Nominating Committee is to: (i) develop and recommend to the Board of Directors a set of corporate governance principles and review them at least annually; (ii) determine the qualifications for board membership and recommend nominees to the stockholders; and (iii) ensure a robust and effective performance evaluation process is in place for the Board, the CEO, and senior management, as well as an effective succession planning process for these positions.

The Amended and Restated Charter of the Governance and Nominating Committee is available on our website as described under “Committees of the Board of Directors.” Our Governance Guidelines are also available on our website at www.crosscountryhealthcare.com by choosing the “Investors” link, clicking on the “Corporate Governance” section, and selecting the guidelines under “View.” The Governance and Nominating Committee consists of Ms. Fitzgerald and Messrs. Trunfio and Mastaler, who are all independent directors under Rule 5605(a) (2) of the Nasdaq Listing Rules. Ms. Fitzgerald was appointed to the Governance and Nominating Committee as its Chairman, effective January 1, 2014; Mr. Trunfio has served on the Committee since October 2001; and Mr. Mastaler was appointed to the Committee, effective January 1, 2014.

The Board’s current policy with regard to the consideration of director candidates recommended by stockholders is that the Governance and Nominating Committee will review and consider any director candidates who have been recommended by stockholders in compliance with the procedures established from time to time by the Board (the current procedures are described below), and conduct inquiries as it deems appropriate. The Governance and Nominating Committee will consider for nomination any such proposed director candidate who is deemed qualified by the Governance and Nominating Committee in light of the minimum qualifications and other criteria for Board membership approved by the Board from time to time. To date, we have not received any recommendation from stockholders requesting that the Governance and Nominating Committee consider a candidate for inclusion among the Governance and Nominating Committee’s slate of nominees in our Proxy Statement.

Certain identification and disclosure rules apply to director candidate proposals submitted to the Governance and Nominating Committee by any single stockholder or group of stockholders that has beneficially owned more than five percent of Common Stock for at least one year, referred to as a Qualified Stockholder Proposal. If the Governance and Nominating Committee receives a Qualified Stockholder Proposal with the necessary notice, information and consent provisions as referenced above, the proxy statement to which the Qualified Stock Proposal referred will disclose the name of the proposed candidate and the stockholder (or stockholder group) who recommended the candidate and will also disclose whether or not the Governance and Nominating Committee chose to nominate the proposed candidate. However, no such disclosure will be made without the

12

written consent of both the stockholder (or stockholder group) and the proposed candidate to be so identified. The procedures described in this paragraph are not meant to replace or limit stockholders’ general nomination rights in any way.

In considering director nominees, the Nominating Committee will consider the following:

the needs of the Company with respect to particular areas of specialized knowledge;
the relevant business experience of the nominee including, but not limited to, extensive experience in healthcare, staffing, IT, business, finance, or accounting;
the personal and professional integrity of the nominee;
the nominee’s ability to commit the resources necessary to be an effective director of a public company, including the nominee’s ability to attend meetings; and
the overall balance and diversity of the Board.

Other than the foregoing, there are no stated minimum criteria for nominees, although the Governance and Nominating Committee may also consider other facts as it may deem are in the best interests of the Company and its stockholders.

All stockholder recommendations for director candidates must be submitted to our legal department at 5201 Congress Avenue, Suite 100B, Boca Raton, Florida, 33487, which will forward all recommendations to the Governance and Nominating Committee. All stockholder recommendations for director candidates must be submitted to us not less than 120 calendar days prior to the first anniversary of the date of our proxy statement released to stockholders in connection with the previous year’s Annual Meeting. All stockholder recommendations for director candidates must include the following information:

the name and address of record of the stockholder;
a representation that the stockholder is a record holder of our securities or, if the stockholder is not a record holder, evidence of ownership in accordance with Rule 14a-8(b) (2) of the Exchange Act;
the name, age, business and residential address, educational background, current principal occupation or employment, and principal occupation or employment for the preceding five full fiscal years of the proposed director candidate;
a description of the qualifications and background of the proposed director candidate that addresses the minimum qualifications and other criteria for Board membership approved by the Board from time to time;
a description of all arrangements or understandings between any stockholder and the proposed director candidate;
the consent of the proposed director candidate (i) to be named in the proxy statement relating to our Annual Meeting of Stockholders and (ii) to serve as a director if elected at such Annual Meeting; and
any other information regarding the proposed director candidate that is required to be included in a proxy statement filed pursuant to the rules of the Commission.

There have been no changes to the procedures by which stockholders may recommend nominees to our Board of Directors since our last disclosure of such procedures, which appeared in the definitive proxy statement for our 2018 Annual Meeting of Stockholders.

The Governance and Nominating Committee pursues a rigorous process of Board evaluations and self-assessments on a continuous basis to determine the needs of the Board in terms of experience, expertise and knowledge. The Committee consults with external advisors on a regular basis to ensure the Board is appropriately staffed and governed in the best interests of the Company and its shareholders. The Governance and Nominating Committee is responsible for identifying and evaluating individuals qualified to become Board members, including nominees recommended by Stockholders, and recommending to the Board the persons to be nominated by the Board for election as directors at the Annual Meeting of Stockholders and the persons to be elected by the Board to fill any vacancies on the Board. Director nominees are selected by the Governance and Nominating Committee in accordance with the policies and principles in its charter and the criteria and process

13

set forth above. There are no differences in the manner in which the Governance and Nominating Committee evaluates director nominees recommended by stockholders and a candidate that has been initially recommended by the Governance and Nominating Committee. The Nominating Committee has the authority to retain a search firm to identify or evaluate or assist in identifying and evaluating potential nominees.

During 2018, there were 6 meetings of the Governance and Nominating Committee.

14

COMPENSATION COMMITTEE INTERLOCKS AND
INSIDER PARTICIPATION

The members of the Compensation Committee are Messrs. Trunfio, Cash, and Perlberg. During 2018:

no officer (or former officer) or employee of the Company or any of its subsidiaries served as a member of the Compensation Committee;
none of the members of the Compensation Committee had a direct or indirect material interest in any transaction in which the Company was a participant;
none of our executive officers served on the Compensation Committee (or another Board committee with similar functions or, if there was no such committee, the entire Board of Directors) of another entity where one of that entity’s executive officers served on our Compensation Committee;
none of our executive officers was a director of another entity where one of that entity’s executive officers served on our Compensation Committee; and
none of our executive officers served on the Compensation Committee (or another Board committee with similar functions or, if there was no such committee, the entire Board of Directors) of another entity where one of that entity’s executive officers served as a director on our Board.

Director Compensation and Other Arrangements

In 2018, each independent director received an annual retainer of $70,000; the Chairman of the Board received an additional annual retainer of $85,000; the Chairman of the Audit Committee received an additional annual retainer of $25,000; the Chairman of the Compensation Committee received an additional annual retainer of $15,000; and the Chairperson of the Governance and Nominating Committee received an additional annual retainer of $10,000. No payments were made for committee member services in 2018. In accordance with the 2014 Omnibus Incentive Plan, Messrs. Cash, Dircks, Mastaler, Perlberg, Trunfio and Ms. Fitzgerald also received a grant of restricted shares of Common Stock on June 1, 2018, the first day of the month following our Annual Meeting, and Mr. Freeman received a grant of restricted shares of Common Stock on August 1, 2018. Each such grant consisted of a number of shares of restricted Common Stock equal to approximately $110,000, based on the closing price of our Common Stock on the date of grant, and a pro rata number of shares of restricted Common Stock equal to approximately $91,678 for Mr. Freeman. The restricted shares vest in three equal installments on the first, second and third anniversaries of the grant date. Directors are required to hold an amount of the Company’s common stock equal to five times the annual cash retainer, which amount may be accumulated over five years. All directors are also reimbursed for the expenses they incur in attending meetings of the Board or Board committees.

15

2018 DIRECTOR COMPENSATION TABLE

The following table provides compensation information for our directors in 2018 except for Mr., Grubbs, our former President and Chief Executive Officer. Compensation earned by Mr. Grubbs for 2018 is included in the Summary Compensation Table on page 32 of this proxy statement.

Name
Fees Earned or
Paid in Cash
($)
Stock
Awards ($)(1)
Total
($)
W. Larry Cash
 
95,000
 
 
110,000
 
 
205,000
 
Thomas C. Dircks
 
155,000
 
 
110,000
 
 
265,000
 
Gale Fitzgerald
 
80,000
 
 
110,000
 
 
190,000
 
Darrell S. Freeman, Sr.
 
58,333
 
 
91,678
 
 
150,011
 
Richard M. Mastaler
 
70,000
 
 
110,000
 
 
180,000
 
Mark Perlberg
 
70,000
 
 
110,000
 
 
180,000
 
Joseph A. Trunfio Ph.D.
 
85,000
 
 
110,000
 
 
195,000
 
(1)Amounts in this column reflect the aggregate grant date fair value of awards of restricted stock granted under our 2014 Omnibus Incentive Plan and computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 718, Compensation-Stock Compensation (ASC Topic 718). The assumptions used in determining the amounts in this column are set forth in Note 14 to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the SEC on March 1, 2019. The aggregate grant date fair value per share of restricted stock granted on June 1, 2018 was $12.19, and granted to Mr. Freeman on August 1, 2018 was $11.86. The restricted stock granted on June 1, 2018 and August 1, 2018 vests in three equal installments on the first, second and third anniversaries of their grant date. Based on a grant date fair value of approximately $110,000, the actual number of shares of restricted stock granted to each Director was 9,024, and 7,730 to Mr. Freeman. Aggregate restricted shares outstanding as of December 31, 2018 for each non-employee director were as follows: W. Larry Cash: 17,649; Thomas C. Dircks: 17,649; Gale Fitzgerald: 17,649; Darrell S. Freeman, Sr.: 7,730; Richard M. Mastaler: 17,649; Mark Perlberg: 17,649 and Joseph A. Trunfio: 17,649.

16

EXECUTIVE OFFICERS

The following table sets forth certain information with respect to our current executive officers other than Mr. Clark whose information is provided as part of Proposal I:

Name
Age
Position
Daniele Addis, MBA
59
SVP, Business Services
Susan E. Ball, JD, MBA, RN
55
EVP, General Counsel and Secretary
William J. Burns, MBA, CPA
49
EVP, Chief Financial Officer and Principal Accounting Officer
William G. Halnon
60
Chief Information Officer
Kip Havel
42
SVP, Chief Marketing Officer
Karen Mote
54
President, Medical Doctor Associates
Christopher R. Pizzi, CPA
48
SVP, Chief Accounting Officer
Buffy Stultz White
45
President – Travel Nurse and Allied and Workforce Solutions
Marisa L. Zaharoff
45
President – Branch Operations

Daniele Addis has served as Senior Vice President, Business Services since January 29, 2014. From September 2011 to January 2014, Ms. Addis was Senior Vice President, Shared Services of Randstad Professionals, a staffing company. Prior to that, she was Vice President, Shared Services and held various other positions at SFN Group, Inc. From January 1998 to January 2006, Ms. Addis was Senior Finance Manager of Office Depot, Inc. Ms. Addis holds a Bachelor in Business from Ecole Superieure de Commerce, Nantes, France, a Master of Arts in Economics from George Mason University and a Master of Business Administration from Jacksonville University.

Susan E. Ball has served as an Executive Vice President of the Company since January 1, 2017, as General Counsel since May 2004 and Secretary since March 2010. Prior to that, Ms. Ball served as our Corporate Counsel from March 2002 to May 2004. Before joining us, Ms. Ball practiced law at Gunster, Yoakley & Stewart, P.A. from November 1998 to March 2002 and at Skadden, Arps, Slate, Meagher and Flom from 1996 to November 1998. Prior to practicing law, Ms. Ball was a registered nurse. Ms. Ball received her Bachelor of Science degree in Nursing from The Ohio State University, her Juris Doctor degree from New York Law School, and her Masters of Business Administration from Florida Atlantic University.

William J. Burns served as Chief Operating Officer from January 25, 2018 through January 31, 2019 at which time he became Chief Financial Officer and Principal Accounting Officer. He also served as Chief Financial Officer, effective from April 1, 2014, and Principal Accounting Officer, from December 1, 2014 in each case through January 24, 2018. He has served as an Executive Vice President of the Company since January 1, 2017. Prior to joining the Company, Mr. Burns served as Group Vice President and Corporate Controller for Gartner, Inc., a technology research and advisory firm, since 2008. From 2006 until 2008, Mr. Burns was the Chief Accounting Officer for CA Technologies, Inc. Mr. Burns earned his Bachelor of Arts in Accounting and Information Systems from Queens College and a Masters of Business Administration from New York University’s Stern School of Business. Mr. Burns is a Certified Public Accountant.

William G. Halnon has served as Chief Information Officer since February 2017. Prior to joining the Company, from February 2016 to February 2017, Mr. Halnon served as President of Albedon Digital, Inc. From January 2007 to February 2016, Mr. Halnon served as Senior Vice President and Chief Information Officer of Republic Services, Inc. and, from January 2005 to January 2007, he served as Senior Vice President and Chief Information Officer of Spherion, Inc. Mr. Halnon holds a Bachelor of Arts in Accounting from Langston University.

Kip Havel joined the Company as Senior Vice President and Chief Marketing Officer in July 2018. Prior to joining the Company, Mr. Havel served as Senior Vice President of Marketing at Randstad USA from October 2015 to July 2018. Before joining Randstad USA, he was Vice President of Integrated Marketing and held other marketing leadership positions at Aflac from 2009 to 2015 and served in various marketing and communications leadership roles at SFN Group (formerly known as Spherion Corporation) from 2001 until 2009. Mr. Havel holds a Bachelor of Science in Communications from the University of Miami.

17

Karen Mote was appointed as President of Medical Doctor Associates (MDA) in February 2019. From March 2015 to February 2019, she served as the Vice President of MDA’s Advanced Practices, after being promoted from Director where she served from 2008 to March 2015. Prior to that, she served as the Manager of Allied Health Group, also a division of MDA from 2000 to her promotion in 2008. Ms. Mote began her career with Medical Doctor Associates in July 1998 in the Physician Permanent Placement Division. Ms. Mote earned a Clinical Laboratory Degree of Applied Science from North Georgia Technical College.

Christopher R. Pizzi has served as Senior Vice President and Chief Accounting Officer since February 1, 2019. Prior to that he served as Senior Vice President and Chief Financial Officer of the Company from January 25, 2018 to January 31, 2019. He joined Cross Country in December 2014 and previously held the positions of Vice President of Finance, Corporate Controller and Treasurer. Prior to joining Cross Country, Mr. Pizzi served as Assistant Vice President, Corporate Finance and Accounting for Health Management Associates, Inc. and held various accounting positions with Pitney Bowes and PricewaterhouseCoopers. Mr. Pizzi earned his Bachelor of Science in Accounting from Central Connecticut State University and is a Certified Public Accountant.

Buffy Stultz White was appointed President, Travel Nurse and Allied in January 2018. In January 2019, Ms. White also became President of Workforce Solutions. She served as Senior Vice President, Recruiting Strategy and Operations since September 30, 2016. Before joining Cross Country Healthcare, Inc., Ms. White served as Executive Vice President, Global Services and Solutions Consulting, of Pontoon (a division of Adecco) from June 2015 to November 2015. Ms. White served in various capacities at Pontoon and Adecco since 2006 and, prior to that, in various roles at SFN Group, Inc. from August 2001 to July 2006.

Marisa Zaharoff was appointed President, Branch Operations in January 2018. She has served as Executive Vice President, Cross Country Staffing Branch Operations since 2015. Ms. Zaharoff has more than 15 years of nursing, quality improvement, sales, operational and branch management experience. She earned her Master of Science in Nursing degree from the University of Illinois and a Bachelor of Science in Nursing degree from the University of Pittsburgh. She is also a Registered Nurse in the State of Illinois and Pennsylvania.

18

COMPENSATION DISCUSSION AND ANALYSIS

This Compensation Discussion and Analysis is designed to provide our shareholders with a clear understanding of our compensation philosophy and objectives, compensation-setting process, and the 2018 compensation of our named executive officers, or NEOs. As discussed in Proposal III, we are conducting a Say-on-Pay vote this year that requests your approval, on an advisory basis, of the compensation of our NEOs as described in this section and in the tables and accompanying narrative.

Our NEOs for 2018 are:

William J. Grubbs, former President and Chief Executive Officer, who retired in January 2019
William J. Burns, Executive Vice President, Chief Financial Officer and Principal Accounting Officer, who served as our Chief Operating Officer during 2018
Susan E. Ball, Executive Vice President, General Counsel and Secretary
Christopher R. Pizzi, Senior Vice President and Chief Accounting Officer, who served as our Chief Financial Officer during 2018
Tim Fischer, former President, Medical Doctor Associates, who resigned from the Company in February 2019
Buffy S. White, President, Travel Nurse and Allied and, effective January 1, 2019, Workforce Solutions

Executive Summary

2018 Business Performance Highlights

practices. We are a national leader in providing healthcare staffing, recruiting and value-added workforce solutions. Through a full suite of innovative workforce solutions and a national presence including 73 office locations throughout the United States, we are able to meet the unique and dynamic needs of our clients. By utilizing our various solutions, clients are able to better plan their personnel needs, outsource recruitment processes, strategically flex their workforce, streamline their purchasing needs, access specialties not available in their local area, access quality healthcare personnel and provide continuity of care for improved patient outcomes. Our solutions are geared towards assisting our clients in solving their labor issues while maintaining high quality outcomes.

Over the past four years we have greatly expanded the number of Managed Service Programs (MSPs) and now service more than 70 different health systems, with approximately $400 million in spend under management. In addition, we have expanded services at many of our facilities to cover additional specialties such as locum tenens and allied professionals. During 2018, we had more than 24,000 healthcare professionals on assignment at 7,400 facilities, and our MSPs served more than 900 facilities.

Highlights from 2018 include:

We remained the #1 provider of per diem healthcare staffing in the United States.
Effective December 1, 2018, we completed the acquisition of AP Staffing, a local provider of staffing, permanent placement and consulting services to clients in the Northeast.
We won 13 MSP contracts with anticipated spend under management of $82 million.
Realized cost savings from targeted actions were in excess of $5 million over the course of the year.
Replacement of our Legacy Applicant Tracking System commenced.

2018 Compensation Highlights

Base Salary: Base salary increases for NEOs, approved in 2018, ranged from $0 to $105,000, or from 0.00% to 42.9% to position salaries of certain executives closer to median market values. Mr. Grubbs and Ms. Ball did not receive an increase in their base salary for 2018 and increases to Mr. Burns, Mr. Pizzi, and Ms. White were for a change in responsibilities.

19

Annual Incentives: Financial results of the Company for 2018 were below the threshold for the Company and for all but one business unit President’s area of responsibility, Ms. White. Ms. White was responsible for the performance of the Company's travel nurse and allied, Advantage, and therapy staffing businesses in 2018 (referred to as TN&A). As a result, bonuses were paid to Messrs. Grubbs, Burns, and Pizzi, and Ms. Ball for the 2018 year solely based on the achievement of individual objectives.

3-Year STI Bonus Payment History

NEOs (1)(2)(3)
Year
Target ($)
Payout ($)
Payout as
% of Target
% Change
vs. Prior Year
William J. Grubbs
 
2018
 
 
730,000
 
 
146,000
 
 
20.0
%
 
0.0
%
 
 
2017
 
 
730,000
 
 
146,000
 
 
20.0
%
 
(66.6
)%
 
 
2016
 
 
685,000
 
 
437,564
 
 
63.9
%
 
(27.1
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
William J. Burns
 
2018
 
 
393,750
 
 
63,000
 
 
16.0
%
 
(5.3
)%
 
 
2017
 
 
332,500
 
 
66,500
 
 
20.0
%
 
(68.0
)%
 
 
2016
 
 
308,000
 
 
207,751
 
 
67.5
%
 
(28.1
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Susan E. Ball
 
2018
 
 
225,000
 
 
45,000
 
 
20.0
%
 
(44.4
)%
 
 
2017
 
 
225,000
 
 
81,000
 
 
36.0
%
 
(43.2
)%
 
 
2016
 
 
201,000
 
 
142,526
 
 
70.9
%
 
(31.3
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Christopher R. Pizzi
 
2018
 
 
245,000
 
 
39,200
 
 
16.0
%
 
100.0
%
 
 
2017
 
 
98,000
 
 
19,600
 
 
20.0
%
 
(70.5
)%
 
 
2016
 
 
88,000
 
 
66,527
 
 
75.6
%
 
(22.3
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buffy S. White
 
2018
 
 
210,000
 
 
37,800
 
 
18.0
%
 
33.8
%
 
 
2017
 
 
150,000
 
 
28,250
 
 
18.8
%
 
12.8
%
 
 
2016
 
 
132,500
 
 
25,042
 
 
18.9
%
 
n/a
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timothy Fischer
 
2018
 
 
150,000
 
 
 
 
%
 
(100.0
)%
 
 
2017
 
 
137,500
 
 
24,750
 
 
18.0
%
 
(74.7
)%
 
 
2016
 
 
137,500
 
 
97,666
 
 
71.0
%
 
n/a
 
(1)On January 25, 2018, Mr. Burns was promoted from Executive Vice President and Chief Financial Officer to Executive Vice President and Chief Operating Officer. On February 1 2019, the Company eliminated the Chief Operating Officer role and Mr. Burns reverted to his prior Chief Financial Officer position.
(2)On January 25, 2018, Mr. Pizzi was promoted from Vice President, Corporate Controller to Senior Vice President and Chief Financial Officer. On February 1, 2019, the Company appointed Mr. Pizzi as its Senior Vice President and Chief Accounting Officer.
(3)On February 1, 2019 Mr. Fischer resigned from the Company, prior to his STI payout.

Long Term Incentives: Executives were awarded long-term incentives which were 50% time-based and 50% performance-based. The performance period for Performance-based Share Awards (PSAs) runs through 2020 and, as such, no PSAs were earned in 2018.

2019 will be a year of transition for the Company with a new CEO who began his employment in January 2019. As a result, the Compensation Committee is evaluating the structure for 2019 executive compensation with the goal of ensuring that total direct compensation levels are sufficiently competitive to attract, motivate and retain the highest quality executives, that performance-based “at-risk” incentive compensation is a substantial portion of total compensation, and that long-term incentive compensation aligns executives' interests with our shareholders' interests to create long-term shareholder value. The Compensation Committee believes structuring the equity incentive to retain key executives will be important during this transition period. The Compensation

20

Committee also intends to structure the equity incentive to take into account the Company's near-term and longer-term strategic objectives which will provide executives with the opportunity to acquire a significant stake in our growth and prosperity. It will also incentivize and reward executives for sound business management, developing a high performance team environment, fostering the accomplishment of strategic and operational objectives, and compensating executives for improvement in shareholder value, all of which are essential to improving our financial performance and creating success.

Pay for Performance

We pay for performance. The core of our executive compensation philosophy is that our executives’ pay should be linked to the performance of the Company. Accordingly, our executives’ compensation is heavily weighted toward compensation that is performance-based or equity-based. Our NEO compensation for 2018 reflects this commitment.

Good Governance

What we do
What we don’t do
Majority of compensation incentive-based and at risk tied to company performance
X
No guaranteed incentive payments
Engage independent compensation consultants
X
No 280G excise tax gross-ups
Engage in peer group benchmarking
X
No pension or retirement plans
Due diligence in setting compensation targets and goals
X
No option repricing
Periodically assess the compensation programs to ensure that they are not reasonably likely to incentivize employee behavior that would result in any material adverse risks to the company
X
Excessive perquisites are not a substantial portion of our NEO pay packages
Provide reasonable severance protection with double trigger protections upon a change in control
X
No pledging and no hedging
Clawbacks of equity and cash incentive payments in the event of a restatement
Robust stock ownership guidelines

Consideration of Shareholder Advisory Vote

As part of its compensation setting process, the Compensation Committee also considers the results of the prior year’s shareholders advisory vote on our executive compensation to provide useful feedback regarding whether shareholders believe the Compensation Committee is achieving its goal of designing an executive compensation program that promotes the best interests of the Company and its shareholders by providing its executives with the appropriate compensation and meaningful incentives. For the eighth straight year, our 2017 executive compensation program received substantial shareholder support and was approved, on an advisory basis, by 98.9% of the votes cast at the 2018 annual stockholder meeting. Our Compensation Committee believes that this vote reflected our shareholders’ strong support of the compensation decisions made by the Compensation Committee for our NEOs for 2018.

COMPENSATION PHILOSOPHY AND OBJECTIVES

The philosophy of our executive compensation program is to align pay with performance, keep overall compensation competitive and ensure that we can recruit, motivate and retain high quality executives. Accordingly, our executives’ compensation is heavily weighted toward compensation that is performance-based or equity-based. Our NEO compensation for 2018 reflects this commitment. Our executives’ compensation for 2018 consisted of a base salary, an annual incentive bonus and long-term equity awards (50% of which are time vested over three years and 50% of which are performance-based). In 2018, the performance-based portion of the long-term equity awards was based on two performance metrics: 3-year cumulative Adjusted EBITDA (weighted 75%) and Adjusted EBITDA margin at the end of the 3-year period (weighted 25%). For 2018, 78% of our

21

CEO’s target total compensation and an average of 63% of our other NEO’s target total compensation were performance-based or equity-based. We do not provide defined benefit pension, supplemental retirement benefits or executive perquisites to our NEOs as they are not tied to performance.

The three principles of our compensation philosophy are as follows:

Total direct compensation levels should be sufficiently competitive to attract, motivate and retain the highest quality executives. Our Committee seeks to establish target total direct compensation (base salary, short-term and long-term incentive) at the 50th percentile of our Peer Group and market data of companies of like size, thereby providing our executives the opportunity to be competitively rewarded for our financial, operational and stock price growth. It is also the Compensation Committee’s intention to set total executive compensation sufficiently high to attract and retain strong, motivated leadership who will not only strive to reach our key operating and strategic objectives, but also demonstrate the utmost integrity in doing so.

Performance-based compensation should constitute a substantial portion of total compensation. We believe in a pay-for-performance culture, with a significant position of total direct compensation being performance -based and/or “at risk.” The performance of our executives, considered in light of general economic and specific company, industry and competitive conditions, serves as the primary basis for determining their overall compensation. Accordingly, a portion of the compensation provided to our executive officers is tied to, and varies with, our financial and operational performance, as well as individual performance. We view our short-term and long-term incentive components of the compensation program as being “at risk.”

Long-term incentive compensation should align executives’ interests with our shareholders’ interest to further the creation of long-term shareholder value. Awards of equity-based compensation encourage executives to focus on our long-term growth and prospects and incentivize executives to manage the Company from the perspective as owners with a meaningful stake, and to encourage them to remain with us for long and productive careers. Our stock ownership guidelines further enhance the incentive to create long-term shareholder value. Equity-based compensation also subjects our executives to market risk similar to our shareholders.

This philosophy serves as the basis of the Compensation Committee’s decisions regarding each of the following three components of pay: base salary, short-term (annual) incentive compensation and long-term (equity) compensation, each of which is discussed below.

THE ROLE OF THE COMPENSATION COMMITTEE, MANAGEMENT AND CONSULTANTS AND THE COMPENSATION SETTING PROCESS

The Committee is comprised solely of independent directors and is responsible for determining the compensation of our CEO and other NEOs. The Committee receives assistance from its independent compensation advisor, Pearl Meyer, and from our CEO (with respect to NEO compensation other than his own).

Annually, the Compensation Committee evaluates the Company’s executive and director compensation design, competitiveness and effectiveness. In 2018, the Compensation Committee continued to engage Pearl Meyer to review the compensation components for our NEOs against our 2018 Peer Group and market data of like-sized companies, assist in the determination of the 2018 compensation for our NEOs, and provide recommendations for our director compensation program. Pearl Meyer does not perform any other services for the Company other than its consulting services to the Compensation Committee and is deemed to be independent and conflict-free under relevant stock exchange standards.

Our NEO compensation program is implemented yearly and it coincides with the completion of our annual financial statement audit and release of annual earnings, as well as the approval of the budget for the then current year. Annual cash incentives earned for the prior year, if any, are determined by the Compensation Committee and paid out at that time. Current year target objectives are also established at that time and any adjustments to base salaries are typically determined by the Compensation Committee at that time.

When making NEO compensation decisions, the Compensation Committee takes many factors into account, including the economy, the NEO’s performance, expected future contributions to the Company’s success, the financial and operational results of individual business units, our financial and operational results as a whole, the NEO’s historical compensation, and any retention concerns. As part of the process, the CEO provides the Compensation Committee with his assessment of the NEOs’ performance and other factors used in developing his recommendation for their compensation, including salary adjustments, cash incentives and equity grant guidelines for the then current year. In looking at historical compensation, the Compensation Committee looks at

22

the progression of salary increases over time, an NEO’s ability to meet targets in prior years, the value inherent in equity awards to be granted to complete the total compensation program for an NEO for a particular year, economic outlook and our stock performance. The Committee uses the same general factors in evaluating the CEO’s performance and compensation as it uses for the other NEOs.

Upon receipt of this information, the Compensation Committee discusses proposed compensation plans for the CEO and other NEOs in detail. Based on our Governance Guidelines, the Compensation Committee is required to annually approve the goals and objectives for compensating the CEO and other NEOs, evaluate their performance in light of these goals before setting their salaries, bonus and other incentive and equity compensation. The Committee adjusts the cash incentive portion of the NEOs’ compensation consistent with its philosophy to incentivize and reward executives to reach certain financial and strategic objectives and reward them based upon their performance. The Committee believes that maintaining the flexibility to make upward or downward adjustments to the various components of the NEOs compensation programs allows the Compensation Committee to appropriately provide incentives to individuals and further aligns the NEOs with the objectives of our stockholders.

THE ROLE OF BENCHMARKING

At the beginning of the executive compensation setting process each year, the Compensation Committee, in consultation with its independent compensation consultant, determines the process by which it will work to ensure that the Company’s compensation programs are competitive. For 2018, the Compensation Committee, with the recommendation of Pearl Meyer, determined it would be appropriate to maintain the group of peer companies which it had established in 2017. The peer group is comprised of companies from both the healthcare staffing and general staffing industry, and it includes the following 11 companies: AMN Healthcare Services, Inc., On Assignment, Inc., KForce, Inc., TrueBlue, Inc., CDI Corp., Hudson Global, Korn/Ferry International, Volt Information Sciences, Inc., Heidrick & Struggles International Inc., GP Strategies Corp., and Barrett Business Services, Inc. (the “2018 Peer Group”). The Compensation Committee determined that the companies in the peer group have business characteristics that are similar to our business.

Although the companies in the 2018 Peer Group are comparable to the Company in certain respects, factors such as revenue, business mix, profitability, business strategy, compensation philosophy, and incentive plan design vary among the peers and such differing factors affect the compensation which they provide to their executives. The Committee reviewed the practices of the 2018 Peer Group and considered their compensation levels as an indicator of the competitive market for our executives for fiscal year 2018, and, while informative to the Compensation Committee, such peer practices are not the sole factor that influences the Compensation Committee’s decisions about executive compensation. The Committee also makes decisions based on the collective experience and knowledge of its members.

Generally, our policy has been to pay our NEOs base salaries at the 50th percentile of our Peer Group. Incentive payouts, at a reduced level, begin upon achievement of a predetermined percentage of targeted objectives (generally 80% or higher for EBITDA and 95% for revenue) which can vary from year to year and from one performance metric to another, so that there is not a disincentive to the NEOs. Payouts may exceed 100% if the performance exceeds 100% of the target objective as set forth in the table on page 33. We believe that an “all or nothing” approach could provide a disincentive compared to our tiered payout approach that is better aligned with our overall operating objectives, and ensures that pay varies in proportion to performance. In determining competitive compensation levels for the NEOs, the Compensation Committee takes into account their responsibilities, past performance, external market practices and the economy.

COMPONENTS OF 2018 NEO PAY PROGRAM

The Committee uses various compensation elements to provide an overall competitive total compensation and benefits package to the NEOs that is tied to creating stockholder value, is commensurate with our financial results and aligns with the business strategy. The Committee’s specific rationale, design, reward process and relating information are outlined below.

Base Salary

We provide the NEOs with a base salary to compensate them for services rendered during the fiscal year. Base salary ranges for NEOs are determined on the basis of each executive’s position, performance and level of responsibility. Base salary levels are reviewed annually. Peer group and market data from like sized companies

23

are utilized in our review. Merit increases for NEOs are considered based on the annual reviews of market data and base salaries, and are adjusted only as needed, not necessarily annually. Base salaries for NEOs are generally benchmarked within a tight range of the market median for our peer groups and companies of like size.

NEO
2018 Base Salary ($)
2017 Base Salary ($)
% Incr/Decr vs Prior Year
William J. Grubbs
 
730,000
 
 
730,000
 
 
%
William J. Burns
 
525,000
 
 
475,000
 
 
10.5
%
Susan E. Ball
 
375,000
 
 
375,000
 
 
%
Christopher R. Pizzi
 
350,000
 
 
245,000
 
 
42.9
%
Buffy S. White
 
350,000
 
 
300,000
 
 
16.7
%
Timothy Fischer
 
300,000
 
 
275,000
 
 
9.1
%

Annual Cash Incentive Program

The annual cash incentive program is a core component of our “pay-for-performance” philosophy. The program is heavily weighted to our financial results or relevant business units and the goals are closely linked to business strategy. The components of this program have historically included the incentive and reward opportunity (expressed as a percentage of base salary) and performance measures determined by the Compensation Committee, such as: revenue, Adjusted EBITDA, segment contribution income, Adjusted earnings per share (EPS) or pre-tax income. To ensure the integrity of the goals and minimize the risk of unanticipated outcomes, each goal has had a performance range built around it with a commensurate increase or decrease in the associated award opportunity. The Committee may adjust performance measures for certain special, unusual or non-recurring items at its sole discretion.

Historically, the Compensation Committee has established performance goals and the weighting of each goal during its first Committee meeting each year. The process for setting the goals begins with the management team establishing preliminary goals based on prior year’s results, the budget, strategic initiatives, industry performance and projected economic conditions. The Committee assesses the difficulty of the goals and their implications for share price appreciation, revenue growth and other related factors. The iterative process results in final goals presented by management to the Compensation Committee at its March meeting.

Incentives and Award Opportunities. Each annual target cash incentive award opportunity is expressed as a percentage of base salary, which may be earned based on both the achievement of certain financial objectives (the “Objective Bonus” component) and subjective considerations (the “Subjective Bonus” component). If results fall below pre-established threshold levels, no cash award is payable under the Objective Bonus component, although a Subjective Bonus may still be paid at the discretion of the Compensation Committee. If results exceed pre-established outstanding goals, the cash award payable under the Objective Bonus component is capped at a maximum award opportunity. The Committee believes that having a maximum cap serves to promote good judgment by the NEOs, reduce the likelihood of windfalls and makes the maximum cost of the plan predictable. The award opportunity is established for each position with the desired emphasis on pay at risk (more pay at risk for senior executives) and internal equity (comparably positioned executives should have comparable award opportunities).

The Subjective Bonus opportunity also is capped at a maximum amount, expressed as a percentage of base salary, which may vary for each position. The use of subjective criteria enables the Compensation Committee to consider a variety of subjective factors relative to each executive’s specific responsibilities. This process allows the Compensation Committee to evaluate performance and to recognize contributions in light of our changing needs.

24

The table below sets forth the percentages of the portion of the 2018 annual incentive bonus that was payable upon achievement of the minimum, target and maximum levels (with interpolation between levels) of the performance metrics set forth in the table below for each of our NEOs.

 
Attainment Range
(Minimum/
Target/
Maximum)
Payout Percentage
(Minimum/
Target/
Maximum)
% of Annual Incentive by
Performance Metric
Performance Metric
Grubbs
Burns
Ball
Pizzi
White
Fischer (1)
Company Annual Revenue
95%/100%/105%
20%/100%/180%
 
20
%
 
20
%
 
20
%
 
20
%
 
2.5
%
 
7.5
%
Company Annual Adjusted EBITDA
80%/100%/120%
20%/100%/180%
 
60
%
 
60
%
 
60
%
 
60
%
 
7.5
%
 
22.5
%
TN&A Revenue
95%/100%/105%
20%/100%/180%
 
n/a
 
 
n/a
 
 
n/a
 
 
n/a
 
 
17.5
%
 
n/a
 
TN&A Contribution Income
80%/100%/120%
20%/100%/180%
 
n/a
 
 
n/a
 
 
n/a
 
 
n/a
 
 
52.5
%
 
n/a
 
MDA Revenue
95%/100%/105%
20%/100%/180%
 
n/a
 
 
n/a
 
 
n/a
 
 
n/a
 
 
n/a
 
 
12.5
%
MDA Contribution Income
80%/100%/120%
20%/100%/180%
 
n/a
 
 
n/a
 
 
n/a
 
 
n/a
 
 
n/a
 
 
37.5
%
Individual Objectives
n/a
20%/100%/180%
 
20
%
 
20
%
 
20
%
 
20
%
 
20
%
 
20
%
Total
 
 
 
 
 
 
 
100
%
 
100
%
 
100
%
 
100
%
 
100
%
 
100
%
(1)Mr. Fischer’s employment with the Company ended prior to the payment of the incentive bonus. Accordingly, pursuant to Company policy no payments were made to him.

As the former President of Medical Doctor Associates, Mr. Fischer was responsible for the performance of the Company’s physician staffing segment which represented approximately 10% of the Company’s total revenue for the full year in 2018. Accordingly, the Compensation Committee had designed his annual incentive bonus to focus on the short-term financial, operational, and qualitative performance metrics to promote long-term growth for both Medical Doctor Associates and the Company.

As the President of Travel Nurse and Allied in 2018, Ms. White was responsible for the performance of the Company’s travel nurse and allied, Advantage, and therapy staffing businesses which represented approximately 50% of the Company’s total revenue for the full year in 2018. Accordingly, the Compensation Committee had designed her annual incentive bonus to focus on the short-term financial, operational, and qualitative performance metrics to promote long-term growth for both those specific businesses and the Company.

The annualized Company Adjusted EBITDA (a non-GAAP financial measure) and annualized Company revenue targets for the NEOs for 2018 were $62.0 million and $970.0 million, respectively. See Annex A of this proxy statement for a reconciliation of non-GAAP financial measures to our results as reported under GAAP.

Determination of 2018 Annual Incentive Bonus Payments

The Committee determined that, for 2018, the Company achieved annualized Adjusted EBITDA of $31.4 million and annualized revenue of $816.5 million. These amounts were 51% and 84% of the target level, respectively, and below the threshold levels necessary to pay out on the financial performance portion of the Annual Incentive Bonuses for Messrs. Grubbs, Burns, Pizzi, and Fischer, and Ms. Ball and Ms. White. Accordingly, Messrs. Grubbs, Burns, and Pizzi and Ms. Ball received 20%, 16%, 16%, and 20% of their Annual Target Incentive, respectively, based on achieving the subjective portion of their bonuses regarding individual objectives.

 
Target Bonus
Opportunity
Annual Incentive Bonus Earned
NEOs
% of Base
Salary
$
% of Target
Bonus
Opportunity
Earned
Individual
Objectives
Achieved
$
William J. Grubbs
 
100
%
 
730,000
 
 
20.0
%(2)
 
100.0
%
 
146,000
 
William J. Burns
 
75
%
 
393,750
 
 
16.0
%(2)
 
80.0
%
 
63,000
 
Susan E. Ball
 
60
%
 
225,000
 
 
20.0
%(2)
 
100.0
%
 
45,000
 
Christopher R. Pizzi
 
70
%
 
245,000
 
 
16.0
%(2)
 
80.0
%
 
39,200
 
Buffy S. White
 
60
%
 
210,000
 
 
18.0
%(1)
 
90.0
%
 
37,800
 
Timothy Fischer
 
50
%
 
150,000
 
 
%(3)
 
%
 
 
(1)Based on achievement levels of the TN&A revenue and contribution income targets, and achievement of individual objectives at 90% for Ms. White.

25

(2)Based on achievement of the individual objectives for Messrs. Grubbs, Burns, and Pizzi and Ms. Ball.
(3)Mr. Fischer resigned from the Company February 1, 2019, prior to the payment of the incentive bonus. Accordingly, pursuant to Company policy no payment was made to him.

Long-Term Incentive Compensation

The Company uses equity-based awards to focus executives on long-term performance, to align executives’ financial interests with those of shareholders and to create retention platforms for key executives. Equity-based awards for NEOs are generally made based on the executive’s position, experience and performance, prior equity-based compensation awards and competitive equity-based compensation levels. Further, the Committee determines the terms and conditions of equity grants taking into account market practices and the objectives of the compensation program. Retaining key talent is a key factor for the Compensation Committee in considering the level of equity awards and the vesting schedule.

In 2018, 50% of the equity awards granted to the NEOs were in the form of time-based Restricted Share Awards (RSAs) and 50% were in the form of Performance-based Share Awards (PSAs) under our 2014 Omnibus Stock Incentive Plan (referred to as the Plan). Since 2014, the Company has issued PSAs instead of Stock Appreciation Rights (SARs) since PSAs more closely tie compensation to specific financial performance goals and are intended to focus management on maximizing shareholder value.

Name
Long-Term Incentive (LTI) Target
Target as % of Base Salary(3)
Grant Date Value of
Restricted Share
Awards
(per share)
Number of
Restricted
Share Awards
Value of Restricted Share Awards
Restricted Share Awards as % of LTI Target
William J. Grubbs(1)
$
1,788,500
 
 
245
%
$
11.11
 
 
80,491
 
$
894,255
 
 
50
%
William J. Burns
$
787,500
 
 
150
%
$
11.11
 
 
35,442
 
$
393,761
 
 
50
%
Susan E. Ball
$
375,000
 
 
100
%
$
11.11
 
 
16,877
 
$
187,503
 
 
50
%
Christopher R. Pizzi
$
437,500
 
 
125
%
$
11.11
 
 
19,690
 
$
218,756
 
 
50
%
Buffy S. White
$
210,000
 
 
60
%
$
11.11
 
 
9,451
 
$
105,001
 
 
50
%
Timothy Fischer(2)
$
180,000
 
 
60
%
$
11.11
 
 
8,101
 
$
90,002
 
 
50
%
(1)Mr. Grubbs retired from the Company on January 15, 2019. Pursuant to his retirement agreement, the Company accelerated the vest date on his outstanding restricted share awards to the date of his retirement. As a result, 74,413 shares were reissued on September 10, 2018 at a grant date value of $9.47 per share. Pursuant to the Company’s policy and applicable plans, his unearned performance equity awards were forfeited.
(2)Mr. Fischer resigned from the Company February 1, 2019 and accordingly, pursuant to the Company’s policy and applicable plans, his unvested equity awards were forfeited.
(3)Based on an analysis conducted by Pearl Meyer and its recommendation, the long-term incentive award percentages for certain executives were increased to provide an opportunity for payout at the 50th percentile based on the Company’s peer group.

26

The Compensation Committee approves a number of RSAs and a target number of PSAs for the NEOs to be granted on March 31st of each year. The grant date values of the RSAs and PSAs granted in 2018 are set forth below and were based on the closing price on the grant date. Individual awards are based on a percentage of individual’s respective base salary at the time the awards are granted. The percentages and eligibility are based on the terms of employment for certain individuals or as may be determined by the Compensation Committee. Messrs. Grubbs, Burns, Pizzi, and Fischer received an amount of PSAs equal to 122.5%, 75.0%, 62.5%, and 30.0% of their respective annual base salaries and Ms. Ball and Ms. White received an amount of PSAs equal to 50.0% and 30.0% of their respective annual base salaries.

Name
Grant Date Value of
Restricted Share
Awards
(per share)
Number of
Restricted
Share Awards
Grant Date Value of
Performance Share
Awards at Target
(per share)
Target
Number of
Performance
Share Awards
William J. Grubbs(1)
$
11.11
 
 
80,491
 
$
11.11
 
 
80,491
 
William J. Burns
$
11.11
 
 
35,442
 
$
11.11
 
 
35,442
 
Susan E. Ball
$
11.11
 
 
16,877
 
$
11.11
 
 
16,877
 
Christopher R. Pizzi
$
11.11
 
 
19,690
 
$
11.11
 
 
19,690
 
Buffy S. White
$
11.11
 
 
9,451
 
$
11.11
 
 
9,451
 
Timothy Fischer(2)
$
11.11
 
 
8,101
 
$
11.11
 
 
8,101
 
(1)Mr. Grubbs retired from the Company on January 15, 2019 and accordingly, pursuant to the Company’s policy and applicable plans, his unearned performance equity awards were forfeited.
(2)Mr. Fischer resigned from the Company February 1, 2019 and accordingly, pursuant to the Company’s policy and applicable plans unvested equity awards were forfeited.

All of the RSAs granted to the NEOs in 2018 provide for vesting of 33 and 1/3% of the award on each of the first, second and third anniversaries of the grant date, subject to the NEO’s continued employment through the vesting date. The PSAs granted to the NEOs in 2018 provide for the issuance of a number of restricted shares based on the level of attainment of cumulative Adjusted EBITDA (a non-GAAP financial measure) over a three-year period (weighted 75%) and the Adjusted EBITDA margin at the end of that three-year period (weighted 25%) as follows:

Performance Level
3-yr Cumulative Adjusted EBITDA Achieved ($000s)
Percentage of the Target Shares Earned
Adjusted EBITDA Margin Achieved
Percentage of the Target Shares Earned
Below Threshold
Less than $157,500
0%
Less than 5.75%
0%
Threshold
$157,500
75%
5.75%
77%
Target
$210,000
100%
7.50%
100%
Maximum
$231,000
110%
8.25%
110%

Any restricted shares issued under the PSA would vest on December 31, 2021, subject to the NEO’s continued employment through such date. See Annex A of this proxy statement for a reconciliation of non-GAAP financial measures to our results as reported under GAAP.

OTHER COMPENSATION AND BENEFITS

Deferred Compensation Plans

We maintain the 2003 Deferred Compensation Plan and the 2017 Nonqualified Deferred Compensation Plan, each an unfunded non-qualified deferred compensation arrangement, intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended, or the Code. Under the deferred compensation plans, designated employees including our NEOs, may elect to defer the receipt of a portion of their annual base salary, bonus and commission to our deferred compensation plans. We may also make a discretionary contribution to the deferred compensation plans on behalf of certain participants. Discretionary contributions to the 2003 Deferred Compensation Plan generally become vested three years from the date such contribution is made to the plan, upon the occurrence of a change in control or upon a participant’s retirement, death during employment or disability. Discretionary contributions to the 2017 Deferred Compensation Plan are subject to such vesting period

27

as determined by the Company at the time of the contribution. Generally, payments under the deferred compensation plans automatically commence upon a participant’s retirement, termination of employment or death during employment. Under certain limited circumstances described in the deferred compensation plans, participants may receive distributions during employment. To enable us to meet our financial commitment under the deferred compensation plans, assets may be set aside in a corporate-owned vehicle, which assets remain available to all our general creditors in the event of our insolvency. Participants of the deferred compensation plans are our unsecured general creditors with respect to the deferred compensation plan benefits. Currently, none of our NEOs have any amounts deferred under the 2013 Deferred Compensation Plan and no discretionary contributions were made to the plan in 2018.

401(k) Plan

We maintain a 401(k) plan. The plan permits eligible employees to make voluntary, pre-tax contributions to the plan up to a specified percentage of compensation, subject to applicable tax limitations. We may make a discretionary matching contribution to the plan equal to a pre-determined percentage of an employee’s voluntary, pre-tax contributions and may make an additional discretionary profit sharing contribution to the plan, subject to applicable tax limitations. Eligible employees who elect to participate in the plan are generally vested in any matching contribution after three years of service with us and fully vested at all times in their employee contributions to the plan. The plan is intended to be tax-qualified under Section 401(k) of the Code, so that contributions to the plan and income earned on plan contributions are not taxable to employees until withdrawn from the plan, and so that our contributions, if any, will be deductible by us when made. Our 401(k) matching contribution has a matching contribution rate equal to 25% of the first 6% of compensation contributed to the plan by eligible participants during each payroll period.

Other Benefits

Executives participate in the health and dental coverage, company-paid term life insurance, disability insurance, paid time off and paid holidays programs applicable to other employees in their locality. These benefits are designed to be competitive with overall market practices and are in place to attract and retain the necessary talent in the business.

Employment Agreements

Mr. Clark, CEO and President

On January 16, 2019 the Board appointed Kevin Clark as our President and Chief Executive Officer. We entered into an employment agreement (the “Clark Agreement”) with Mr. Clark with an initial term expiring on December 31, 2021, subject to automatic renewal for successive one year terms unless prior to the end of the initial term or any renewal term either party has given at least 90 days prior written notice of the intention not to renew the Clark Agreement. The Clark Agreement provides for Mr. Clark to receive an annual base salary of $825,000. Mr. Clark’s base salary will be reviewed for increase on an annual basis by the Board of Directors or the Compensation Committee. For each calendar year during the term, Mr. Clark is eligible to participate in the Company’s annual bonus plan with a target bonus of 100% of his base salary, based on achieving performance goals to be established by the Compensation Committee. In addition, for each calendar year during the term, Mr. Clark is eligible to participate in the Company’s long term incentive plan and receive awards valued at 275% of his base salary. Such awards will be upon terms and conditions determined by the Compensation Committee. Mr. Clark is also eligible to participate in all other benefit plans and fringe benefit arrangements available to the Company’s senior executives.

If Mr. Clark’s employment is terminated by the Company without cause (as defined in the Clark Agreement) or if Mr. Clark terminates his employment for good reason (as defined in the Clark Agreement), subject to his execution of a release, he will be entitled to a severance payment equal to the sum of (i) two years of his base salary plus (ii) an amount equal to two times the bonus Mr. Clark would have earned during the year in which such termination occurs (such amount to be determined by the Compensation Committee). In addition, all benefits will continue for a period of two years and all unvested stock appreciation rights, performance stock awards, stock options or other equity awards will immediately vest. If Mr. Clark’s employment is terminated because the Company has given Mr. Clark notice of non-renewal he will be entitled to a non-renewal payment equal to 18 months of his base salary.

28

During Mr. Clark’s employment and for a period of two years thereafter, Mr. Clark may not compete with the Company in any jurisdiction in which the Company’s business is conducted nor may he intentionally interfere with the Company’s relationship with any of its suppliers, customers or employees.

Mr. Grubbs, former CEO and President

On January 15, 2019, William J. Grubbs retired from his position as President and Chief Executive Officer of the Company and resigned as a Director.

On September 10, 2018, the Company entered into an agreement with Mr. Grubbs regarding his anticipated retirement. It provided, among other things, that Mr. Grubbs would (1) cease to serve as Chief Executive Officer and President of the Company and would resign and retire on the first to occur of (i) March 31, 2019 or (ii) the date on which the Board elects or appoints a new Chief Executive Officer; (2) receive his base salary through March 31, 2019, the bonus earned by him under the Company’s annual bonus plan for 2018, and health insurance coverage through March 31, 2019; and (3) vest in all stock awards that would by their terms vest on or prior to March 31, 2019 (95,552 shares), plus an additional 74,421 restricted stock awards. Other than as set forth above, Mr. Grubbs was not entitled to any additional benefits or compensation upon retirement.

Prior to the transition agreement, Mr. Grubbs was a party to an employment agreement with the Company. His base salary was subject to annual review by the Compensation Committee and Mr. Grubbs was eligible to receive an annual bonus of a target at 100% of his base salary but not in excess of 180% of his base salary based on the level of achievement of performance goals to be established by the Compensation Committee. Mr. Grubbs was eligible to participate in the Company’s equity incentive plan, as well as all benefit plans and fringe benefit arrangements available to our senior executives. If Mr. Grubbs’ employment agreement was not renewed by us at the end of any employment term, was terminated by us without cause or Mr. Grubbs terminates his employment for good reason (see “Potential Payments Upon Termination or Change in Control” below), and if he was not otherwise entitled to receive severance benefits under our Executive Severance Policy, subject to his execution of a release, he would have been entitled to a severance payment equal to the sum of (i) two years base salary and (ii) two times the average annual bonus paid in the immediately three prior calendar years and (iii) two years health benefits. In addition, any and all unvested stock appreciation rights, performance stock awards, stock options or other equity shall immediately vest upon such termination without cause or for good reason.

Mr. Burns, Executive Vice President and Chief Financial Officer

On February 1, 2019, the Company amended its employment agreement with William J. Burns to appoint him as its Executive Vice President and Chief Financial Officer. Mr. Burns previously served as the Company’s Chief Operating Officer from January 25, 2018 to February 1, 2019 and as the Company’s Chief Financial Officer since April 2013 to January 2018. His base salary remained unchanged at $525,000 per year and remains subject to annual review by the Compensation Committee, however, his eligibility to receive an annual bonus was reduced to a target of 70% of his base salary as a short-term incentive and 125% as a long-term incentive based on the level of achievement of performance goals as Chief Financial Officer to be established by the Compensation Committee.

On January 26, 2018, the Company had previously amended and restated its employment agreement with Mr. Burns in connection with his promotion to Chief Operating Officer. At that time, his base salary was increased from $440,000 to $525,000 per year when he was promoted to Chief Operating Officer. His base salary remained subject to annual review by the Compensation Committee and in his capacity as Chief Operating Officer, Mr. Burns was eligible to receive an annual bonus with a target of 75% of his base salary as a short-term incentive and 150% as a long-term incentive based on the level of achievement of performance goals as Chief Operating Officer to be established by the Compensation Committee.

Mr. Burns remains eligible to participate in the Company’s equity incentive plan, as well as all benefit plans and fringe benefit arrangements available to our senior executives. If Mr. Burns’ employment is terminated by us without cause or Mr. Burns terminates his employment for good reason, and if he is not otherwise entitled to receive severance benefits under our Executive Severance Policy, subject to his execution of a release, he will be entitled to a severance payment equal to one year’s base salary and benefits.

29

Severance/Change of Control Arrangements

We maintain an Executive Severance Policy, or the Severance Policy pursuant to which, subject to executing a release, each NEO is entitled to receive certain severance payments and benefits if, within 90 days prior to, or within 18 months after, a “Change of Control” (as defined in the Severance Policy) of the Company, such NEO is terminated without cause or incurs an “involuntary termination” (i.e. a resignation for good reason). It is a “double-trigger” policy as a “Change of Control” must occur and the NEO must be terminated without Cause (as defined in the Severance Policy) or the NEO terminates for “Good Reason” (as defined in the Severance Policy). Under the Severance Policy, Mr. Grubbs, Mr. Burns, Mr. Pizzi, and Ms. Ball were entitled to receive continued base salary for a period of two years following termination, plus two times the amount of their target bonus for the year in which a Change of Control occurs. In addition, during such period, we would continue to make group health, life or other similar insurance plans available to such NEO and his or her dependents, and we would pay for such coverage to the extent we paid for such coverage prior to the termination of employment. The severance benefits payable under the Severance Policy are subject to: (1) the six-month delay under Section 409A of the Code; (2) the execution of a release; and (3) reduction to avoid any excise tax on “parachute payments” if the NEO would benefit from such reduction as compared to paying the excise tax.

In addition, under our general severance pay policy for all of our eligible employees, if an NEO (other than Mr. Grubbs and Mr. Burns whose arrangements are included in their employment agreements) is terminated without cause (as defined in our general severance pay policy) other than in connection with a Change of Control, the NEO, subject to executing a release would be entitled to one week’s base salary for each full year of continuous service with us.

Perquisites

Our NEOs are not entitled to any perquisites that are not otherwise available to all of our employees. In this regard, it should be noted that we do not provide defined benefit pension arrangements, post-retirement health coverage or similar benefits for our executives or employees.

Stock Ownership Guidelines

Effective as of January 1, 2014, our Company’s chief executive officer must hold shares of Common Stock equal to three times his base salary, to be accumulated over three years, and the Company’s other senior executives must hold shares of Common Stock equal to one times his or her base salary, to be accumulated over three years. All senior executives who have served in that capacity for more than three years are in compliance with this guideline.

Impact of Accounting and Tax Matters

As a general matter, the Compensation Committee reviews and considers the various tax and accounting implications of compensation vehicles that we utilize. With respect to accounting matters, the Compensation Committee examines the accounting cost associated with equity compensation in light of ASC Topic 718.

With respect to tax matters, the Compensation Committee considers the impact of Section 162(m) of the Code, which generally prohibits any publicly-held corporation from taking a Federal income tax deduction for compensation paid in excess of $1 million in any taxable year to the chief executive officer and certain other executive officers. Prior to the enactment of the Tax Cuts and Jobs Act in December 2017, certain types of compensation were deductible if the requirements of Section 162(m) of the Internal Revenue Code with respect to performance-based compensation were satisfied. Historically, the Compensation Committee has attempted to maximize the effectiveness of our executive compensation plans in this regard while retaining the discretion to grant awards (such as restricted stock with time-based vesting) not complying with the performance-based exception of 162(m) if deemed to be in the best interests of the Company to do so. As was the case prior to the enactment of the Tax Cuts and Jobs Act, the Compensation Committee will continue to monitor issues concerning the deductibility of executive compensation. Since corporateour compensation policies and practices to determine whether our risk management objectives may not always be consistent with the requirements for tax deductibility, the Compensation Committee is prepared, when it deems appropriate, to enter into compensation arrangements under which payments will not be deductible under Section 162(m) of the Internal Revenue Code. Thus, deductibility will be one of many factors considered by the Compensation Committee in ascertaining appropriate levels or modes of compensation.

30

Incentive Compensation Recoupment “Clawback” Policy

The Company has an Incentive Compensation Recoupment Policy (“Clawback Policy”) for executive officers. This policy further strengthens the risk mitigation program by defining the economic consequences that misconduct has on the executive officer’s incentive-related compensation. If there is a “Restatement” and the Board of Directors determines that an executive received incentive compensation over a 3-year look back period (during which the policy was in effect) in excess of the amount that would have been paid to the executive had such incentive compensation been calculated based on the restatement, regardless of fault, the Board of Directors has the discretion to (i) require the executive to repay all or a portion of any cash incentive compensation, (ii) cancel all or a portion of any vested or unvested incentive compensation awarded to the executive, and (iii) require the executive to repay all or a portion of any gains realizedare being met with respect to the award. Under the policy, “Restatement” means any restatement ofincentivizing the Company’s financial statements due to non-compliance with any accounting requirement where such restatement is due to the covered person’s fraud or misconduct, errors or omissions or other related activities.employees.

49

COMPENSATION COMMITTEE REPORT

The Compensation Committee of the Company has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management and, based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in the Proxy Statement.

THE COMPENSATION COMMITTEE

Joseph A. Trunfio, PhD,Ph.D., Chairman

W. Larry Cash, Member

Darrell S. Freeman, Sr., Member

Mark Perlberg, JD, Member

50

31

SUMMARY COMPENSATION TABLE

The following table provides a summary of the compensation received by our NEOs for the fiscal years ended December 31, 2018, 20172020, 2019, and 2016.2018.

Name and Principal
Position(1)(4)
Year
Salary
($)
Bonus
($)
Stock
Awards
($)(2)
Option
Awards
($)
Non-Equity
Incentive
Plan
Compensation
($)
Change in
Pension Value
and
Nonqualified
Deferred
Compensation
Earnings
($)
All Other
Compensation
($)(3)
Total
($)
William J. Grubbs
 
2018
 
 
730,000
 
 
 
 
1,788,510
 
 
 
 
146,000
 
 
 
 
 
 
2,664,510
 
Former Chief Executive Officer
 
2017
 
 
730,000
 
 
 
 
1,788,509
 
 
 
 
146,000
 
 
 
 
 
 
2,664,509
 
and President
 
2016
 
 
685,000
 
 
 
 
1,370,014
 
 
 
 
437,564
 
 
 
 
 
 
2,492,578
 
William J. Burns
 
2018
 
 
521,154
 
 
 
 
787,520
 
 
 
 
63,000
 
 
 
 
 
 
1,371,674
 
Chief Financial Officer and
 
2017
 
 
475,000
 
 
 
 
593,757
 
 
 
 
66,500
 
 
 
 
 
 
1,135,257
 
Principal Accounting Officer
 
2016
 
 
440,000
 
 
 
 
396,002
 
 
 
 
207,751
 
 
 
 
1,656
 
 
1,045,409
 
Susan E. Ball
 
2018
 
 
375,000
 
 
 
 
375,006
 
 
 
 
45,000
 
 
 
 
 
 
795,006
 
General Counsel
 
2017
 
 
375,000
 
 
 
 
375,026
 
 
 
 
81,000
 
 
 
 
 
 
831,026
 
and Secretary
 
2016
 
 
335,000
 
 
 
 
234,507
 
 
 
 
142,526
 
 
 
 
1,656
 
 
713,689
 
Christopher R. Pizzi
 
2018
 
 
341,923
 
 
 
 
437,512
 
 
 
 
39,200
 
 
 
 
 
 
818,635
 
Chief Accounting
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Officer
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buffy S. White
 
2018
 
 
347,308
 
 
 
 
210,000
 
 
 
 
37,800
 
 
 
 
 
 
595,108
 
President, Travel Nurse
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and Allied and Workforce Solutions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timothy Fischer
 
2018
 
 
300,000
 
 
 
 
180,004
 
 
 
 
 
 
 
 
 
 
480,004
 
President, Medical
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Doctor Associates
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Name and Principal

Position

 Year Salary ($) 

Stock

Awards

($)(1)

 

Non-Equity

Incentive

Plan Compensation

($)

 All Other Compensation ($)(2) 

Total

($)

             

Kevin C. Clark

Chief Executive Officer

and President

 2020 790,731 2,268,758 1,067,073  4,126,562
 2019 786,923 2,268,764 368,915  3,424,602
             

William J. Burns

Chief Financial Officer and

Principal Accounting Officer

 2020 511,269 656,260 478,272  1,645,801
 2019 525,000 656,258 164,335  1,345,593
 2018 521,154 787,520 63,000  1,371,674
             

Susan E. Ball, Chief

Administrative Officer, General
Counsel and Secretary

 2020 409,015 420,003 409,948  1,238,966
 2019 413,077 375,008 131,468  919,553
 2018 375,000 375,006 45,000  795,006
             
Stephen A. Saville, Group
President, Locums, Education
and Corporate Development
 2020 418,754 322,509 419,708 19,203 1,180,174
 2019 305,962 322,500 144,212 44,654 817,328
             

Buffy S. White

Group President,

Workforce Solutions

 2020 411,831 322,509 419,708 26,387 1,180,435
 2019 392,308 210,000 186,128 84,486 872,922
 2018 347,308 210,000 37,800  595,108

(1)On January 25, 2018, Mr. Burns was promoted from Executive Vice President and Chief Financial Officer to Executive Vice President and Chief Operating Officer. On February 1 2019, the Company eliminated the Chief Operating Officer role and Mr. Burns reverted to his prior Chief Financial Officer position. On January 25, 2018, Mr. Pizzi was promoted from Vice President, Corporate Controller to Senior Vice President and Chief Financial Officer. On February 1, 2019, the Company appointed Mr. Pizzi as its Senior Vice President and Chief Accounting Officer.
(2)Amounts in this column reflect the aggregate grant date fair value of awards of restricted stockRSAs and Performance-based Share AwardsPSAs granted under our 20142020 Omnibus Incentive Plan and computed in accordance with ASC Topic 718. The grant date fair value of the Performance-based Share Awards is based on the probable outcome of the performance conditions as of the grant date, in accordance with Item 402 of Regulation S-K. The aggregate grant date fair value per share of stock awards granted on March 31, 2018,2020 was $11.11.$6.74. The grant date fair value of the PSAs is based on the probable outcome of the performance conditions as of the grant date. The fair value of awardsthe 2020 PSAs at the maximum level of achievement for performance awards for 2018 was as follows: Mr. Grubbs, $1,967,370;Clark, $2,419,855; Mr. Burns, $866,280; Mr. Pizzi, $481,263; Mr. Fischer, $198,014;$699,969; Ms. Ball, $412,514;$447,974; Mr. Saville, $343,989; and Ms. White, $231,010.$343,989. Further information regarding the 2018Fiscal 2020 awards is included in the “Grants of Plan-Based Awards” and “Outstanding Equity Awards at 20182020 Year-End” tables later in this proxy statement. See Note 1415 of the notes to our consolidated financial statements contained in our 20182020 Annual Report on Form 10-K filed on March 1, 2019February 25, 2021 for a discussion of all assumptions made by us in determining the values of equity awards.
(3)(2)The “All Other Compensation” column consists of relocation expenses for Ms. White and Mr. Saville of $15,000 and $14,000, respectively, in Fiscal 2020, and reimbursement of related taxes for Ms. White and Mr. Saville of $7,906 and $5,203, respectively, in Fiscal 2020. In addition, “All Other Compensation” includes 401K employer matching contributions of Ms. White in 2016.Fiscal 2020 of $3,481.

(4)51Mr. Fischer resigned from the Company February 1, 2019 and pursuant to the Company’s policy and applicable plans the incentive bonus was not paid and unvested equity awards were forfeited. Mr. Grubbs retired from the Company on January 15, 2019. Pursuant to his retirement agreement, the Company accelerated the vest date on his outstanding restricted share awards to the date of his retirement. Pursuant to the Company’s policy and applicable plans, his unearned performance equity awards were forfeited.

32

GRANTS OF PLAN-BASED AWARDS

The following table summarizes equity and non-equity incentive plan awards granted to our NEOs during the last fiscal year.Fiscal 2020.

Name
 
 
   
   
Estimated Future Payouts
Under Non-Equity
Incentive Plan Awards(1)
Estimated Future Payouts
Under Equity Incentive
Plan Awards(2)
All Other
Stock Awards:
Number Of
Shares Of
Stock Or
Units (#)(3)
Grant Date
Fair Value
of Stock
Awards
($)(4)
Grant
Date
Committee
Action Date
Threshold
($)
Target
($)
Maximum
($)
Threshold
(#)
Target
(#)
Maximum
(#)
William J. Grubbs(5)
 
3/31/18
 
 
2/19/18
 
 
146,000
 
 
730,000
 
 
1,314,000
 
 
 
 
 
 
 
 
 
 
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
16,099
 
 
80,491
 
 
96,590
 
 
 
 
894,255
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80,491
 
 
894,255
 
William J. Burns
 
3/31/18
 
 
2/19/18
 
 
78,750
 
 
393,750
 
 
708,750
 
 
 
 
 
 
 
 
 
 
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
7,089
 
 
35,442
 
 
42,531
 
 
 
 
393,760
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35,442
 
 
393,760
 
Susan E. Ball
 
3/31/18
 
 
2/19/18
 
 
45,000
 
 
225,000
 
 
405,000
 
 
 
 
 
 
 
 
 
 
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
3,376
 
 
16,877
 
 
20,253
 
 
 
 
187,503
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16,877
 
 
187,503
 
Christopher R. Pizzi
 
3/31/18
 
 
2/19/18
 
 
49,000
 
 
245,000
 
 
441,000
 
 
 
 
 
 
 
 
 
 
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
3,398
 
 
19,690
 
 
23,628
 
 
 
 
218,756
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19,690
 
 
218,756
 
Buffy S. White
 
3/31/18
 
 
2/19/18
 
 
42,000
 
 
210,000
 
 
378,000
 
 
 
 
 
 
 
 
 
 
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
1,891
 
 
9,451
 
 
11,342
 
 
 
 
105,000
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9,451
 
 
105,000
 
Timothy Fischer(5)
 
3/31/18
 
 
2/19/18
 
 
30,000
 
 
150,000
 
 
270,000
 
 
 
 
 
 
 
 
 
 
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
1,621
 
 
8,101
 
 
9,722
 
 
 
 
90,002
 
 
 
3/31/18
 
 
2/19/18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8,101
 
 
90,002
 

      Estimated Future Payouts
Under Non-Equity
Incentive Plan Awards(1)
 Estimated Future Payouts
Under Equity Incentive
Plan Awards(2)
 All Other
Stock Awards:
Number Of
Shares Of
Stock Or
Units (#)(3)
 Grant Date
Fair Value
of Stock
Awards
($)(4)
Name Grant
Date
 Committee
Action
Date
 Threshold
($)
 Target
($)
 Maximum
($)
 Threshold
(#)
 Target
(#)
 Maximum
(#)
Kevin C. Clark 3/31/20 2/18/20 165,000 825,000 1,485,000     
  3/31/20 2/18/20    22,418 112,092 134,510  755,500
  3/31/20 2/18/20       224,519 1,513,258
                     
William J. Burns 3/31/20 2/18/20 73,500 367,500 661,500     
  3/31/20 2/18/20    6,485 32,424 38,909  218,538
  3/31/20 2/18/20       64,944 437,723
                     
Susan E. Ball 3/31/20 2/18/20 63,000 315,000 567,000     
  3/31/20 2/18/20    4,150 20,751 24,901  139,862
  3/31/20 2/18/20       41,564 280,141
                     
Stephen A. Saville 3/31/20 2/18/20 64,500 322,500 580,500     
  3/31/20 2/18/20    3,187 15,934 19,121  107,395
  3/31/20 2/18/20       31,916 215,114
                     
Buffy S. White 3/31/20 2/18/20 64,500 322,500 580,500     
  3/31/20 2/18/20    3,187 15,934 19,121  107,395
  3/31/20 2/18/20       31,916 215,114

(1)Amounts relate toConstitutes threshold, target, and maximum award opportunities for our NEOs under the NEOs individualCompany’s annual cash incentive program, as described in the Compensation Discussion and Analysis contained herein.section.
(2)TheConstitutes threshold, target, and maximum number of shares relaterelated to the Performance-based Share Awards (PSAs)PSAs granted to the NEOs for 2018 withFiscal 2020. PSAs have a three-year performance period ending on March 31, 2021.2023. The PSAs provide for the issuance of a number of restricted shares after the three-year performance period based on the level of attainment of cumulative Adjusted EBITDA (a non-GAAP financial measure) (weighted 75%) and Adjusted EBITDA Margin (weighted 25%) at the end of the three-year period as discussed above. Any restricted shares issued under the PSAs would vest, if at all, on or about March 31, 2021.2023.

(3)All other stock awards include restricted stock awardsRSAs granted to the NEOs for 2018,Fiscal 2020, as described in the Compensation Discussion and Analysis contained herein.section. All of the restricted stock awardsRSAs provide for vesting of 33 and 1/3%33.33% of the award on each of the first, second and third anniversaries of the grant date, subject to the NEO’s continued employment through the vesting date.

(4)Grant date fair value is calculated by multiplying the number of shares times the fair value per award.each equity award, computed in accordance with ASC Topic 718. The grant date fair value of the Performance-based Share AwardsPSAs is based on the probable outcome of the performance conditions as of the grant date. Refer to the footnotes to the Summary Compensation Table above.

(5)52Mr. Fischer resigned from the Company February 1, 2019 and pursuant to the Company’s policy and applicable plans the incentive bonus was not paid and unvested equity awards were forfeited. Mr. Grubbs retired from the Company on January 15, 2019. Pursuant to his retirement agreement, the Company accelerated the vest date on his outstanding restricted share awards to the date of his retirement. Pursuant to the Company’s policy and applicable plans, his unearned performance equity awards were forfeited.

33

OUTSTANDING EQUITY AWARDS AT 20182020 YEAR-END

The following table summarizes the outstanding equity awards as of December 31, 20182020 held by our NEOs.

 
 
Option Awards
Stock Awards
Name
Grant
Date
Number of
Securities
Underlying
Unexercised
Options
Exercisable
(#)
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
(#)(1)
Equity
Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)
Option
Exercise
Price
($)
Option
Expiration
Date
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)(1)
Market
Value of
Shares
or Units
of Stock
That
Have Not
Vested
($)(2)
Equity
Incentive Plan
Awards:
Number of
Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
(#)(3)
Equity
Incentive Plan
Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)(2)
William J. Grubbs(4)
 
3/31/2016
 
 
 
 
 
 
 
 
 
 
 
 
19,633
 
 
143,910
 
 
 
 
 
 
 
3/31/2017
 
 
 
 
 
 
 
 
 
 
 
 
20,758
 
 
152,156
 
 
62,274
 
 
456,468
 
 
 
3/31/2018
 
 
 
 
 
 
 
 
 
 
 
 
101,249
 
 
742,155
 
 
80,491
 
 
589,999
 
William J. Burns
 
3/31/2016
 
 
 
 
 
 
 
 
 
 
 
 
5,675
 
 
41,598
 
 
 
 
 
 
 
3/31/2017
 
 
 
 
 
 
 
 
 
 
 
 
13,782
 
 
101,022
 
 
20,674
 
 
151,540
 
 
 
3/31/2018
 
 
 
 
 
 
 
 
 
 
 
 
35,442
 
 
259,790
 
 
35,442
 
 
259,790
 
Susan E. Ball
 
6/01/2013
 
 
5,625
 
 
 
 
 
 
5.21
 
 
6/01/2020
 
 
 
 
 
 
 
 
 
 
 
3/31/2016
 
 
 
 
 
 
 
 
 
 
 
 
3,361
 
 
24,636
 
 
 
 
 
 
 
3/31/2017
 
 
 
 
 
 
 
 
 
 
 
 
8,705
 
 
63,808
 
 
13,058
 
 
95,715
 
 
 
3/31/2018
 
 
 
 
 
 
 
 
 
 
 
 
16,877
 
 
123,708
 
 
16,877
 
 
123,708
 
Christopher R. Pizzi
 
3/31/2016
 
 
 
 
 
 
 
 
 
 
 
 
1,204
 
 
8,825
 
 
 
 
 
 
 
3/31/2017
 
 
 
 
 
 
 
 
 
 
 
 
5,525
 
 
40,498
 
 
3,065
 
 
22,466
 
 
 
3/31/2018
 
 
 
 
 
 
 
 
 
 
 
 
19,690
 
 
144,328
 
 
19,690
 
 
144,328
 
Buffy S. White
 
3/31/2017
 
 
 
 
 
 
 
 
 
 
 
 
3,691
 
 
27,055
 
 
5,537
 
 
40,586
 
 
 
3/31/2018
 
 
 
 
 
 
 
 
 
 
 
 
9,451
 
 
69,276
 
 
9,451
 
 
69,276
 
Timothy Fischer(4)
 
4/11/2016
 
 
 
 
 
 
 
 
 
 
 
 
2,377
 
 
17,423
 
 
 
 
 
 
 
3/31/2017
 
 
 
 
 
 
 
 
 
 
 
 
3,830
 
 
28,074
 
 
5,746
 
 
42,118
 
 
 
3/31/2018
 
 
 
 
 
 
 
 
 
 
 
 
8,101
 
 
59,380
 
 
8,101
 
 
59,380
 

    Stock Awards
  Grant
Date
 Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)(1)
 Market
Value of
Shares
or Units
of Stock
That
Have Not
Vested
($)(2)
 Equity
Incentive Plan
Awards:
Number of
Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
(#)(3)
 Equity
Incentive Plan
Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)(2)
Kevin C. Clark 3/31/19 161,346 1,431,139 80,682 715,649
  3/31/20 224,519 1,991,484 112,092 994,256
           
William J. Burns 3/31/18 11,812 104,772 35,442 314,371
 3/31/19 46,670 413,963 23,338 207,008
 3/31/20 64,944 576,053 32,424 287,601
           
Susan E. Ball 3/31/18 5.625 49,894 16,877 149,699
 3/31/19 26,669 236,554 13,336 118,290
 3/31/20 41,564 368,673 20,751 184,061
           
Stephen A. Saville 4/15/19 21,497 190,678 10,750 95,353
  3/31/20 31,916 283,095 15,934 141,335
           
Buffy S. White 3/31/18 3,150 27,941 9,451 83,830
 3/31/19 14,934 132,465 7,468 66,241
 3/31/20 31,916 283,095 15,934 141,335

(1)Awards vest in three equal installments on the anniversary of the grant date, provided that the officer continues to be employed with us through each vesting date.
(2)Market value of shares is measured by reference to ourthe Company’s closing stock price as of December 31, 20182020 of $7.33.$8.87.

(3)Performance-based Share Awards (PSAs),PSAs, if earned, provide for the issuance of a number of restricted shares after a three-year performance period. The amounts reflected in the table assume that all goals under the Performance-based Share AwardsPSAs will be achieved at the target level. The amounts indicated are not necessarily indicative of the amounts that may be realized by our NEOs.

(4)53Mr. Fischer resigned from the Company February 1, 2019 and pursuant to the Company’s policy and applicable plans, unvested equity awards were forfeited. Mr. Grubbs retired from the Company January 15, 2019 and, pursuant to the Company’s policy and applicable plans, his unearned performance equity awards were forfeited.

34

OPTION EXERCISES AND STOCK VESTED IN 20182020

 
Option Awards
Stock Awards
Name
Number of
Shares
Acquired on
Exercise
(#)
Value Realized
on Exercise
($)
Number of
Shares
Acquired on
Vesting
(#)
Value Realized
on Vesting
($)(1)
William J. Grubbs
 
 
 
 
 
84,091
 
 
827,164
 
William J. Burns
 
 
 
 
 
25,815
 
 
255,850
 
Susan E. Ball
 
 
 
 
 
15,857
 
 
157,842
 
Christopher R. Pizzi
 
 
 
 
 
6,886
 
 
69,938
 
Buffy S. White
 
 
 
 
 
1,846
 
 
20,509
 
Timothy Fischer
 
 
 
 
 
7,723
 
 
73,360
 
 Stock Awards
Name

Number of

Shares Acquired

on Vesting

(#)

 

Value Realized

on Vesting

($)(1)

Kevin C. Clark80,698 543,905
William J. Burns42,047 283,397
Susan E. Ball23,317 157,157
Stephen A. Saville10,753 72,475
Buffy S. White12,466 84,021

(1)Value realized upon vesting of the stock awards represents the total number of shares vested multiplied by the closing price on the vesting date.

NONQUALIFIED DEFERRED COMPENSATION 2020

Name 

Executive

Contribution

in Last FY

($)(a)(1)

 

Registrants

Contributions

in Last FY

($)(b)

 

Aggregate

Earnings in

Last FY

($)(c)

 

Aggregate

Withdrawals/

Distributions

($)(d)

 

Aggregate

Balance at

Last FYE

($)(e)(2)(3)

Kevin C. Clark     
William J. Burns     
Susan E. Ball     
Stephen A. Saville     
Buffy S. White 21,361  18,433  108,134

(1)Includes aggregate deferred cash compensation in Fiscal 2020.
(2)Amounts in column (a) are included in the NEOs compensation for 2020 as reflected in the Summary of Compensation Table on page 51. On a cumulative basis, $80,888 for Ms. White has been reported as compensation to the NEO on the Summary of Compensation Table, and on prior Company proxy statements, and is included in column (e).

(3)A description of the Nonqualified Deferred Compensation Plans is set forth in the Compensation Discussion and Analysis section.

54

Potential Payments Upon Termination or Change in Control

The tables below describe and estimate the amounts and benefits that our NEOs would have been entitled to receive upon a change of control or a termination of their employment in certain circumstances, assuming such events occurred as of December 31, 20182020 (based on the plans and arrangements in effect on such date). Where applicable, the amounts payable assume a $7.33an $8.87 fair value of our Common Stock (the closing price on December 31, 2018)2020). The estimated payments are not necessarily indicative of the actual amounts any of our NEOs would have received in such circumstances. The tables exclude (i) compensation amounts accrued through December 31, 20182020 that would be paid in the normal course of continued employment, such as accrued but unpaid salary and (ii) vested account balances under our retirement plans that are generally available to all of our salaried employees. In addition, where applicable, the Cash Payment amounts include the actual amount paid to the NEOs for 2018,2020, since the hypothetical termination or change of control date is the last day of the fiscal year for which the bonus is to be determined.

William J. Grubbs:
Non-Change
of Control
Termination
without Cause
or for Good
Reason
($)(1)
Termination
for Cause or
Resignation
without Good
Reason
($)
Change of
Control
Termination
without
Cause or for
Good Reason
($)
Change of
Control
without
Termination
($)
Cash Payment
 
1,933,043
(2)
 
 
 
2,920,000
(8)
 
 
Health and Life Insurance Benefits
 
22,048
(2)
 
 
 
22,048
(9)
 
 
Acceleration of Equity Awards
 
2,084,689
(2)
 
 
 
2,084,689
(3)
 
2,084,689
(3)
Total Termination Benefits:
 
4,039,780
 
 
 
 
5,026,737
 
 
2,084,689
 

Mr. Kevin C. Clark:Non-Change
of Control
Termination
without Cause
or for Good
Reason
($)(1)
Termination
for Cause or
Resignation
without Good
Reason
($)
Change of
Control
Termination
without
Cause or for
Good Reason
($)
Change of
Control
without
Termination
($)
Cash Payment 3,300,000(2)   3,300,000(2)  
Health and Life Insurance Benefits 1,632(3)   1,632(3)  
Acceleration of Equity Awards 5,132,528(4)   5,132,528(4) 5,132,528(4)
Total Termination Benefits: 8,434,160    8,434,160  5,132,528 

William J. Burns:Non-Change
of Control
Termination
without Cause
($)(1)
Termination
for Cause or
Resignation
($)
Change of
Control
Termination
without
Cause or for
Good Reason
($)
Change of
Control
without
Termination
($)
Cash Payment 525,000(5)   1,785,000(2)  
Health and Life Insurance Benefits 17,908(5)   35,816(3)  
Acceleration of Equity Awards     1,903,768(4) 1,903,768(4)
Total Termination Benefits: 542,908    3,724,584  1,903,768 

Susan E. Ball:Non-Change
of Control
Termination
without Cause
($)
Termination
for Cause or
Resignation
($)(6)
Change of
Control
Termination
without
Cause or for
Good Reason
($)(7)(8)
Change of
Control
without
Termination
($)
Cash Payment 145,385(9)   1,470,000(2)  
Health and Life Insurance Benefits     26,812(3)  
Acceleration of Equity Awards     1,107,171(4) 1,107,171(4)
Total Termination Benefits: 145,385    2,603,983  1,107,171 

William J. Burns:
Non-Change
of Control
Termination
without Cause
($)(1)
Termination
for Cause or
Resignation
($)
Change of
Control
Termination
without
Cause or for
Good Reason
($)
Change of
Control
without
Termination
($)
Cash Payment
 
525,000
(2)
 
 
 
1,837,500
(8)
 
 
Health and Life Insurance Benefits
 
14,424
(2)
 
 
 
28,848
(9)
 
 
Acceleration of Equity Awards
 
 
 
 
 
813,740
(3)
 
813,740
(3)
Total Termination Benefits:
 
539,424
 
 
 
 
2,680,088
 
 
813,740
 
55

35

Stephen A. Saville:Non-Change
of Control
Termination
without Cause
($)(1)
Termination
for Cause or
Resignation
($)(6)
Change of
Control
Termination
without
Cause or for
Good Reason
($)(7)(8)
Change of
Control
without
Termination
($)
Cash Payment 430,000(10)   752,500(11)  
Health and Life Insurance Benefits     17,851(12)  
Acceleration of Equity Awards     710,460(4) 710,460(4)
Total Termination Benefits: 430,000    1,480,811  710,460 

Buffy S. White:

Non-Change
of Control
Termination

without Cause

($)(1)

Termination for Cause or

Resignation

($)(6)

Change of
Control
Termination
without
Cause or for
Good Reason
($)(7)(8)

Change of
Control
without
Termination

($)

Cash Payment 430,000(10)   752,500(11)  
Health and Life Insurance Benefits     351(12)  
Acceleration of Equity Awards     734,906(4) 734,906(4)
Total Termination Benefits: 430,000    1,487,757  734,906 

Susan E. Ball:
Non-Change
of Control
Termination
without Cause
($)
Termination
for Cause or
Resignation
($)(4)
Change of
Control
Termination
without
Cause or for
Good Reason
($)(5)(6)
Change of
Control
without
Termination
($)
Cash Payment
 
115,385
(7)
 
 
 
1,200,000
(8)
 
 
Health and Life Insurance Benefits
 
 
 
 
 
22,269
(9)
 
 
Acceleration of Equity Awards
 
 
 
 
 
443,501
(3)
 
443,501
(3)
Total Termination Benefits:
 
115,385
 
 
 
 
1,665,770
 
 
443,501
 
Christopher R. Pizzi:
Non-Change
of Control
Termination
without Cause
($)
Termination
for Cause or
Resignation
($)(4)
Change of
Control
Termination
without
Cause or for
Good Reason
($)(5)(6)
Change of
Control
without
Termination
($)
Cash Payment
 
26,923
(7)
 
 
 
1,190,000
(8)
 
 
Health and Life Insurance Benefits
 
 
 
 
 
28,560
(9)
 
 
Acceleration of Equity Awards
 
 
 
 
 
360,445
(3)
 
360,445
(3)
Total Termination Benefits:
 
26,923
 
 
 
 
1,579,005
 
 
360,445
 
Buffy S. White:
Non-Change
of Control
Termination
without Cause
($)
Termination
for Cause or
Resignation
($)(4)
Change of
Control
Termination
without
Cause or for
Good Reason
($)(5)(6)
Change of
Control
without
Termination
($)
Cash Payment
 
13,462
(7)
 
 
 
560,000
(10)
 
 
Health and Life Insurance Benefits
 
 
 
 
 
336
(11)
 
 
Acceleration of Equity Awards
 
 
 
 
 
206,193
(3)
 
206,193
(3)
Total Termination Benefits:
 
13,462
 
 
 
 
766,529
 
 
206,193
 
Timothy Fischer (12):
Non-Change
of Control
Termination
without Cause
($)
Termination
for Cause or
Resignation
($)(4)
Change of
Control
Termination
without
Cause or for
Good Reason
($)(5)(6)
Change of
Control
without
Termination
($)
Cash Payment
 
11,538
(7)
 
 
 
450,000
(10)
 
 
Health and Life Insurance Benefits
 
 
 
 
 
14,232
(11)
 
 
Acceleration of Equity Awards
 
 
 
 
 
206,376
(3)
 
206,376
(3)
Total Termination Benefits:
 
11,538
 
 
 
 
670,608
 
 
206,376
 

(1)“Cause” is generally defined under both Mr. Grubbs’ and Mr. Burns’Clark’s employment agreementsagreement as: (i) an act or acts of fraud or dishonesty which results in the personal enrichment of him or another person or entity at the expense of the Company; (ii) his admission, confession, pleading of guilty or nolo contendere to, or conviction of (x) any felony (other than third degree vehicular infractions), or (y) of any other crime or offense involving misuse or misappropriation of money or other property; (iii) his continuedknowing, intentional and material breach of the Company’s Code of Conduct or any obligations under his employment agreement for 30 days after the Company has given him notice thereof in reasonable detail, if such breach has not been cured by him during such period;Senior Officers; or (iv) his gross negligence or willful misconduct with respect to his duties or gross misfeasance of office.that results in material harm to the Company.

“Cause” is generally defined under Mr. Burns’ employment agreement as: (i) an act or acts of fraud or dishonesty which results in the personal enrichment of him or another person or entity at the expense of the Company; (ii) admission, confession, pleading of guilty or nolo contendere to, or conviction of (x) any felony (other than third degree vehicular infractions), or (y) of any other crime or offense involving misuse or misappropriation of money or other property; (iii) continued material breach of the Company’s Code of Conduct or any obligations under the employment agreement for 30 days after the Company has given notice thereof in reasonable detail, if such breach has not been cured by him during such period; or (iv) gross negligence or willful misconduct with respect to his/her duties or gross misfeasance of office.

“Cause” is generally defined under Mr. Saville’s offer letter and Ms. White’s agreements as: (i) an act or acts of fraud or dishonesty which results in the personal enrichment of him/her or another person or entity at the expense of the Company; (ii) pleading of guilty or nolo contendere to, or conviction of (x) any felony (other than third degree vehicular infractions), or (y) of any other crime or offense involving misuse or misappropriation of money or other property; (iii) knowing, intentional and material breach of the Company’s Code of Conduct for Senior Officers; or (iv) gross negligence or willful misconduct with respect to his/her duties or gross misfeasance of office that results in material harm to the Company.

56

36

“Good Reason” is generally defined under both Mr. Grubbs’ and Mr. Burns’Clark’s employment agreementsagreement as, without his written consent, the occurrence of any of the following events that are not cured by the Company within 30 days of written notice specifying the occurrence such Good Reason event, which notice will be given to the Company within 90 days after the occurrence of the Good Reason event: (i) a material diminution in his then authority, duties or responsibilities; (ii) a material diminution in his base salary;compensation components; (iii) a relocation of his principal business location to a location more than 25 miles outside of Boca Raton, Florida; or (iv) any material breach of the employment agreement by the Company.

“Good Reason” is generally defined under Mr. Burns’ employment agreement as, without his written consent, the occurrence of any of the following events that are not cured by the Company within 30 days of written notice specifying the occurrence such Good Reason event, which notice will be given to the Company within 90 days after the occurrence of the Good Reason event: (i) a material diminution in his then authority, duties or responsibilities; (ii) a material diminution in his Base Salary; (iii) a relocation of his principal business location to a location more than 50 miles outside of Boca Raton, Florida; or (iv) any material breach of the employment agreement by the Company.

“Good Reason” is generally defined under both Mr. Saville’s offer letter as well as Ms. White’s agreements as, without his written consent, the occurrence of any of the following events that are not cured by the Company within 30 days of written notice specifying the occurrence such Good Reason event, which notice will be given to the Company within 90 days after the occurrence of the Good Reason event: (i) a material diminution in his/her then authority, duties or responsibilities or assignment of duties that are inconsistent with his/her status, title or position; (ii) a material diminution in his/her base salary or other compensation components; (iii) a relocation of his principal business location to a location more than 50 miles outside of Boca Raton, Florida; or (iv) any material breach of the employment agreement by the Company.

(2)Effective April 1, 2016, a new employment agreement was approved for Mr. Grubbs, revising the amounts to equalRepresents two times the sum of (i) two years base salary and (ii) two timestarget bonus. The severance benefits payable under the average annual bonusSeverance Policy are subject to reduction to avoid any excise tax on “parachute payments” if the NEO would benefit from such reduction as compared to paying the excise tax. Severance payments are paid in the immediately three prior calendar years and (iii) two years health benefits and (iv) any and all unvested stock appreciation rights, performance stock awards, stock options or other equity shall immediately vest upon such termination without Cause or for Good Reason. For Mr. Burns, represents the sum of (i)pro-rata over one year base salary and (ii) one year benefits.in accordance with the Company’s normal payroll practices starting 60 days after separation from service.

(3)Represents two years of continued health and life insurance benefits, paid in accordance with the Company’s normal practices.

(4)Represents the value of unvested outstanding options, stock appreciation rights and restricted stock that would accelerate and vest on a change in control (as defined in the 20142020 Omnibus Incentive Plan). In the case of options and stock appreciation rights, the value is calculated by multiplying the number of shares underlying each accelerated unvested award by the difference between the per share closing price of the Common Stock on December 31, 2018 and the per share exercise price. In the case of restricted stock, theThe value is calculated by multiplying the number of shares of restricted stock that accelerate by the per share closing price of the Common Stock on December 31, 20182020 of $7.33.$8.87. Awards issued on or after June 20, 2014 do not vest on change in control except at discretion of Committee. The above table assumes that all awards will vest upon a change in control.

(4)(5)Represents the sum of one-year base salary and one year of benefits for Mr. Burns, paid pro-rata over one year in accordance with the Company’s normal payroll practices.

57

(6)“Cause” is generally defined under our general severance pay policy as: (i) an NEO engaging in actions that are injurious to us (monetarily or otherwise) or (ii) an NEO’s conviction for any felony or any criminal violation involving dishonesty or fraud.

(5)(7)Under the Severance Policy, “cause” is as defined under an NEO’s employment agreement with us, but if the NEO does not have an employment agreement with us that defines “cause,” then “cause” is defined as termination due to an NEO’s insubordination, dishonesty, fraud, incompetence, moral turpitude, misconduct, refusal to perform his or her duties or responsibilities for any reason other than illness or incapacity or materially unsatisfactory performance of his or her duties for us or an affiliate as determined by the Compensation Committee of the Board of Directors in its sole discretion; or (ii) in the case where there is an employment agreement, or similar agreement, in effect between us or an affiliate and the NEO at the termination date that defines “cause” (or words of like import), “cause” as defined under such agreement; provided, however, that with regard to any agreement that conditions “cause” on occurrence of a change of control, such definition of “cause” shall not apply until a change of control actually takes place and then only with regard to a termination thereafter. Notwithstanding the foregoing, an NEO shall be deemed to be terminated for “Cause” if the NEO: (i) breaches the terms of any agreement between the Company or an affiliate and the NEO including, without limitation, an employment agreement or non-competition agreement or (ii) discloses to anyone outside the Company or its affiliates, or uses in other than the Company’s or its affiliates’ business, without written authorization from the Company, any confidential information or proprietary information, relating to the business of the Company or its affiliates acquired by the NEO prior to the termination date.

(6)(8)“Good reason” (called an “involuntary termination” under the Severance Policy) is generally defined under the Severance Policy as: (i) without the Employee’s express written consent, a significant reduction of the Employee’sEmployee��s duties, position or responsibilities relative to the NEO’s duties, position or responsibilities in effect immediately prior to such reduction, or the removal of the NEO from such position, duties and responsibilities, unless the NEO is provided with comparable duties, position and responsibilities; provided, however, that a reduction in duties, position or responsibilities solely by virtue of the Company being acquired and made part of a larger entity shall not constitute an “Involuntary Termination”; (ii) a reduction by the Company of the NEO’s base salary as in effect immediately prior to such reduction; (iii) a material reduction by the Company in the kind or level of employee benefits to which the NEO is entitled

37

immediately prior to such reduction with the result that the NEO’s overall benefits package is materially reduced (unless such reduction is applicable to all employees); or (iv) without the NEO’s express written consent, the relocation of the NEO to a facility or a location more than thirty-five (35) miles from his or her current location.

(7)(9)Represents one week’s base salary for each full year of continuous service with us.

(8)(10)Represents two timesone year of base salary for Mr. Saville and Ms. White, paid pro-rata over one year in accordance with the Company’s normal payroll practices.

58

(11)Represents the sum of base salary plus target bonus.bonus, paid pro-rata over one year in accordance with the Company’s normal payroll practices. The severance benefits payable under the Severance Policy are subject to reduction to avoid any excise tax on “parachute payments” if the NEO would benefit from such reduction as compared to paying the excise tax.

(9)Represents two years of continued health and life insurance benefits.
(10)Represents the sum of base salary plus target bonus. The severance benefits payable under the Severance Policy are subject to reduction to avoid any excise tax on “parachute payments” if the NEO would benefit from such reduction as compared to paying the excise tax.
(11)(12)Represents one year of continued health and life insurance benefits.benefits, paid in accordance with the Company’s normal practices.
(12)Mr. Fischer resigned from the Company February 1, 2019.

CEO Pay Ratio

As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(u) of Regulation S-K, we are providing the following information about the relationship of the annual total compensation of the individual identified as our “median” paid employee and the annual total compensation of William J. Grubbs,Kevin C. Clark, our former President and Chief Executive Officer (“Former CEO”).

For purposes of determining our pay ratio for 2018,Fiscal 2020, the median of the annual total compensation of all employees of our company (other than our CEO) was $22,688$30,429 and the annualannualized total compensation of our Former CEO was $2,664,510.$4,126,562. Based on this information, the ratio of the annual total compensation of our CEO to the median of the annual total compensation of all employees for 20182020 was 117136 to 1.

The methodology and material assumptions, adjustments, and estimates used to identify our median employee for this purpose were as follows:

We determined that, as of October 7, 2018,December 31, 2020, our employee population, including our full-time, part-time and temporary employees, consisted of approximately 9,7587,756 individuals, with 9,5267,575 of these individuals located in the U.S. and 232181 individuals located outside the U.S. Under SEC rules, which provide an exemption for a de minimusminimis number of employees located outside of the U.S., we excluded 232181 employees located in India from this employee population. For purposes of determining our pay ratio, our designated employee population included a total of 9,5267,575 U.S. employees and 0 non-U.S. employees.

To identify the median employee, we used total cash compensation as our consistently applied compensation measure. For new employees, who were hired in fiscal 2018Fiscal 2020 but did not work for the company for the entire fiscal year, compensation was annualized for the full year and compensation for part-time employees was annualized but not converted into a full-time equivalent. We did not make any cost-of-living adjustments in identifying the median employee. Using this methodology, we determined our median employee based on the actual cash compensation, consisting of salary, overtime pay, bonus and commissions, and other cash earnings, paid to each employee in the identified employee population for the period from January 1, 20182020 through December 31, 2018.2020.

Once we identified our median employee, the employee’s total compensation for 20182020 was determined in accordance with Item 402(c)(2)(x) of Regulation S-K, resulting in the annual total compensation amount reported above. With respect to our CEO’s annual total compensation,

59

we used the amount reported in the Total column in the Summary Compensation Table of this proxy statement.

We believe the above pay ratio disclosure is a reasonable estimate calculated in a manner consistent with SEC rules and guidance.guidance; however, due to the flexible approaches permitted in calculating the CEO pay ratio, comparisons among companies may not be very meaningful.

38

RELATED PARTY TRANSACTIONS

The Company documents its processes and controls surrounding the validity, accuracy, and completeness of related party transactions. We compile related party listings which management discusses during quarterly disclosure committee meetings. Accounting teams review general ledger and sub-ledger transactions based on the listings to identify and quantify related party transactions. Contracts associated with related party transactions are sent to General Counsel, who discusses the contracts with the Chief Executive Officer and the Chief Financial Officer for further action. The Company has deemed it reasonable to establish a $0 threshold and to disclose all related party transactions.

On an ongoing basis, the Audit Committee reviews all “relatedrelated party transactions”transactions (those transactions that are required to be disclosed in this proxy statement by SEC Regulation S-K, Item 404 and under Nasdaq’s rules), if any, for potential conflicts of interest and all such transactions must be approved by the Audit Committee.

Mark Fortunato is employed by Cross Country Healthcare, Inc. as Vice President of Corporate Development. He is the son-in-law of Kevin C. Clark, Chief Executive Officer and President of Cross Country Healthcare, Inc. In 2020, Mr. Fortunato’s compensation and benefits were comparable to those generally available to similarly situated employees. The Company also transacts business with companies that would be considered related party transactions. These related party transactions are included in Note 17 to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

The Company’s Code of Conduct, which is signed by all employees on an annual basis, requires that all employees avoid any conflict, or the appearance of a conflict, between an individual’s personal interests and the interests of the Company, and must disclose any such conflicts to the Company. Members of the Board of Directors and the NEOs are each required to compete an annual questionnaire which includes disclosure of any interests they have in companies which transact business with Cross Country Healthcare, Inc. or any of its affiliates.

REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

The Audit Committee oversees the Company’s financial reporting process on behalf of the Board, of Directors, including the Company’s internal controls, the quality of its financial reporting and the independence and performance of the Company’s independent registered public accounting firm. The Board of Directors has adopted a written charter for the Audit Committee, a copy of which is available on our website at www.crosscountryhealthcare.com.

60

Management has the primary responsibility for the Company’s financial statements and the overall reporting process, including the Company’s system of internal controls. The Company’s independent registered public accounting firm audits the annual financial statements prepared by management, expresses an opinion as to whether those financial statements fairly present the consolidated financial position, results of operations and cash flows of the Company and its subsidiaries in conformity with U.S. generally accepted accounting principles, as well as expresses an opinion on the effectiveness of internal control over financial reporting, and discusses with us any issues they believe should be raised with us.

The Audit Committee reviewed the Company’s unaudited financial statements for each calendar quarter of 20182020 as well as the Company’s audited financial statements for the 20182020 fiscal year and reviewed and discussed the financial statements with management and Deloitte & Touche LLP (“D&T”), the Company’s independent registered public accounting firm. Management has represented to us that the financial statements were prepared in accordance with U.S. generally accepted accounting principles.

We have received from D&T the written disclosures and the letter required by Rule 3526 of Public Company Accounting Oversight Board (“PCAOB”), “Communication with Audit Committee Concerning Independence” and discussed with D&T its independence from the Company and its management. The Audit Committee also discussed with D&T any matters required to be discussed by PCAOB Auditing Standard No. 1301, “Communications with Audit Committees”.Committees.”

Based on these reviews and discussions, the Audit Committee recommended to the Board of Directors that the Company’s audited consolidated financial statements be included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.2020.

THE AUDIT COMMITTEE

W. Larry Cash, Chairman
Gale Fitzgerald, Member
Darrell S. Freeman, Sr., Member
Richard M. Mastaler, Member

39

PROPOSAL I

ELECTION OF EIGHT DIRECTORS TO THE COMPANY’S BOARD OF DIRECTORS

The election of the following eight directors to our Board of Directors to hold office until the next Annual Meeting or until their successors are duly elected and qualified:

W. Larry Cash,

Kevin C. Clark

Thomas C. Dircks Chairman

Gale Fitzgerald, Member

Darrell S. Freeman, Sr., Member

Richard M. MastalerJanice E. Nevin, M.D., MPH, Member

61

PROPOSAL NO. 2

Mark Perlberg

Joseph A. Trunfio, Ph.D.

RECOMMENDATIONRATIFICATION OF THE BOARD OF DIRECTORS

THE BOARD OF DIRECTORS UNANIMOUSLY
RECOMMENDS A VOTE FOR THE ELECTION OF EACH NOMINEE UNDER PROPOSAL I.

40

PROPOSAL II

APPOINTMENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM

Our independent registered public accounting firm for the year ended December 31, 20182020 was Deloitte & Touche LLP (“D&T”). D&T’s fees for services rendered during the fiscal years ended December 31, 20182020 and December 31, 20172019 are set forth below.

 
2018
2017
Audit Fees
$
1,743,000
 
$
1,633,000
 
Audit-Related Fees
 
112,635
 
 
179,026
 
Tax Fees
 
 
 
81,826
 
All Other Fees
 
1,895
 
 
1,895
 
Total
$
1,857,530
 
$
1,895,747
 

Members of D&T are expected to be present at the Annual Meeting, will have an opportunity to make a statement if they desire to do so and will be available to respond to appropriate questions.

 2020 2019
Audit Fees$1,527,161 $1,710,000
Audit-Related Fees15,750 242,613
Tax Fees7,875 10,500
All Other Fees 1,895
Total$1,550,786 $1,965,008

Audit Feesconsist of the fees billed for professional services rendered forin connection with our annual financial statementsaudit and review of the financial statements included in our Form 10-Qquarterly reports and services that are provided in connection with statutory and regulatory filings or engagements. Audit Fees for 20182020 and 20172019 included three quarterly reviews for each year. This category also includes: fees for comfort letters, consents, assistance with and review of documents filed with the Commission,SEC, Section 404 attestattestation services, work done by tax professionals in connection with the audit or quarterly review, and accounting consultations billed as audit services, as well as other accounting and financial reporting consultation and research work necessary to comply with generally accepted auditing standards.

Audit-Related Feesconsist of the fees for assurance and related services (due diligence services related to mergers and acquisitions) that are reasonably related to the performance of the audit and review of our financial statements and are not reported under Audit Fees.

Tax Feesconsist of services rendered for tax compliance, advice and planning.

All Other Feesconsist of subscription fees for products and services other than the services reported above.a D&T’s accounting research tool.

All of the fees described above were approved by the Audit Committee or the Chairman of the Audit Committee in advance, as allowed by the Audit Committee charter. The Audit Committee has considered, and is satisfied that, the provision of the services provided by D&T represented under the headings “Audit-Related Fees,” “Tax Fees” and “All Other Fees” is compatible with maintaining the principal accountants’ independence.

62

Policy on Audit Committee Pre-Approval of Audit and Non-Audit Services of the Independent Registered Public Accounting Firm

It is the Company’s policy that the Audit Committee pre-approve all audit and non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services. The Audit Committee will consider annually and, if appropriate, approve the scope of the audit services to be performed during the fiscal year. The Chairman of the Audit Committee has been vested with the authority to approve or pre-approve services to be provided by the independent auditors when expedition of services is necessary, provided that the Chairman reports any approval or pre-approval decisions to the Audit Committee at its next scheduled meeting.

The Audit Committee is prohibited from delegating its responsibility to pre-approve services of the independent auditor to management. None of the services of the independent auditors were approved by the Audit Committee pursuant to a waiver of the Commission’sSEC’s rules regarding pre-approval.

Recommendations

The Audit Committee deems the ratification of the appointment of D&T as our independent registered public accounting firm to be in the best interest of the Company and its stockholders and recommends that holders of the Common Stock vote FOR Proposal II.No. 2.

The affirmative vote of holders of a majority of shares represented at the Annual Meeting, in person or by proxy and entitled to vote is required for the appointment of the Audit Committee’s selection of D&T as our independent registered public accounting firm for the fiscal year ending December 31, 2019.2021.

41

RECOMMENDATIONTHE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE
RATIFICATION OF THE BOARDAPPOINTMENT OF DIRECTORSDeloitte & Touche LLP AS

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDSCOMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
A VOTE FOR THE ADOPTION OF (PROPOSAL II.NO. 2 ON YOUR PROXY CARD)

63

PROPOSAL III

NO. 3

NON-BINDING ADVISORY VOTE TO APPROVE COMPENSATION OF OUR
NAMED EXECUTIVE OFFICERS

We urge stockholders to read the “Compensation Discussion and Analysis” beginning on page 1930 of this proxy statement, which describes in more detail how our executive compensation policies and procedures operate and are designed to achieve our compensation objectives, as well as the Summary Compensation Table and other related compensation tables and narrative, beginning on page 32,51, which provide detailed information on the compensation of our named executive officers. The Compensation Committee and the Board of Directors believe that the policies and procedures articulated in the “Compensation Discussion and Analysis” are effective in achieving our goals and that the compensation of our named executive officers reported in this proxy statement has contributed to the Company’s recent and long-term success.

In accordance with Section 14A of the Exchange Act, and as a matter of good corporate governance, we are asking stockholders to approve the following advisory resolution at the 20192021 annual meeting of stockholders:

RESOLVED, that the stockholders of the Company approve, on an advisory basis, the compensation of the Company’s named executive officers disclosed in the Compensation Discussion and Analysis, the Summary Compensation Table and the related compensation tables, notes and narrative in the Proxy Statement for the Company’s 20192021 annual meeting of stockholders.

This advisory resolution, commonly referred to as a “say-on-pay” resolution, is non-binding on the Board of Directors.Board. Although non-binding, the Board and the Compensation Committee will review and consider the voting results when making future decisions regarding our executive compensation program.

The Board of Directors has adopted a policy providing for an annual “say-on-pay” advisory vote. UnlessAt our 2017 annual meeting of stockholders, our stockholders voted to conduct the Board of Directors modifies its policy“say-on-pay” advisory vote on an annual basis, which we will continue to do until the next vote on the frequency of holding “say-on-pay”our advisory say-on-pay votes the next “say-on-pay” advisory vote will occur in 2020.2023.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS ATHAT YOU VOTE “FOR” APPROVAL OF
“FOR” THE ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO OUR
NAMED EXECUTIVE OFFICER COMPENSATION AS DISCLOSED PURSUANT TO ITEM 402
OF REGULATION S-K, INCLUDEDOFFICERS IN THE COMPENSATION DISCUSSION AND ANALYSIS, THE SUMMARY COMPENSATION TABLE AND OTHER COMPENSATION TABLES, AND ANY RELATED INFORMATION CONTAINED IN THIS2020
(PROPOSAL NO. 3 ON YOUR PROXY STATEMENT. PROXIES SOLICITED BY THE
BOARD WILL BE VOTED “FOR” THIS PROPOSAL UNLESS OTHERWISE INSTRUCTED.CARD)

64

42

DEADLINES FOR SUBMISSION OF PROXYSTOCKHOLDER PROPOSALS AND OTHER BUSINESSDIRECTOR NOMINATIONS

Stockholder proposals intended to be included in the Proxy Statement and form of proxy for the Annual Meeting of Stockholders to be held in 2020,2022, in addition to meeting certain eligibility requirements established by the Commission,SEC, must be in writing and received by the General Counsel at the Company’s principal executive offices on or prior to December 31, 2019.2, 2021. If the date of next year’s Annual Meeting is moved more than 30 days before or after the anniversary date of this year’s Annual Meeting, the deadline for inclusion of proposals in our proxy materials is instead a reasonable time before we begin to print and mail our proxy materials. Notice of any stockholder proposal must include various matters as prescribed by the Commission,SEC, including a clear and concise description of the proposal, and the reasons for proposing it. The proxy solicited

Any stockholder who wishes (i) to propose business to be considered by the Board of Directors forstockholders at the 2020 Annual Meeting of Stockholders to be held in 2022, other than a proposal to be included in the Proxy Statement and form of proxy, or (ii) who wants to nominate a person for election to our Board at that meeting, must provide a written notice that sets forth the specified information described in our Amended and Restated Bylaws (the “Bylaws”) concerning the proposed business or nominee. The notice must be delivered to the Corporate Secretary at our principal executive offices, at the address set forth on the first page of this Proxy Statement, no later than February 13, 2022. A copy of our Bylaws can be obtained upon request directed to the address set forth on the first page of this proxy statement or are available on our website at www.crosscountryhealthcare.com by choosing the “Investors” link, clicking on the “Corporate Governance” section, and selecting the Bylaws under “View.”

HOUSEHOLDING OF PROXY MATERIALS

The SEC has adopted rules that permit companies and intermediaries to satisfy delivery requirements for notices of Internet availability of proxy materials and, if applicable, proxy statements and annual reports to stockholders, with respect to two or more stockholders sharing the same address by delivering a single copy of the material addressed to those stockholders. This process, commonly referred to as “householding,” is designed to reduce duplicate printing and postage costs. We and some brokers may household notices of Internet availability of proxy materials and, if applicable, annual reports to stockholders and proxy materials, by delivering a single copy of the material to multiple stockholders sharing the same address unless contrary instructions have been received from the affected stockholders.

If a stockholder wishes in the future to receive a separate notice of Internet availability of proxy materials or, if applicable, the annual report to stockholders and proxy statement, or if a stockholder received multiple copies of some or all of these materials and would prefer to receive a single copy in the future, the stockholder should submit a request by telephone or in writing to the stockholder’s broker if the shares are held in a brokerage account or, if the shares are registered in the name of the stockholder, to our transfer agent, at 877-219-7066 or Computershare, P.O. Box 50500, Louisville, KY 40233. We promptly will confer discretionary authority to vote assend additional copies of the proxy holders deem advisable on such stockholder proposals that are considered untimely.relevant material following receipt of a request for additional copies.

65

ANNUAL REPORT

The Company has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2018,2020, or the 20182020 Form 10-K, with the CommissionSEC which is available free of charge through our Internet website,www.crosscountryhealthcare.com. Stockholders may obtain a printed copy of the 20182020 Form 10-K by writing to our Investor Relations department at 5201 Congress Avenue, Suite 100B,6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida, 33487. In response to such request, we will furnish without charge the 20182020 Form 10-K including financial statements, financial schedules and a list of exhibits. A copy of our Annual Report for the year ended December 31, 2018,2020, which includes the 20182020 Form 10-K, is being mailed concurrently with this Proxy Statement to all stockholders entitled to notice of and to vote at the Annual Meeting and who request a 20182020 Form 10-K be mailed to them. The Annual Report is not incorporated into this Proxy Statement and is not considered proxy solicitation material.

Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Exchange Act, that might incorporate by reference this Proxy statement or future filings made by the Company under those statutes, the Compensation Committee Report, the Audit Committee Report, references to the Audit Committee Charter and reference to the independence of the Audit Committee members are not deemed filed with the Commission,SEC, are not deemed soliciting material and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by the Company under those statutes, except to the extent that the Company specifically incorporates such information by reference into a previous or future filing, or specifically requests that such information be treated as soliciting material, in each case under those statutes.

By Order of the Board of Directors,


 

Susan E. Ball

Executive Vice President, Chief Administrative
Officer, General Counsel and Secretary

April 1, 2019

March 30, 2021

66

43

AnnexANNEX A

Reconciliation of

RECONCILIATION OF GAAP and Non-GAAP Financial MeasuresAND NON-GAAP FINANCIAL MEASURES

The Company reports its financial results in accordance with U.S. GAAP. However, management believes that certain non-GAAP financial measures provide additional financial information that is meaningful and uses these measures to help evaluate operational results and make financial, operating and planning decisions. Management also uses these non-GAAP financial measures as performance measures in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure typically used in the Company’s credit facilities in calculating various ratios. We believe these non-GAAP measures should be considered by investors and others when reviewing the Company’s performance.

We use Adjusted EBITDA and Adjusted EPS as supplemental measures to the financial measures we present in accordance with GAAP. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by revenue from services. These non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. These non-GAAP financial measures are provided for consistency and comparability to prior year results, and management believes they are useful to investors when evaluating the Company’s performance as they exclude certain items that management believes are not indicative of the Company’s operating performance. These non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies.

Cross Country Healthcare, Inc.
Reconciliation of Non-GAAP Financial Measures
(Unaudited. amounts in thousands, except per share data)

Year Ended December 31,
 Year Ended December 31,
2018
2017
 2020 2019
Reconciliation of Adjusted EPS(1)
 
 
 
 
 
 
    
Diluted EPS, GAAP
$
(0.48
)
$
1.01
 
 $(0.36) $(1.61)
Non-GAAP adjustments - pretax:
 
 
 
 
 
 
        
Acquisition-related contingent consideration
 
0.08
 
 
 
Acquisition and integration costs
 
0.01
 
 
0.06
 
Restructuring costs
 
0.08
 
 
0.03
 
  0.16   0.10 
Impairment charges
 
0.63
 
 
0.40
 
Gain on derivative liability
 
 
 
(0.05
)
Legal settlements and fees  0.09   0.05 
Impairment charges (excluding rebranding impacts)  0.45   0.05 
Rebranding impairments and accelerated amortization  0.09   0.48 
Loss on derivative  —     0.04 
Loss on early extinguishment of debt
 
 
 
0.14
 
  —     0.05 
Applicant tracking system costs
 
0.02
 
 
 
  0.05   0.06 
Nonrecurring income tax adjustments
 
 
 
(0.97
)
  0.01   0.98 
Tax impact of non-GAAP adjustments
 
(0.22
)
 
(0.06
)
  (0.03)  (0.05)
Adjustment for change in dilutive shares
 
 
 
0.05
 
Adjusted EPS, non-GAAP
$
0.12
 
$
0.61
 
 $ 0.46  0.15 

 
Year Ended December 31,
 
2018
2017
Reconciliation of Adjusted EBITDA(2)
 
 
 
 
 
 
Net (loss) income attributable to common shareholders
$
(16,951
)
$
37,513
 
Depreciation and Amortization
 
11,780
 
 
10,174
 
Interest expense
 
5,654
 
 
4,214
 
Income tax benefit
 
(2,478
)
 
(34,501
)
Acquisition-related contingent consideration
 
2,557
 
 
44
 
Acquisition and integration costs
 
491
 
 
1,975
 
Restructuring costs
 
2,758
 
 
1,026
 
Impairment charges
 
22,423
 
 
14,356
 
Gain on derivative liability
 
 
 
(1,581
)
Loss on early extinguishment and modification of debt
 
79
 
 
4,969
 
Other income, net
 
(418
)
 
(155
)
Equity compensation
 
3,575
 
 
4,080
 
Applicant tracking system costs
 
658
 
 
 
Net income attributable to noncontrolling interest in subsidiary
 
1,234
 
 
1,289
 
Adjusted EBlTDA
$
31,362
 
$
43,403
 
67

A-1

  Year Ended December 31,
  2020 2019
Reconciliation of Adjusted EBITDA(2)    
Net loss attributable to common shareholders $(12,962) $(57,713)
Interest expense  2,890   5,306 
Income tax (benefit) expense  (188)  31,732 
Depreciation and amortization  12,671   14,075 
Acquisition and integration-related costs  77   201 
Restructuring costs  6,052   3,571 
Legal settlements and fees  2,998   1,600 
Impairment charges  16,248   16,306 
Loss on derivative  —     1,284 
Loss on early extinguishment of debt  —     1,978 
Loss on disposal of fixed assets  364   —   
Other income, net  (84)  (68)
Equity compensation  5,403   3,396 
Applicant tracking system costs  2,033   2,030 
Net income attributable to noncontrolling interest in subsidiary  820   1,770 
Adjusted EBlTDA $ 36,322  $ 25,468 

(1)Adjusted EPS. a non-GAAP financial measure, is defined as net income (loss) income attributable to common shareholders per diluted share (diluted EPS, GAAP) before the diluted EPS impact of acquisition-related contingent consideration, acquisition and integrationintegration-related costs, restructuring costs, legal settlements and fees, impairment charges, rebranding impairments and accelerated amortization, gain or loss on derivative, liability, loss on early extinguishment of debt, gain or loss on sale of business, applicant tracking system costs, legal settlement charges, and nonrecurring income tax adjustments.

(2)Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) income attributable to common shareholders before interest expense, income tax expense (benefit) expense,, depreciation and amortization, acquisition-related contingent consideration, acquisition and integrationintegration-related costs, restructuring costs, legal settlements and fees, impairment charges, gain or loss on derivative, liability, loss on early extinguishment of debt, gain or loss on disposal of fixed assets, gain or loss on sale of business, other income,expense (income), net, equity compensation, applicant tracking system costs, legal settlement charges, and includes net income attributable to noncontrolling interest in subsidiary.

68

A-2